Background  ||| S:24 E:43 ||| NN
The  ||| S:43 E:47 ||| DT
p53  ||| S:47 E:51 ||| NN
tumor  ||| S:51 E:57 ||| NN
suppressor  ||| S:57 E:68 ||| NN
gene  ||| S:68 E:73 ||| NN
is  ||| S:73 E:76 ||| VBZ
activated  ||| S:76 E:86 ||| VBN
during  ||| S:86 E:101 ||| IN
several  ||| S:101 E:109 ||| JJ
cellular  ||| S:109 E:118 ||| JJ
processes ||| S:118 E:127 ||| NNS
.  ||| S:127 E:129 ||| .
These  ||| S:129 E:135 ||| DT
include  ||| S:135 E:143 ||| JJ
DNA  ||| S:143 E:147 ||| NN
damage  ||| S:147 E:154 ||| NN
caused  ||| S:154 E:169 ||| VBN
by  ||| S:169 E:172 ||| IN
Ionizing  ||| S:172 E:181 ||| NNP
Radiation  ||| S:181 E:191 ||| NNP
and  ||| S:191 E:195 ||| CC
genotoxic  ||| S:195 E:205 ||| JJ
agents  ||| S:205 E:212 ||| NNS
[  ||| S:212 E:214 ||| -LRB-
1 ||| S:214 E:215 ||| LS
] ||| S:215 E:216 ||| -RRB-
,  ||| S:216 E:218 ||| ,
by  ||| S:218 E:229 ||| IN
expression  ||| S:229 E:240 ||| NN
of  ||| S:240 E:243 ||| IN
activated  ||| S:243 E:253 ||| JJ
oncogenes  ||| S:253 E:263 ||| NNS
such  ||| S:263 E:268 ||| JJ
as  ||| S:268 E:271 ||| IN
ras  ||| S:271 E:275 ||| NN
or  ||| S:275 E:278 ||| CC
myc  ||| S:278 E:282 ||| NNS
[  ||| S:282 E:284 ||| -LRB-
2 ||| S:284 E:285 ||| LS
] ||| S:285 E:286 ||| -RRB-
,  ||| S:286 E:296 ||| ,
or  ||| S:296 E:299 ||| CC
during  ||| S:299 E:306 ||| IN
progression  ||| S:306 E:318 ||| NN
of  ||| S:318 E:321 ||| IN
primary  ||| S:321 E:329 ||| JJ
cells  ||| S:329 E:335 ||| NNS
to  ||| S:335 E:338 ||| TO
senescence  ||| S:338 E:349 ||| VB
[  ||| S:349 E:351 ||| -LRB-
3 ||| S:351 E:352 ||| LS
] ||| S:352 E:353 ||| -RRB-
.  ||| S:353 E:363 ||| .
The  ||| S:363 E:367 ||| DT
activation  ||| S:367 E:378 ||| NN
of  ||| S:378 E:381 ||| IN
p53  ||| S:381 E:385 ||| NN
by  ||| S:385 E:388 ||| IN
these  ||| S:388 E:394 ||| DT
diverse  ||| S:394 E:402 ||| JJ
stimuli  ||| S:402 E:410 ||| NNS
can  ||| S:410 E:414 ||| MD
initiate  ||| S:414 E:431 ||| VB
either  ||| S:431 E:438 ||| DT
growth  ||| S:438 E:445 ||| NN
arrest  ||| S:445 E:452 ||| NN
or  ||| S:452 E:455 ||| CC
apoptosis  ||| S:455 E:465 ||| VBP
depending  ||| S:465 E:475 ||| VBG
on  ||| S:475 E:478 ||| IN
the  ||| S:478 E:482 ||| DT
cellular  ||| S:482 E:499 ||| JJ
context  ||| S:499 E:507 ||| NN
[  ||| S:507 E:509 ||| -LRB-
1 ||| S:509 E:510 ||| CD
,  ||| S:510 E:512 ||| ,
2 ||| S:512 E:513 ||| CD
,  ||| S:513 E:515 ||| ,
3 ||| S:515 E:516 ||| LS
] ||| S:516 E:517 ||| -RRB-
.  ||| S:517 E:519 ||| .
p53  ||| S:519 E:523 ||| FW
posses  ||| S:523 E:530 ||| FW
sequence-specific  ||| S:530 E:548 ||| FW
DNA  ||| S:548 E:560 ||| NNP
binding  ||| S:560 E:568 ||| JJ
activity  ||| S:568 E:577 ||| NN
and  ||| S:577 E:581 ||| CC
functions  ||| S:581 E:591 ||| NNS
in  ||| S:591 E:594 ||| IN
the  ||| S:594 E:598 ||| DT
cell  ||| S:598 E:603 ||| NN
as  ||| S:603 E:606 ||| IN
a  ||| S:606 E:616 ||| DT
transcriptional  ||| S:616 E:632 ||| JJ
regulator ||| S:632 E:641 ||| NN
.  ||| S:641 E:643 ||| .
Many  ||| S:643 E:648 ||| JJ
p53  ||| S:648 E:652 ||| NN
regulated  ||| S:652 E:662 ||| VBN
genes  ||| S:662 E:668 ||| NNS
have  ||| S:668 E:681 ||| VBP
been  ||| S:681 E:686 ||| VBN
identified  ||| S:686 E:697 ||| VBN
[  ||| S:697 E:699 ||| -LRB-
3 ||| S:699 E:700 ||| LS
,  ||| S:700 E:702 ||| ,
4 ||| S:702 E:703 ||| CD
,  ||| S:703 E:705 ||| ,
5 ||| S:705 E:706 ||| CD
] ||| S:706 E:707 ||| -RRB-
,  ||| S:707 E:709 ||| ,
and  ||| S:709 E:713 ||| CC
the  ||| S:713 E:717 ||| DT
majority  ||| S:717 E:726 ||| NN
of  ||| S:726 E:729 ||| IN
the  ||| S:729 E:741 ||| DT
cellular  ||| S:741 E:750 ||| JJ
effects  ||| S:750 E:758 ||| NNS
of  ||| S:758 E:761 ||| IN
p53  ||| S:761 E:765 ||| NN
activation  ||| S:765 E:776 ||| NNS
can  ||| S:776 E:780 ||| MD
be  ||| S:780 E:783 ||| VB
attributed  ||| S:783 E:794 ||| VBN
to  ||| S:794 E:797 ||| TO
the  ||| S:797 E:809 ||| DT
activation  ||| S:809 E:820 ||| NN
of  ||| S:820 E:823 ||| IN
these  ||| S:823 E:829 ||| DT
p53  ||| S:829 E:833 ||| NN
target  ||| S:833 E:840 ||| NN
genes ||| S:840 E:845 ||| NNS
.  ||| S:845 E:855 ||| .
The  ||| S:855 E:859 ||| DT
mechanism  ||| S:859 E:869 ||| NN
of  ||| S:869 E:872 ||| IN
p53  ||| S:872 E:876 ||| NN
activation  ||| S:876 E:887 ||| NN
in  ||| S:887 E:890 ||| IN
response  ||| S:890 E:899 ||| NN
to  ||| S:899 E:902 ||| TO
either  ||| S:902 E:917 ||| DT
DNA  ||| S:917 E:921 ||| NN
damage  ||| S:921 E:928 ||| NN
or  ||| S:928 E:931 ||| CC
oncogene  ||| S:931 E:940 ||| JJ
expression  ||| S:940 E:951 ||| NN
occurs  ||| S:951 E:958 ||| VBZ
through  ||| S:958 E:974 ||| IN
stabilization  ||| S:974 E:988 ||| NN
of  ||| S:988 E:991 ||| IN
the  ||| S:991 E:995 ||| DT
p53  ||| S:995 E:999 ||| NN
protein ||| S:999 E:1006 ||| NN
.  ||| S:1006 E:1008 ||| .
In  ||| S:1008 E:1011 ||| IN
unstimulated  ||| S:1011 E:1024 ||| JJ
cells ||| S:1024 E:1029 ||| NNS
,  ||| S:1029 E:1039 ||| ,
the  ||| S:1039 E:1043 ||| DT
mdm2  ||| S:1043 E:1048 ||| JJ
protein  ||| S:1048 E:1056 ||| NN
binds  ||| S:1056 E:1062 ||| NN
to  ||| S:1062 E:1065 ||| TO
the  ||| S:1065 E:1069 ||| DT
N-terminal  ||| S:1069 E:1080 ||| JJ
transactivation  ||| S:1080 E:1104 ||| JJ
domain  ||| S:1104 E:1111 ||| NN
of  ||| S:1111 E:1114 ||| IN
p53  ||| S:1114 E:1118 ||| NN
and  ||| S:1118 E:1122 ||| CC
targets  ||| S:1122 E:1130 ||| NNS
it  ||| S:1130 E:1133 ||| PRP
for  ||| S:1133 E:1137 ||| IN
ubiquitin-dependent  ||| S:1137 E:1165 ||| JJ
degradation  ||| S:1165 E:1177 ||| NNS
[  ||| S:1177 E:1179 ||| -LRB-
6 ||| S:1179 E:1180 ||| CD
,  ||| S:1180 E:1182 ||| ,
7 ||| S:1182 E:1183 ||| CD
] ||| S:1183 E:1184 ||| -RRB-
.  ||| S:1184 E:1186 ||| .
Activation  ||| S:1186 E:1197 ||| NNP
of  ||| S:1197 E:1200 ||| IN
p53  ||| S:1200 E:1204 ||| NN
requires  ||| S:1204 E:1213 ||| VBZ
disruption  ||| S:1213 E:1232 ||| NN
of  ||| S:1232 E:1235 ||| IN
the  ||| S:1235 E:1239 ||| DT
mdm2-p53  ||| S:1239 E:1248 ||| JJ
interaction  ||| S:1248 E:1260 ||| NN
to  ||| S:1260 E:1263 ||| TO
allow  ||| S:1263 E:1269 ||| VB
p53  ||| S:1269 E:1273 ||| NN
accumulation  ||| S:1273 E:1286 ||| NN
in  ||| S:1286 E:1297 ||| IN
the  ||| S:1297 E:1301 ||| DT
cell.  ||| S:1301 E:1307 ||| CD
2  ||| S:1307 E:1309 ||| CD
distinct  ||| S:1309 E:1318 ||| JJ
mechanisms  ||| S:1318 E:1329 ||| NNS
for  ||| S:1329 E:1333 ||| IN
p53  ||| S:1333 E:1337 ||| NN
activation  ||| S:1337 E:1348 ||| NNS
have  ||| S:1348 E:1353 ||| VBP
so  ||| S:1353 E:1364 ||| RB
far  ||| S:1364 E:1368 ||| RB
been  ||| S:1368 E:1373 ||| VBN
elucidated ||| S:1373 E:1383 ||| NN
.  ||| S:1383 E:1385 ||| .
The  ||| S:1385 E:1389 ||| DT
expression  ||| S:1389 E:1400 ||| NN
of  ||| S:1400 E:1403 ||| IN
oncogenes  ||| S:1403 E:1413 ||| JJ
such  ||| S:1413 E:1418 ||| JJ
as  ||| S:1418 E:1429 ||| IN
ras  ||| S:1429 E:1433 ||| NN
in  ||| S:1433 E:1436 ||| IN
untransformed  ||| S:1436 E:1450 ||| JJ
cells  ||| S:1450 E:1456 ||| NNS
stimulates  ||| S:1456 E:1467 ||| VBP
transcription  ||| S:1467 E:1481 ||| VBN
of  ||| S:1481 E:1484 ||| IN
the  ||| S:1484 E:1496 ||| DT
p14  ||| S:1496 E:1500 ||| NNP
Arfgene  ||| S:1500 E:1508 ||| NNP
[  ||| S:1508 E:1510 ||| -LRB-
2 ||| S:1510 E:1511 ||| LS
] ||| S:1511 E:1512 ||| -RRB-
.  ||| S:1512 E:1514 ||| .
p14  ||| S:1514 E:1518 ||| FW
Arfbinds  ||| S:1518 E:1527 ||| FW
to  ||| S:1527 E:1530 ||| TO
and  ||| S:1530 E:1534 ||| CC
sequesters  ||| S:1534 E:1545 ||| CD
mdm2 ||| S:1545 E:1549 ||| CD
,  ||| S:1549 E:1559 ||| ,
allowing  ||| S:1559 E:1568 ||| VBG
free  ||| S:1568 E:1573 ||| JJ
p53  ||| S:1573 E:1577 ||| NN
protein  ||| S:1577 E:1585 ||| NN
to  ||| S:1585 E:1588 ||| TO
accumulate  ||| S:1588 E:1599 ||| VB
in  ||| S:1599 E:1602 ||| IN
the  ||| S:1602 E:1606 ||| DT
cells  ||| S:1606 E:1612 ||| NNS
[  ||| S:1612 E:1614 ||| -LRB-
8 ||| S:1614 E:1615 ||| CD
] ||| S:1615 E:1616 ||| -RRB-
.  ||| S:1616 E:1626 ||| .
Activation  ||| S:1626 E:1637 ||| NNP
of  ||| S:1637 E:1640 ||| IN
p53  ||| S:1640 E:1644 ||| NN
by  ||| S:1644 E:1647 ||| IN
DNA  ||| S:1647 E:1651 ||| NNP
damage  ||| S:1651 E:1658 ||| NN
is  ||| S:1658 E:1661 ||| VBZ
also  ||| S:1661 E:1666 ||| RB
brought  ||| S:1666 E:1674 ||| VBN
about  ||| S:1674 E:1680 ||| RB
by  ||| S:1680 E:1691 ||| IN
inhibition  ||| S:1691 E:1702 ||| NN
of  ||| S:1702 E:1705 ||| IN
p53-mdm2  ||| S:1705 E:1714 ||| CD
interaction ||| S:1714 E:1725 ||| NNS
.  ||| S:1725 E:1727 ||| .
The  ||| S:1727 E:1731 ||| DT
product  ||| S:1731 E:1739 ||| NN
of  ||| S:1739 E:1742 ||| IN
the  ||| S:1742 E:1754 ||| DT
Ataxia  ||| S:1754 E:1761 ||| NNP
Telangiectasia  ||| S:1761 E:1776 ||| NNP
gene ||| S:1776 E:1780 ||| NN
,  ||| S:1780 E:1782 ||| ,
the  ||| S:1782 E:1786 ||| DT
ATM  ||| S:1786 E:1790 ||| NNP
protein  ||| S:1790 E:1798 ||| NN
kinase  ||| S:1798 E:1805 ||| NNS
[  ||| S:1805 E:1807 ||| -LRB-
9 ||| S:1807 E:1808 ||| CD
] ||| S:1808 E:1809 ||| -RRB-
,  ||| S:1809 E:1819 ||| ,
directly  ||| S:1819 E:1828 ||| RB
phosphorylates  ||| S:1828 E:1843 ||| CD
serine  ||| S:1843 E:1850 ||| CD
15  ||| S:1850 E:1853 ||| CD
of  ||| S:1853 E:1856 ||| IN
the  ||| S:1856 E:1860 ||| DT
p53  ||| S:1860 E:1864 ||| NN
protein  ||| S:1864 E:1872 ||| NN
in  ||| S:1872 E:1883 ||| IN
response  ||| S:1883 E:1892 ||| NN
to  ||| S:1892 E:1895 ||| TO
Ionizing  ||| S:1895 E:1904 ||| NNP
Radiation  ||| S:1904 E:1914 ||| NNP
[  ||| S:1914 E:1916 ||| -LRB-
10 ||| S:1916 E:1918 ||| CD
,  ||| S:1918 E:1920 ||| ,
11 ||| S:1920 E:1922 ||| CD
] ||| S:1922 E:1923 ||| -RRB-
.  ||| S:1923 E:1925 ||| .
In  ||| S:1925 E:1928 ||| IN
addition ||| S:1928 E:1936 ||| NN
,  ||| S:1936 E:1938 ||| ,
ATM  ||| S:1938 E:1950 ||| NNP
phosphorylates  ||| S:1950 E:1965 ||| NN
and  ||| S:1965 E:1969 ||| CC
activates  ||| S:1969 E:1979 ||| FW
chk2  ||| S:1979 E:1984 ||| FW
kinase  ||| S:1984 E:1991 ||| FW
[  ||| S:1991 E:1993 ||| -LRB-
12 ||| S:1993 E:1995 ||| CD
] ||| S:1995 E:1996 ||| -RRB-
.  ||| S:1996 E:1998 ||| .
Activated  ||| S:1998 E:2016 ||| NNP
chk2  ||| S:2016 E:2021 ||| NNP
can  ||| S:2021 E:2025 ||| MD
then  ||| S:2025 E:2030 ||| RB
directly  ||| S:2030 E:2039 ||| RB
phosphorylate  ||| S:2039 E:2053 ||| CD
serine  ||| S:2053 E:2060 ||| CD
20  ||| S:2060 E:2063 ||| CD
of  ||| S:2063 E:2066 ||| IN
p53  ||| S:2066 E:2070 ||| NN
[  ||| S:2070 E:2072 ||| -LRB-
13 ||| S:2072 E:2074 ||| CD
,  ||| S:2074 E:2084 ||| ,
14 ||| S:2084 E:2086 ||| CD
] ||| S:2086 E:2087 ||| -RRB-
.  ||| S:2087 E:2089 ||| .
ATM  ||| S:2089 E:2093 ||| NNP
therefore  ||| S:2093 E:2103 ||| RB
controls  ||| S:2103 E:2112 ||| VBZ
the  ||| S:2112 E:2116 ||| DT
phosphorylation  ||| S:2116 E:2132 ||| NN
of  ||| S:2132 E:2135 ||| IN
serines  ||| S:2135 E:2151 ||| CD
15  ||| S:2151 E:2154 ||| CD
and  ||| S:2154 E:2158 ||| CC
20  ||| S:2158 E:2161 ||| CD
of  ||| S:2161 E:2164 ||| IN
p53 ||| S:2164 E:2167 ||| NN
.  ||| S:2167 E:2169 ||| .
In  ||| S:2169 E:2172 ||| IN
addition ||| S:2172 E:2180 ||| NN
,  ||| S:2180 E:2182 ||| ,
DNA  ||| S:2182 E:2186 ||| NNP
damage  ||| S:2186 E:2193 ||| NN
increases  ||| S:2193 E:2203 ||| VBZ
the  ||| S:2203 E:2215 ||| DT
phosphorylation  ||| S:2215 E:2231 ||| NN
of  ||| S:2231 E:2234 ||| IN
serines  ||| S:2234 E:2242 ||| CD
33  ||| S:2242 E:2245 ||| CD
and  ||| S:2245 E:2249 ||| CC
37  ||| S:2249 E:2252 ||| CD
of  ||| S:2252 E:2255 ||| IN
p53  ||| S:2255 E:2259 ||| NN
through  ||| S:2259 E:2267 ||| IN
an  ||| S:2267 E:2278 ||| DT
ATM-independent  ||| S:2278 E:2294 ||| JJ
mechanism  ||| S:2294 E:2304 ||| NN
[  ||| S:2304 E:2306 ||| -LRB-
15 ||| S:2306 E:2308 ||| CD
,  ||| S:2308 E:2310 ||| ,
16 ||| S:2310 E:2312 ||| CD
,  ||| S:2312 E:2314 ||| ,
17 ||| S:2314 E:2316 ||| CD
,  ||| S:2316 E:2318 ||| ,
18 ||| S:2318 E:2320 ||| CD
] ||| S:2320 E:2321 ||| -RRB-
.  ||| S:2321 E:2323 ||| .
These  ||| S:2323 E:2329 ||| DT
DNA  ||| S:2329 E:2341 ||| NN
damage-induced  ||| S:2341 E:2356 ||| JJ
phosphorylations  ||| S:2356 E:2373 ||| NN
of  ||| S:2373 E:2376 ||| IN
p53  ||| S:2376 E:2380 ||| NN
block  ||| S:2380 E:2386 ||| VB
the  ||| S:2386 E:2390 ||| DT
binding  ||| S:2390 E:2398 ||| NN
of  ||| S:2398 E:2409 ||| IN
mdm2  ||| S:2409 E:2414 ||| CD
to  ||| S:2414 E:2417 ||| TO
the  ||| S:2417 E:2421 ||| DT
N-terminal  ||| S:2421 E:2432 ||| JJ
of  ||| S:2432 E:2435 ||| IN
the  ||| S:2435 E:2439 ||| DT
p53  ||| S:2439 E:2443 ||| NN
protein  ||| S:2443 E:2451 ||| NN
[  ||| S:2451 E:2453 ||| -LRB-
18 ||| S:2453 E:2455 ||| CD
] ||| S:2455 E:2456 ||| -RRB-
.  ||| S:2456 E:2458 ||| .
Thus  ||| S:2458 E:2471 ||| RB
phosphorylation  ||| S:2471 E:2487 ||| VBN
of  ||| S:2487 E:2490 ||| IN
the  ||| S:2490 E:2494 ||| DT
p53  ||| S:2494 E:2498 ||| NN
protein  ||| S:2498 E:2506 ||| NN
in  ||| S:2506 E:2509 ||| IN
response  ||| S:2509 E:2518 ||| NN
to  ||| S:2518 E:2521 ||| TO
DNA  ||| S:2521 E:2533 ||| NNP
damage  ||| S:2533 E:2540 ||| NN
or  ||| S:2540 E:2543 ||| CC
expression  ||| S:2543 E:2554 ||| NN
of  ||| S:2554 E:2557 ||| IN
p14Arf  ||| S:2557 E:2564 ||| NNP
prevents  ||| S:2564 E:2573 ||| VBZ
mdm2  ||| S:2573 E:2578 ||| CD
binding  ||| S:2578 E:2586 ||| NNS
and  ||| S:2586 E:2598 ||| CC
p53  ||| S:2598 E:2602 ||| NN
protein  ||| S:2602 E:2610 ||| NN
then  ||| S:2610 E:2615 ||| RB
accumulates  ||| S:2615 E:2627 ||| VBN
in  ||| S:2627 E:2630 ||| IN
the  ||| S:2630 E:2634 ||| DT
cell ||| S:2634 E:2638 ||| NN
.  ||| S:2638 E:2648 ||| .
Although  ||| S:2648 E:2657 ||| IN
stabilization  ||| S:2657 E:2671 ||| NN
of  ||| S:2671 E:2674 ||| IN
the  ||| S:2674 E:2678 ||| DT
p53  ||| S:2678 E:2682 ||| NN
protein  ||| S:2682 E:2690 ||| NN
is  ||| S:2690 E:2693 ||| VBZ
the  ||| S:2693 E:2697 ||| DT
initial  ||| S:2697 E:2713 ||| JJ
step  ||| S:2713 E:2718 ||| NN
in  ||| S:2718 E:2721 ||| IN
p53  ||| S:2721 E:2725 ||| NN
activation ||| S:2725 E:2735 ||| NN
,  ||| S:2735 E:2737 ||| ,
subsequent  ||| S:2737 E:2748 ||| JJ
steps ||| S:2748 E:2753 ||| NNS
,  ||| S:2753 E:2755 ||| ,
including  ||| S:2755 E:2773 ||| VBG
activation  ||| S:2773 E:2784 ||| NN
of  ||| S:2784 E:2787 ||| IN
p53 ||| S:2787 E:2790 ||| NN
's  ||| S:2790 E:2793 ||| POS
DNA  ||| S:2793 E:2797 ||| NN
binding  ||| S:2797 E:2805 ||| JJ
activity  ||| S:2805 E:2814 ||| NN
and  ||| S:2814 E:2818 ||| CC
changes  ||| S:2818 E:2826 ||| NNS
in  ||| S:2826 E:2837 ||| IN
p53 ||| S:2837 E:2840 ||| NN
's  ||| S:2840 E:2843 ||| POS
transcriptional  ||| S:2843 E:2859 ||| JJ
activity ||| S:2859 E:2867 ||| NN
,  ||| S:2867 E:2869 ||| ,
are  ||| S:2869 E:2873 ||| VBP
also  ||| S:2873 E:2878 ||| RB
involved ||| S:2878 E:2886 ||| VBN
.  ||| S:2886 E:2888 ||| .
For  ||| S:2888 E:2900 ||| IN
example ||| S:2900 E:2907 ||| NN
,  ||| S:2907 E:2909 ||| ,
p53 ||| S:2909 E:2912 ||| NN
's  ||| S:2912 E:2915 ||| POS
DNA  ||| S:2915 E:2919 ||| NN
binding  ||| S:2919 E:2927 ||| JJ
activity  ||| S:2927 E:2936 ||| NN
is  ||| S:2936 E:2939 ||| VBZ
increased  ||| S:2939 E:2949 ||| VBN
by  ||| S:2949 E:2952 ||| IN
the  ||| S:2952 E:2956 ||| DT
DNA  ||| S:2956 E:2968 ||| NN
damage-induced  ||| S:2968 E:2983 ||| JJ
acetylation  ||| S:2983 E:2995 ||| NN
of  ||| S:2995 E:2998 ||| IN
the  ||| S:2998 E:3002 ||| DT
C-terminal  ||| S:3002 E:3013 ||| JJ
of  ||| S:3013 E:3016 ||| IN
p53  ||| S:3016 E:3020 ||| NN
[  ||| S:3020 E:3022 ||| -LRB-
16 ||| S:3022 E:3024 ||| CD
,  ||| S:3024 E:3034 ||| ,
19 ||| S:3034 E:3036 ||| CD
] ||| S:3036 E:3037 ||| -RRB-
,  ||| S:3037 E:3039 ||| ,
and  ||| S:3039 E:3043 ||| CC
this  ||| S:3043 E:3048 ||| DT
acetylation  ||| S:3048 E:3060 ||| NN
requires  ||| S:3060 E:3069 ||| VBZ
the  ||| S:3069 E:3073 ||| DT
prior  ||| S:3073 E:3087 ||| JJ
phosphorylation  ||| S:3087 E:3103 ||| NN
of  ||| S:3103 E:3106 ||| IN
the  ||| S:3106 E:3110 ||| DT
N-terminal  ||| S:3110 E:3121 ||| JJ
of  ||| S:3121 E:3124 ||| IN
p53  ||| S:3124 E:3128 ||| NN
[  ||| S:3128 E:3130 ||| -LRB-
16 ||| S:3130 E:3132 ||| CD
] ||| S:3132 E:3133 ||| -RRB-
.  ||| S:3133 E:3135 ||| .
In  ||| S:3135 E:3146 ||| IN
addition ||| S:3146 E:3154 ||| NN
,  ||| S:3154 E:3156 ||| ,
phosphorylation  ||| S:3156 E:3172 ||| VBG
of  ||| S:3172 E:3175 ||| IN
the  ||| S:3175 E:3179 ||| DT
N-terminal  ||| S:3179 E:3190 ||| JJ
transactivation  ||| S:3190 E:3214 ||| JJ
domain  ||| S:3214 E:3221 ||| NN
of  ||| S:3221 E:3224 ||| IN
p53  ||| S:3224 E:3228 ||| NN
may  ||| S:3228 E:3232 ||| MD
be  ||| S:3232 E:3235 ||| VB
required  ||| S:3235 E:3244 ||| VBN
to  ||| S:3244 E:3247 ||| TO
stimulate  ||| S:3247 E:3257 ||| VB
transcriptional  ||| S:3257 E:3281 ||| JJ
activation  ||| S:3281 E:3292 ||| NN
of  ||| S:3292 E:3295 ||| IN
p53  ||| S:3295 E:3299 ||| NN
target  ||| S:3299 E:3306 ||| NN
genes ||| S:3306 E:3311 ||| NNS
.  ||| S:3311 E:3313 ||| .
Multiple  ||| S:3313 E:3322 ||| JJ
phosphorylation  ||| S:3322 E:3346 ||| JJ
sites  ||| S:3346 E:3352 ||| NNS
have  ||| S:3352 E:3357 ||| VBP
been  ||| S:3357 E:3362 ||| VBN
detected  ||| S:3362 E:3371 ||| VBN
in  ||| S:3371 E:3374 ||| IN
the  ||| S:3374 E:3378 ||| DT
N-terminal  ||| S:3378 E:3389 ||| JJ
of  ||| S:3389 E:3392 ||| IN
p53 ||| S:3392 E:3395 ||| NN
,  ||| S:3395 E:3405 ||| ,
including  ||| S:3405 E:3415 ||| VBG
serines  ||| S:3415 E:3423 ||| CD
6 ||| S:3423 E:3424 ||| CD
,  ||| S:3424 E:3426 ||| ,
9 ||| S:3426 E:3427 ||| CD
,  ||| S:3427 E:3429 ||| ,
15 ||| S:3429 E:3431 ||| CD
,  ||| S:3431 E:3433 ||| ,
20 ||| S:3433 E:3435 ||| CD
,  ||| S:3435 E:3437 ||| ,
33 ||| S:3437 E:3439 ||| CD
,  ||| S:3439 E:3441 ||| ,
37  ||| S:3441 E:3444 ||| CD
and  ||| S:3444 E:3448 ||| CC
46  ||| S:3448 E:3451 ||| CD
[  ||| S:3451 E:3453 ||| -LRB-
10 ||| S:3453 E:3455 ||| CD
,  ||| S:3455 E:3457 ||| ,
11 ||| S:3457 E:3459 ||| CD
,  ||| S:3459 E:3461 ||| ,
12 ||| S:3461 E:3463 ||| CD
,  ||| S:3463 E:3473 ||| ,
13 ||| S:3473 E:3475 ||| CD
,  ||| S:3475 E:3477 ||| ,
14 ||| S:3477 E:3479 ||| CD
,  ||| S:3479 E:3481 ||| ,
20 ||| S:3481 E:3483 ||| CD
,  ||| S:3483 E:3485 ||| ,
21 ||| S:3485 E:3487 ||| CD
,  ||| S:3487 E:3489 ||| ,
22 ||| S:3489 E:3491 ||| CD
] ||| S:3491 E:3492 ||| -RRB-
.  ||| S:3492 E:3494 ||| .
While  ||| S:3494 E:3500 ||| IN
phosphorylation  ||| S:3500 E:3516 ||| NN
of  ||| S:3516 E:3519 ||| IN
serines  ||| S:3519 E:3527 ||| CD
15  ||| S:3527 E:3538 ||| CD
and  ||| S:3538 E:3542 ||| CC
20  ||| S:3542 E:3545 ||| CD
of  ||| S:3545 E:3548 ||| IN
p53  ||| S:3548 E:3552 ||| NN
are  ||| S:3552 E:3556 ||| VBP
clearly  ||| S:3556 E:3564 ||| RB
dependent  ||| S:3564 E:3574 ||| JJ
on  ||| S:3574 E:3577 ||| IN
the  ||| S:3577 E:3581 ||| DT
ATM  ||| S:3581 E:3585 ||| NNP
and  ||| S:3585 E:3589 ||| CC
chk2  ||| S:3589 E:3602 ||| CD
protein  ||| S:3602 E:3610 ||| NN
kinases  ||| S:3610 E:3618 ||| NNS
[  ||| S:3618 E:3620 ||| -LRB-
10 ||| S:3620 E:3622 ||| CD
,  ||| S:3622 E:3624 ||| ,
11 ||| S:3624 E:3626 ||| CD
,  ||| S:3626 E:3628 ||| ,
12 ||| S:3628 E:3630 ||| CD
,  ||| S:3630 E:3632 ||| ,
13 ||| S:3632 E:3634 ||| CD
,  ||| S:3634 E:3636 ||| ,
14 ||| S:3636 E:3638 ||| CD
] ||| S:3638 E:3639 ||| -RRB-
,  ||| S:3639 E:3641 ||| ,
the  ||| S:3641 E:3645 ||| DT
kinases  ||| S:3645 E:3661 ||| JJ
responsible  ||| S:3661 E:3673 ||| JJ
for  ||| S:3673 E:3677 ||| IN
phosphorylation  ||| S:3677 E:3693 ||| NN
of  ||| S:3693 E:3696 ||| IN
the  ||| S:3696 E:3700 ||| DT
remaining  ||| S:3700 E:3710 ||| JJ
serine  ||| S:3710 E:3725 ||| JJ
residues  ||| S:3725 E:3743 ||| NNS
in  ||| S:3743 E:3746 ||| IN
vivo  ||| S:3746 E:3751 ||| NN
is  ||| S:3751 E:3754 ||| VBZ
not  ||| S:3754 E:3758 ||| RB
clear ||| S:3758 E:3763 ||| JJ
.  ||| S:3763 E:3773 ||| .
The  ||| S:3773 E:3777 ||| DT
activation  ||| S:3777 E:3788 ||| NN
of  ||| S:3788 E:3791 ||| IN
p53  ||| S:3791 E:3795 ||| NN
by  ||| S:3795 E:3798 ||| IN
DNA  ||| S:3798 E:3802 ||| NNP
damage  ||| S:3802 E:3809 ||| NN
or  ||| S:3809 E:3812 ||| CC
oncogenes  ||| S:3812 E:3822 ||| JJ
such  ||| S:3822 E:3827 ||| JJ
as  ||| S:3827 E:3838 ||| IN
ras  ||| S:3838 E:3842 ||| JJ
results  ||| S:3842 E:3850 ||| NNS
in  ||| S:3850 E:3853 ||| IN
either  ||| S:3853 E:3860 ||| DT
growth  ||| S:3860 E:3867 ||| NN
arrest  ||| S:3867 E:3874 ||| NN
or  ||| S:3874 E:3877 ||| CC
apoptosis  ||| S:3877 E:3887 ||| NN
of  ||| S:3887 E:3890 ||| IN
the  ||| S:3890 E:3902 ||| DT
affected  ||| S:3902 E:3911 ||| JJ
cell ||| S:3911 E:3915 ||| NN
.  ||| S:3915 E:3917 ||| .
In  ||| S:3917 E:3920 ||| IN
this  ||| S:3920 E:3925 ||| DT
study ||| S:3925 E:3930 ||| NN
,  ||| S:3930 E:3932 ||| ,
we  ||| S:3932 E:3935 ||| PRP
have  ||| S:3935 E:3940 ||| VBP
examined  ||| S:3940 E:3949 ||| VBN
how  ||| S:3949 E:3953 ||| WRB
Glycogen  ||| S:3953 E:3970 ||| NNP
Synthase  ||| S:3970 E:3979 ||| NNP
Kinase  ||| S:3979 E:3986 ||| NNP
3β  ||| S:3986 E:3989 ||| NNP
( ||| S:3989 E:3990 ||| -LRB-
GSK3β ||| S:3990 E:3995 ||| NNP
) ||| S:3995 E:3996 ||| -RRB-
,  ||| S:3996 E:3998 ||| ,
a  ||| S:3998 E:4000 ||| DT
protein  ||| S:4000 E:4008 ||| NN
kinase  ||| S:4008 E:4015 ||| VBZ
involved  ||| S:4015 E:4024 ||| VBN
in  ||| S:4024 E:4035 ||| IN
tumorigenesis ||| S:4035 E:4048 ||| NN
,  ||| S:4048 E:4050 ||| ,
differentiation  ||| S:4050 E:4066 ||| NN
and  ||| S:4066 E:4070 ||| CC
apoptosis ||| S:4070 E:4079 ||| NN
,  ||| S:4079 E:4081 ||| ,
regulates  ||| S:4081 E:4091 ||| VBZ
the  ||| S:4091 E:4103 ||| DT
function  ||| S:4103 E:4112 ||| NN
of  ||| S:4112 E:4115 ||| IN
p53  ||| S:4115 E:4119 ||| NN
[  ||| S:4119 E:4121 ||| -LRB-
23 ||| S:4121 E:4123 ||| CD
,  ||| S:4123 E:4125 ||| ,
24 ||| S:4125 E:4127 ||| CD
] ||| S:4127 E:4128 ||| -RRB-
.  ||| S:4128 E:4130 ||| .
GSK3β  ||| S:4130 E:4136 ||| NNP
phosphorylates  ||| S:4136 E:4151 ||| VBD
several  ||| S:4151 E:4167 ||| JJ
transcription  ||| S:4167 E:4181 ||| JJ
factors ||| S:4181 E:4188 ||| NNS
,  ||| S:4188 E:4190 ||| ,
including  ||| S:4190 E:4200 ||| VBG
NFATc  ||| S:4200 E:4206 ||| JJ
and  ||| S:4206 E:4210 ||| CC
HSF1  ||| S:4210 E:4215 ||| NNP
[  ||| S:4215 E:4217 ||| -LRB-
24 ||| S:4217 E:4219 ||| CD
,  ||| S:4219 E:4221 ||| ,
25 ||| S:4221 E:4223 ||| CD
,  ||| S:4223 E:4233 ||| ,
26 ||| S:4233 E:4235 ||| CD
,  ||| S:4235 E:4237 ||| ,
27 ||| S:4237 E:4239 ||| CD
] ||| S:4239 E:4240 ||| -RRB-
.  ||| S:4240 E:4242 ||| .
GSK3β  ||| S:4242 E:4248 ||| NNP
is  ||| S:4248 E:4251 ||| VBZ
constitutively  ||| S:4251 E:4266 ||| JJ
active  ||| S:4266 E:4273 ||| JJ
in  ||| S:4273 E:4276 ||| IN
resting  ||| S:4276 E:4284 ||| JJ
cells  ||| S:4284 E:4298 ||| NNS
but  ||| S:4298 E:4302 ||| CC
is  ||| S:4302 E:4305 ||| VBZ
inhibited  ||| S:4305 E:4315 ||| VBN
when  ||| S:4315 E:4320 ||| WRB
cells  ||| S:4320 E:4326 ||| NNS
are  ||| S:4326 E:4330 ||| VBP
exposed  ||| S:4330 E:4338 ||| VBN
to  ||| S:4338 E:4341 ||| TO
growth  ||| S:4341 E:4348 ||| NN
factors  ||| S:4348 E:4356 ||| NNS
[  ||| S:4356 E:4366 ||| -LRB-
24 ||| S:4366 E:4368 ||| CD
,  ||| S:4368 E:4370 ||| ,
28 ||| S:4370 E:4372 ||| CD
] ||| S:4372 E:4373 ||| -RRB-
.  ||| S:4373 E:4383 ||| .
GSK3  ||| S:4383 E:4388 ||| NNP
inhibition  ||| S:4388 E:4399 ||| NN
occurs  ||| S:4399 E:4406 ||| VBZ
when  ||| S:4406 E:4411 ||| WRB
the  ||| S:4411 E:4415 ||| DT
p110-PI  ||| S:4415 E:4423 ||| NNP
3-kinase ||| S:4423 E:4431 ||| NNP
/ ||| S:4431 E:4432 ||| NNP
Protein  ||| S:4432 E:4448 ||| NNP
Kinase  ||| S:4448 E:4455 ||| NNP
B  ||| S:4455 E:4457 ||| NNP
( ||| S:4457 E:4458 ||| -LRB-
PKB ||| S:4458 E:4461 ||| NNP
)  ||| S:4461 E:4463 ||| -RRB-
pathway  ||| S:4463 E:4471 ||| NN
is  ||| S:4471 E:4474 ||| VBZ
activated  ||| S:4474 E:4484 ||| VBN
by  ||| S:4484 E:4487 ||| IN
growth  ||| S:4487 E:4494 ||| NN
factors  ||| S:4494 E:4502 ||| NNS
[  ||| S:4502 E:4504 ||| -LRB-
23 ||| S:4504 E:4506 ||| CD
,  ||| S:4506 E:4516 ||| ,
24 ||| S:4516 E:4518 ||| CD
,  ||| S:4518 E:4520 ||| ,
25 ||| S:4520 E:4522 ||| CD
,  ||| S:4522 E:4524 ||| ,
29 ||| S:4524 E:4526 ||| CD
] ||| S:4526 E:4527 ||| -RRB-
.  ||| S:4527 E:4529 ||| .
Activated  ||| S:4529 E:4539 ||| NNP
PKB  ||| S:4539 E:4543 ||| NNP
then  ||| S:4543 E:4548 ||| RB
phosphorylates  ||| S:4548 E:4563 ||| CD
GSK3β ||| S:4563 E:4568 ||| CD
,  ||| S:4568 E:4578 ||| ,
inhibiting  ||| S:4578 E:4589 ||| FW
GSK3  ||| S:4589 E:4594 ||| FW
kinase  ||| S:4594 E:4601 ||| FW
activity  ||| S:4601 E:4610 ||| FW
[  ||| S:4610 E:4612 ||| -LRB-
29 ||| S:4612 E:4614 ||| CD
] ||| S:4614 E:4615 ||| -RRB-
.  ||| S:4615 E:4617 ||| .
This  ||| S:4617 E:4622 ||| DT
activation  ||| S:4622 E:4633 ||| NN
of  ||| S:4633 E:4644 ||| IN
the  ||| S:4644 E:4648 ||| DT
p110-PI  ||| S:4648 E:4656 ||| NNP
3-kinase ||| S:4656 E:4664 ||| NNP
/ ||| S:4664 E:4665 ||| NNP
PKB  ||| S:4665 E:4669 ||| NNP
pathway ||| S:4669 E:4676 ||| NN
,  ||| S:4676 E:4678 ||| ,
and  ||| S:4678 E:4682 ||| CC
inhibition  ||| S:4682 E:4693 ||| NN
of  ||| S:4693 E:4696 ||| IN
GSK3 ||| S:4696 E:4700 ||| NNP
,  ||| S:4700 E:4710 ||| ,
delivers  ||| S:4710 E:4719 ||| VBZ
a  ||| S:4719 E:4721 ||| DT
strong  ||| S:4721 E:4728 ||| JJ
anti-apoptotic  ||| S:4728 E:4743 ||| JJ
signal  ||| S:4743 E:4750 ||| NN
to  ||| S:4750 E:4753 ||| TO
the  ||| S:4753 E:4757 ||| DT
cell  ||| S:4757 E:4762 ||| NN
[  ||| S:4762 E:4764 ||| -LRB-
23 ||| S:4764 E:4766 ||| CD
,  ||| S:4766 E:4776 ||| ,
24 ||| S:4776 E:4778 ||| CD
,  ||| S:4778 E:4780 ||| ,
25 ||| S:4780 E:4782 ||| CD
] ||| S:4782 E:4783 ||| -RRB-
.  ||| S:4783 E:4785 ||| .
Given  ||| S:4785 E:4791 ||| VBN
the  ||| S:4791 E:4795 ||| DT
well  ||| S:4795 E:4800 ||| RB
characterized  ||| S:4800 E:4814 ||| VBN
role  ||| S:4814 E:4819 ||| NN
of  ||| S:4819 E:4822 ||| IN
p53  ||| S:4822 E:4826 ||| NN
in  ||| S:4826 E:4837 ||| IN
apoptosis  ||| S:4837 E:4847 ||| NNS
[  ||| S:4847 E:4849 ||| -LRB-
3 ||| S:4849 E:4850 ||| LS
,  ||| S:4850 E:4852 ||| ,
4 ||| S:4852 E:4853 ||| CD
,  ||| S:4853 E:4855 ||| ,
5 ||| S:4855 E:4856 ||| CD
] ||| S:4856 E:4857 ||| -RRB-
,  ||| S:4857 E:4859 ||| ,
we  ||| S:4859 E:4862 ||| PRP
examined  ||| S:4862 E:4871 ||| VBD
if  ||| S:4871 E:4874 ||| IN
GSK3p  ||| S:4874 E:4880 ||| CD
participates  ||| S:4880 E:4893 ||| NN
in  ||| S:4893 E:4904 ||| IN
the  ||| S:4904 E:4908 ||| DT
regulation  ||| S:4908 E:4919 ||| NN
of  ||| S:4919 E:4922 ||| IN
the  ||| S:4922 E:4926 ||| DT
p53  ||| S:4926 E:4930 ||| NN
protein ||| S:4930 E:4937 ||| NN
.  ||| S:4937 E:4947 ||| .
GSK3  ||| S:4947 E:4952 ||| NNP
phosphorylates  ||| S:4952 E:4967 ||| VBD
the  ||| S:4967 E:4971 ||| DT
consensus  ||| S:4971 E:4981 ||| NN
sequence  ||| S:4981 E:4998 ||| NN
Ser-X-X-X-Ser ||| S:4998 E:5011 ||| NNS
( ||| S:5011 E:5012 ||| -LRB-
P ||| S:5012 E:5013 ||| NN
) ||| S:5013 E:5014 ||| -RRB-
,  ||| S:5014 E:5016 ||| ,
where  ||| S:5016 E:5022 ||| WRB
the  ||| S:5022 E:5026 ||| DT
C-terminal  ||| S:5026 E:5037 ||| JJ
serine  ||| S:5037 E:5044 ||| JJ
residue  ||| S:5044 E:5052 ||| NN
is  ||| S:5052 E:5063 ||| VBZ
already  ||| S:5063 E:5071 ||| RB
phosphorylated  ||| S:5071 E:5086 ||| JJ
[  ||| S:5086 E:5088 ||| -LRB-
24 ||| S:5088 E:5090 ||| CD
,  ||| S:5090 E:5092 ||| ,
28 ||| S:5092 E:5094 ||| CD
] ||| S:5094 E:5095 ||| -RRB-
.  ||| S:5095 E:5097 ||| .
Thus  ||| S:5097 E:5102 ||| RB
GSK3  ||| S:5102 E:5107 ||| RB
only  ||| S:5107 E:5120 ||| RB
phosphorylates  ||| S:5120 E:5135 ||| JJ
target  ||| S:5135 E:5142 ||| NN
proteins  ||| S:5142 E:5151 ||| NNS
which  ||| S:5151 E:5157 ||| WDT
have  ||| S:5157 E:5162 ||| VBP
already  ||| S:5162 E:5170 ||| RB
been  ||| S:5170 E:5183 ||| VBN
phosphorylated  ||| S:5183 E:5198 ||| VBN
by  ||| S:5198 E:5201 ||| IN
a  ||| S:5201 E:5203 ||| DT
separate ||| S:5203 E:5211 ||| JJ
,  ||| S:5211 E:5213 ||| ,
priming  ||| S:5213 E:5221 ||| CD
kinase.  ||| S:5221 E:5229 ||| CD
p53  ||| S:5229 E:5233 ||| NN
contains  ||| S:5233 E:5250 ||| VBZ
5  ||| S:5250 E:5252 ||| CD
potential  ||| S:5252 E:5262 ||| JJ
GSK3  ||| S:5262 E:5267 ||| CD
phosphorylation  ||| S:5267 E:5283 ||| CD
sites ||| S:5283 E:5288 ||| NNS
,  ||| S:5288 E:5290 ||| ,
3  ||| S:5290 E:5292 ||| CD
in  ||| S:5292 E:5295 ||| IN
the  ||| S:5295 E:5299 ||| DT
N-terminal  ||| S:5299 E:5318 ||| JJ
transactivation  ||| S:5318 E:5334 ||| JJ
domain  ||| S:5334 E:5341 ||| NN
and  ||| S:5341 E:5345 ||| CC
2  ||| S:5345 E:5347 ||| CD
in  ||| S:5347 E:5350 ||| IN
the  ||| S:5350 E:5354 ||| DT
C-terminal  ||| S:5354 E:5365 ||| JJ
regulatory  ||| S:5365 E:5384 ||| JJ
domain ||| S:5384 E:5390 ||| NN
.  ||| S:5390 E:5392 ||| .
Here ||| S:5392 E:5396 ||| RB
,  ||| S:5396 E:5398 ||| ,
we  ||| S:5398 E:5401 ||| PRP
show  ||| S:5401 E:5406 ||| VBP
that  ||| S:5406 E:5411 ||| IN
GSK3β ||| S:5411 E:5416 ||| NNP
,  ||| S:5416 E:5418 ||| ,
but  ||| S:5418 E:5422 ||| CC
not  ||| S:5422 E:5426 ||| RB
GSK3α ||| S:5426 E:5431 ||| CD
,  ||| S:5431 E:5433 ||| ,
can  ||| S:5433 E:5445 ||| MD
phosphorylate  ||| S:5445 E:5459 ||| VB
serine  ||| S:5459 E:5466 ||| CD
33  ||| S:5466 E:5469 ||| CD
of  ||| S:5469 E:5472 ||| IN
p53  ||| S:5472 E:5485 ||| NN
in  ||| S:5485 E:5488 ||| IN
vitro  ||| S:5488 E:5494 ||| NN
when  ||| S:5494 E:5499 ||| WRB
serine  ||| S:5499 E:5506 ||| JJ
37  ||| S:5506 E:5509 ||| CD
is  ||| S:5509 E:5512 ||| VBZ
already  ||| S:5512 E:5528 ||| RB
phosphorylated ||| S:5528 E:5542 ||| VBN
.  ||| S:5542 E:5544 ||| .
Further ||| S:5544 E:5551 ||| RB
,  ||| S:5551 E:5553 ||| ,
GSK3β  ||| S:5553 E:5559 ||| NNP
can  ||| S:5559 E:5563 ||| MD
increase  ||| S:5563 E:5572 ||| VB
p53 ||| S:5572 E:5575 ||| NN
's  ||| S:5575 E:5586 ||| POS
transcriptional  ||| S:5586 E:5602 ||| JJ
activity  ||| S:5602 E:5620 ||| NN
in  ||| S:5620 E:5623 ||| IN
vivo ||| S:5623 E:5627 ||| NN
,  ||| S:5627 E:5629 ||| ,
and  ||| S:5629 E:5633 ||| CC
this  ||| S:5633 E:5638 ||| DT
activation  ||| S:5638 E:5649 ||| NN
is  ||| S:5649 E:5652 ||| VBZ
lost  ||| S:5652 E:5665 ||| VBN
when  ||| S:5665 E:5670 ||| WRB
serine  ||| S:5670 E:5677 ||| JJ
33  ||| S:5677 E:5680 ||| CD
is  ||| S:5680 E:5683 ||| VBZ
mutated  ||| S:5683 E:5691 ||| VBN
to  ||| S:5691 E:5694 ||| TO
alanine ||| S:5694 E:5701 ||| VB
.  ||| S:5701 E:5725 ||| .
Results  ||| S:5725 E:5741 ||| NNS
The  ||| S:5741 E:5745 ||| DT
p53  ||| S:5745 E:5749 ||| NN
protein  ||| S:5749 E:5757 ||| NN
contains  ||| S:5757 E:5766 ||| VBZ
several  ||| S:5766 E:5774 ||| JJ
serine  ||| S:5774 E:5781 ||| JJ
residues  ||| S:5781 E:5790 ||| NNS
which  ||| S:5790 E:5804 ||| WDT
are  ||| S:5804 E:5808 ||| VBP
located  ||| S:5808 E:5816 ||| VBN
within  ||| S:5816 E:5823 ||| IN
potential  ||| S:5823 E:5833 ||| JJ
GSK3  ||| S:5833 E:5838 ||| CD
phosphorylation  ||| S:5838 E:5854 ||| CD
sites ||| S:5854 E:5859 ||| NNS
.  ||| S:5859 E:5869 ||| .
Protein  ||| S:5869 E:5877 ||| NN
kinases  ||| S:5877 E:5885 ||| NNS
which  ||| S:5885 E:5891 ||| WDT
can  ||| S:5891 E:5895 ||| MD
phosphorylate  ||| S:5895 E:5909 ||| VB
p53  ||| S:5909 E:5913 ||| NN
within  ||| S:5913 E:5920 ||| IN
these  ||| S:5920 E:5934 ||| DT
predicted  ||| S:5934 E:5944 ||| VBD
GSK3  ||| S:5944 E:5949 ||| CD
sites  ||| S:5949 E:5955 ||| NNS
include  ||| S:5955 E:5963 ||| VBP
MAP  ||| S:5963 E:5967 ||| JJ
kinase ||| S:5967 E:5973 ||| NN
,  ||| S:5973 E:5975 ||| ,
Protein  ||| S:5975 E:5983 ||| NNP
Kinase  ||| S:5983 E:5990 ||| NNP
A ||| S:5990 E:5991 ||| NNP
,  ||| S:5991 E:6001 ||| ,
Protein  ||| S:6001 E:6009 ||| NNP
Kinase  ||| S:6009 E:6016 ||| NNP
C ||| S:6016 E:6017 ||| NNP
,  ||| S:6017 E:6019 ||| ,
Casein  ||| S:6019 E:6026 ||| NNP
Kinase  ||| S:6026 E:6033 ||| NNP
II ||| S:6033 E:6035 ||| NNP
,  ||| S:6035 E:6037 ||| ,
Jun  ||| S:6037 E:6041 ||| NNP
kinase  ||| S:6041 E:6048 ||| NNS
( ||| S:6048 E:6049 ||| -LRB-
JNK ||| S:6049 E:6052 ||| NNP
)  ||| S:6052 E:6054 ||| -RRB-
and  ||| S:6054 E:6066 ||| CC
DNA-dependent  ||| S:6066 E:6080 ||| NNP
Protein  ||| S:6080 E:6088 ||| NNP
Kinase  ||| S:6088 E:6095 ||| NNP
( ||| S:6095 E:6096 ||| -LRB-
DNA-PK ||| S:6096 E:6102 ||| NNP
)  ||| S:6102 E:6104 ||| -RRB-
[  ||| S:6104 E:6106 ||| -LRB-
30 ||| S:6106 E:6108 ||| CD
,  ||| S:6108 E:6110 ||| ,
31 ||| S:6110 E:6112 ||| CD
,  ||| S:6112 E:6114 ||| ,
32 ||| S:6114 E:6116 ||| CD
,  ||| S:6116 E:6118 ||| ,
33 ||| S:6118 E:6120 ||| CD
,  ||| S:6120 E:6122 ||| ,
34 ||| S:6122 E:6124 ||| CD
,  ||| S:6124 E:6134 ||| ,
35 ||| S:6134 E:6136 ||| CD
] ||| S:6136 E:6137 ||| -RRB-
.  ||| S:6137 E:6139 ||| .
These  ||| S:6139 E:6145 ||| DT
kinases  ||| S:6145 E:6153 ||| NN
were  ||| S:6153 E:6158 ||| VBD
examined  ||| S:6158 E:6167 ||| VBN
to  ||| S:6167 E:6170 ||| TO
determine  ||| S:6170 E:6180 ||| VB
if  ||| S:6180 E:6183 ||| IN
they  ||| S:6183 E:6188 ||| PRP
can  ||| S:6188 E:6200 ||| MD
act  ||| S:6200 E:6204 ||| VB
as  ||| S:6204 E:6207 ||| IN
the  ||| S:6207 E:6211 ||| DT
priming  ||| S:6211 E:6219 ||| JJ
kinase  ||| S:6219 E:6226 ||| NN
for  ||| S:6226 E:6230 ||| IN
either  ||| S:6230 E:6237 ||| RB
of  ||| S:6237 E:6240 ||| IN
the  ||| S:6240 E:6244 ||| DT
2  ||| S:6244 E:6246 ||| CD
isoforms  ||| S:6246 E:6255 ||| NN
of  ||| S:6255 E:6266 ||| IN
GSK3 ||| S:6266 E:6270 ||| NNP
,  ||| S:6270 E:6272 ||| ,
GSK3α  ||| S:6272 E:6278 ||| NNP
and  ||| S:6278 E:6282 ||| CC
GSK3β ||| S:6282 E:6287 ||| NNP
.  ||| S:6287 E:6289 ||| .
The  ||| S:6289 E:6293 ||| DT
general  ||| S:6293 E:6301 ||| JJ
protocol  ||| S:6301 E:6310 ||| NN
was  ||| S:6310 E:6314 ||| VBD
to  ||| S:6314 E:6317 ||| TO
incubate  ||| S:6317 E:6334 ||| VB
purified  ||| S:6334 E:6343 ||| JJ
priming  ||| S:6343 E:6351 ||| JJ
kinases  ||| S:6351 E:6359 ||| NN
with  ||| S:6359 E:6364 ||| IN
p53-GST  ||| S:6364 E:6372 ||| CD
fusion  ||| S:6372 E:6379 ||| NN
protein  ||| S:6379 E:6387 ||| NN
and  ||| S:6387 E:6399 ||| CC
ATP  ||| S:6399 E:6403 ||| NNP
for  ||| S:6403 E:6407 ||| IN
5  ||| S:6407 E:6409 ||| CD
h ||| S:6409 E:6410 ||| NN
,  ||| S:6410 E:6412 ||| ,
then  ||| S:6412 E:6417 ||| RB
heat  ||| S:6417 E:6422 ||| VB
inactivate  ||| S:6422 E:6433 ||| VBN
the  ||| S:6433 E:6437 ||| DT
priming  ||| S:6437 E:6445 ||| JJ
kinase ||| S:6445 E:6451 ||| NN
.  ||| S:6451 E:6461 ||| .
Preliminary  ||| S:6461 E:6473 ||| JJ
experiments  ||| S:6473 E:6485 ||| NNS
indicated  ||| S:6485 E:6495 ||| VBD
that  ||| S:6495 E:6500 ||| IN
each  ||| S:6500 E:6505 ||| DT
of  ||| S:6505 E:6508 ||| IN
the  ||| S:6508 E:6512 ||| DT
tested  ||| S:6512 E:6527 ||| JJ
kinases  ||| S:6527 E:6535 ||| NN
was  ||| S:6535 E:6539 ||| VBD
able  ||| S:6539 E:6544 ||| JJ
to  ||| S:6544 E:6547 ||| TO
phosphorylate  ||| S:6547 E:6561 ||| CD
p53-GST  ||| S:6561 E:6569 ||| CD
under  ||| S:6569 E:6575 ||| IN
the  ||| S:6575 E:6587 ||| DT
experimental  ||| S:6587 E:6600 ||| JJ
conditions  ||| S:6600 E:6611 ||| NNS
( ||| S:6611 E:6612 ||| -LRB-
data  ||| S:6612 E:6617 ||| NNS
not  ||| S:6617 E:6621 ||| RB
shown ||| S:6621 E:6626 ||| VBN
) ||| S:6626 E:6627 ||| -RRB-
.  ||| S:6627 E:6629 ||| .
Aliquots  ||| S:6629 E:6638 ||| NNP
of  ||| S:6638 E:6641 ||| IN
the  ||| S:6641 E:6653 ||| DT
prephosphorylated  ||| S:6653 E:6671 ||| JJ
p53-GST  ||| S:6671 E:6679 ||| NN
were  ||| S:6679 E:6684 ||| VBD
then  ||| S:6684 E:6689 ||| RB
incubated  ||| S:6689 E:6699 ||| VBN
with  ||| S:6699 E:6704 ||| IN
or  ||| S:6704 E:6715 ||| CC
without  ||| S:6715 E:6723 ||| IN
recombinant  ||| S:6723 E:6735 ||| JJ
GSK3α  ||| S:6735 E:6741 ||| NN
or  ||| S:6741 E:6744 ||| CC
GSK3β  ||| S:6744 E:6750 ||| NNP
and  ||| S:6750 E:6754 ||| CC
32P-ATP  ||| S:6754 E:6762 ||| CD
to  ||| S:6762 E:6765 ||| TO
measure  ||| S:6765 E:6781 ||| VB
p53  ||| S:6781 E:6785 ||| CD
phosphorylation.  ||| S:6785 E:6810 ||| CD
p53-GST  ||| S:6810 E:6818 ||| CD
preincubated  ||| S:6818 E:6831 ||| NN
in  ||| S:6831 E:6834 ||| IN
buffer  ||| S:6834 E:6841 ||| NN
alone ||| S:6841 E:6846 ||| RB
,  ||| S:6846 E:6848 ||| ,
and  ||| S:6848 E:6852 ||| CC
then  ||| S:6852 E:6857 ||| RB
exposed  ||| S:6857 E:6873 ||| VBN
to  ||| S:6873 E:6876 ||| TO
the  ||| S:6876 E:6880 ||| DT
heat  ||| S:6880 E:6885 ||| NN
inactivation  ||| S:6885 E:6898 ||| NN
protocol  ||| S:6898 E:6907 ||| NN
was  ||| S:6907 E:6911 ||| VBD
not  ||| S:6911 E:6915 ||| RB
phosphorylated  ||| S:6915 E:6930 ||| VBN
by  ||| S:6930 E:6941 ||| IN
either  ||| S:6941 E:6948 ||| DT
GSK3α  ||| S:6948 E:6954 ||| NNP
or  ||| S:6954 E:6957 ||| CC
GSK3β  ||| S:6957 E:6963 ||| NNP
( ||| S:6963 E:6964 ||| -LRB-
fig  ||| S:6964 E:6968 ||| CD
1 ||| S:6968 E:6969 ||| CD
,  ||| S:6969 E:6971 ||| ,
Control ||| S:6971 E:6978 ||| NNP
) ||| S:6978 E:6979 ||| -RRB-
.  ||| S:6979 E:6981 ||| .
Autophosphorylation  ||| S:6981 E:7009 ||| NNP
of  ||| S:7009 E:7012 ||| IN
GSK3α  ||| S:7012 E:7018 ||| NNP
and  ||| S:7018 E:7022 ||| CC
GSK3β  ||| S:7022 E:7028 ||| NNP
can  ||| S:7028 E:7032 ||| MD
be  ||| S:7032 E:7035 ||| VB
seen  ||| S:7035 E:7040 ||| VBN
( ||| S:7040 E:7041 ||| -LRB-
figure  ||| S:7041 E:7048 ||| NN
1 ||| S:7048 E:7049 ||| CD
) ||| S:7049 E:7050 ||| -RRB-
.  ||| S:7050 E:7052 ||| .
Unphosphorylated  ||| S:7052 E:7077 ||| NNP
p53-GST  ||| S:7077 E:7085 ||| NNP
is  ||| S:7085 E:7088 ||| VBZ
therefore  ||| S:7088 E:7098 ||| RB
not  ||| S:7098 E:7102 ||| RB
a  ||| S:7102 E:7104 ||| DT
substrate  ||| S:7104 E:7114 ||| NN
for  ||| S:7114 E:7118 ||| IN
GSK3α  ||| S:7118 E:7124 ||| NNP
or  ||| S:7124 E:7127 ||| CC
GSK3β  ||| S:7127 E:7142 ||| CD
in  ||| S:7142 E:7145 ||| IN
vitro.  ||| S:7145 E:7152 ||| NNP
p53-GST  ||| S:7152 E:7160 ||| NNP
was  ||| S:7160 E:7164 ||| VBD
then  ||| S:7164 E:7177 ||| RB
prephosphorylated  ||| S:7177 E:7195 ||| VBN
with  ||| S:7195 E:7200 ||| IN
MAP  ||| S:7200 E:7204 ||| NNP
kinase ||| S:7204 E:7210 ||| NN
,  ||| S:7210 E:7212 ||| ,
S6  ||| S:7212 E:7215 ||| CD
kinase ||| S:7215 E:7221 ||| NN
,  ||| S:7221 E:7223 ||| ,
Protein  ||| S:7223 E:7239 ||| NNP
Kinase  ||| S:7239 E:7246 ||| NNP
A ||| S:7246 E:7247 ||| NNP
,  ||| S:7247 E:7249 ||| ,
DNA-PK  ||| S:7249 E:7256 ||| JJ
and  ||| S:7256 E:7260 ||| CC
Protein  ||| S:7260 E:7268 ||| NNP
Kinase  ||| S:7268 E:7275 ||| NNP
C  ||| S:7275 E:7277 ||| NNP
( ||| S:7277 E:7278 ||| -LRB-
fig  ||| S:7278 E:7282 ||| CD
1 ||| S:7282 E:7283 ||| CD
)  ||| S:7283 E:7285 ||| -RRB-
or  ||| S:7285 E:7288 ||| CC
Casein  ||| S:7288 E:7303 ||| NNP
Kinase  ||| S:7303 E:7310 ||| NNP
II  ||| S:7310 E:7313 ||| NNP
and  ||| S:7313 E:7317 ||| CC
JNK1 ||| S:7317 E:7321 ||| NNP
/ ||| S:7321 E:7322 ||| NNP
JNK2  ||| S:7322 E:7327 ||| NNP
( ||| S:7327 E:7328 ||| -LRB-
data  ||| S:7328 E:7333 ||| NNS
not  ||| S:7333 E:7337 ||| RB
shown ||| S:7337 E:7342 ||| VBN
) ||| S:7342 E:7343 ||| -RRB-
.  ||| S:7343 E:7345 ||| .
Following  ||| S:7345 E:7363 ||| VBG
incubation  ||| S:7363 E:7374 ||| NN
in  ||| S:7374 E:7377 ||| IN
each  ||| S:7377 E:7382 ||| DT
of  ||| S:7382 E:7385 ||| IN
the  ||| S:7385 E:7389 ||| DT
primary  ||| S:7389 E:7397 ||| JJ
kinases ||| S:7397 E:7404 ||| NN
,  ||| S:7404 E:7406 ||| ,
the  ||| S:7406 E:7418 ||| DT
prephosphorylated  ||| S:7418 E:7436 ||| JJ
p53-GST  ||| S:7436 E:7444 ||| NN
was  ||| S:7444 E:7448 ||| VBD
then  ||| S:7448 E:7453 ||| RB
incubated  ||| S:7453 E:7463 ||| VBN
with  ||| S:7463 E:7468 ||| IN
32P-ATP  ||| S:7468 E:7484 ||| NNP
and  ||| S:7484 E:7488 ||| CC
either  ||| S:7488 E:7495 ||| DT
GSK3α  ||| S:7495 E:7501 ||| NNP
or  ||| S:7501 E:7504 ||| CC
GSK3β ||| S:7504 E:7509 ||| NNP
.  ||| S:7509 E:7511 ||| .
Prephosphorylation  ||| S:7511 E:7530 ||| NNP
of  ||| S:7530 E:7533 ||| IN
p53-GST  ||| S:7533 E:7541 ||| CD
by  ||| S:7541 E:7552 ||| IN
MAP  ||| S:7552 E:7556 ||| NNP
kinase ||| S:7556 E:7562 ||| NN
,  ||| S:7562 E:7564 ||| ,
S6  ||| S:7564 E:7567 ||| CD
kinase ||| S:7567 E:7573 ||| NN
,  ||| S:7573 E:7575 ||| ,
Protein  ||| S:7575 E:7583 ||| NNP
Kinase  ||| S:7583 E:7590 ||| NNP
A  ||| S:7590 E:7592 ||| NNP
or  ||| S:7592 E:7595 ||| CC
Protein  ||| S:7595 E:7603 ||| NNP
Kinase  ||| S:7603 E:7610 ||| NNP
C  ||| S:7610 E:7620 ||| NNP
( ||| S:7620 E:7621 ||| -LRB-
fig  ||| S:7621 E:7625 ||| CD
1 ||| S:7625 E:7626 ||| CD
)  ||| S:7626 E:7628 ||| -RRB-
or  ||| S:7628 E:7631 ||| CC
Casein  ||| S:7631 E:7638 ||| NNP
Kinase  ||| S:7638 E:7645 ||| NNP
II  ||| S:7645 E:7648 ||| NNP
or  ||| S:7648 E:7651 ||| CC
JNK1  ||| S:7651 E:7656 ||| NNP
or  ||| S:7656 E:7659 ||| CC
JNK  ||| S:7659 E:7663 ||| NNP
2  ||| S:7663 E:7665 ||| CD
( ||| S:7665 E:7666 ||| -LRB-
data  ||| S:7666 E:7671 ||| NNS
not  ||| S:7671 E:7683 ||| RB
shown ||| S:7683 E:7688 ||| VBN
)  ||| S:7688 E:7690 ||| -RRB-
failed  ||| S:7690 E:7697 ||| VBD
to  ||| S:7697 E:7700 ||| TO
create  ||| S:7700 E:7707 ||| VB
a  ||| S:7707 E:7709 ||| DT
phosphorylation  ||| S:7709 E:7725 ||| JJ
site  ||| S:7725 E:7730 ||| NN
for  ||| S:7730 E:7734 ||| IN
either  ||| S:7734 E:7749 ||| DT
GSK3α  ||| S:7749 E:7755 ||| NNP
or  ||| S:7755 E:7758 ||| CC
GSK3β ||| S:7758 E:7763 ||| NNP
.  ||| S:7763 E:7765 ||| .
However ||| S:7765 E:7772 ||| RB
,  ||| S:7772 E:7774 ||| ,
prephosphorylation  ||| S:7774 E:7793 ||| VBG
of  ||| S:7793 E:7796 ||| IN
p53-GST  ||| S:7796 E:7804 ||| CD
by  ||| S:7804 E:7815 ||| IN
DNA-PK  ||| S:7815 E:7822 ||| NNP
resulted  ||| S:7822 E:7831 ||| VBD
in  ||| S:7831 E:7834 ||| IN
strong  ||| S:7834 E:7841 ||| JJ
phosphorylation  ||| S:7841 E:7857 ||| NN
of  ||| S:7857 E:7860 ||| IN
p53  ||| S:7860 E:7864 ||| NN
by  ||| S:7864 E:7867 ||| IN
GSK3β  ||| S:7867 E:7881 ||| NNP
( ||| S:7881 E:7882 ||| -LRB-
fig  ||| S:7882 E:7886 ||| CD
1 ||| S:7886 E:7887 ||| CD
)  ||| S:7887 E:7889 ||| -RRB-
but  ||| S:7889 E:7893 ||| CC
not  ||| S:7893 E:7897 ||| RB
GSK3α ||| S:7897 E:7902 ||| CD
.  ||| S:7902 E:7904 ||| .
GST  ||| S:7904 E:7908 ||| NNP
protein  ||| S:7908 E:7916 ||| NN
alone  ||| S:7916 E:7922 ||| RB
incubated  ||| S:7922 E:7932 ||| VBN
with  ||| S:7932 E:7945 ||| IN
DNA-PK  ||| S:7945 E:7952 ||| NNP
was  ||| S:7952 E:7956 ||| VBD
not  ||| S:7956 E:7960 ||| RB
phosphorylated  ||| S:7960 E:7975 ||| VBN
by  ||| S:7975 E:7978 ||| IN
GSK3β  ||| S:7978 E:7984 ||| NNP
( ||| S:7984 E:7985 ||| -LRB-
data  ||| S:7985 E:7990 ||| NNS
not  ||| S:7990 E:7994 ||| RB
shown ||| S:7994 E:7999 ||| VBN
) ||| S:7999 E:8000 ||| -RRB-
.  ||| S:8000 E:8010 ||| .
Since  ||| S:8010 E:8016 ||| IN
there  ||| S:8016 E:8022 ||| EX
was  ||| S:8022 E:8026 ||| VBD
no  ||| S:8026 E:8029 ||| DT
significant  ||| S:8029 E:8041 ||| JJ
phosphorylation  ||| S:8041 E:8057 ||| NN
of  ||| S:8057 E:8060 ||| IN
p53-GST  ||| S:8060 E:8076 ||| CD
by  ||| S:8076 E:8079 ||| IN
GSK3α  ||| S:8079 E:8085 ||| NNP
( ||| S:8085 E:8086 ||| -LRB-
fig  ||| S:8086 E:8090 ||| CD
1 ||| S:8090 E:8091 ||| CD
) ||| S:8091 E:8092 ||| -RRB-
,  ||| S:8092 E:8094 ||| ,
this  ||| S:8094 E:8099 ||| DT
indicates  ||| S:8099 E:8109 ||| VBZ
that  ||| S:8109 E:8114 ||| DT
phosphorylation  ||| S:8114 E:8130 ||| NN
of  ||| S:8130 E:8141 ||| IN
p53  ||| S:8141 E:8145 ||| NN
by  ||| S:8145 E:8148 ||| IN
DNA-PK ||| S:8148 E:8154 ||| NNP
,  ||| S:8154 E:8165 ||| ,
in  ||| S:8165 E:8168 ||| IN
vitro ||| S:8168 E:8173 ||| NN
,  ||| S:8173 E:8175 ||| ,
creates  ||| S:8175 E:8183 ||| VBZ
a  ||| S:8183 E:8185 ||| DT
site  ||| S:8185 E:8190 ||| NN
for  ||| S:8190 E:8194 ||| IN
GSK3β  ||| S:8194 E:8200 ||| CD
to  ||| S:8200 E:8211 ||| TO
phosphorylate  ||| S:8211 E:8225 ||| VB
p53 ||| S:8225 E:8228 ||| NN
.  ||| S:8228 E:8238 ||| .
Next ||| S:8238 E:8242 ||| JJ
,  ||| S:8242 E:8244 ||| ,
we  ||| S:8244 E:8247 ||| PRP
set  ||| S:8247 E:8251 ||| VBD
out  ||| S:8251 E:8255 ||| RP
to  ||| S:8255 E:8258 ||| TO
identify  ||| S:8258 E:8267 ||| VB
the  ||| S:8267 E:8271 ||| DT
exact  ||| S:8271 E:8277 ||| JJ
amino-acid ||| S:8277 E:8287 ||| NN
( ||| S:8287 E:8288 ||| -LRB-
s ||| S:8288 E:8289 ||| LS
)  ||| S:8289 E:8299 ||| -RRB-
within  ||| S:8299 E:8306 ||| IN
the  ||| S:8306 E:8310 ||| DT
p53  ||| S:8310 E:8314 ||| NN
protein  ||| S:8314 E:8322 ||| NN
which  ||| S:8322 E:8328 ||| WDT
were  ||| S:8328 E:8333 ||| VBD
phosphorylated  ||| S:8333 E:8348 ||| VBN
by  ||| S:8348 E:8351 ||| IN
GSK3β.  ||| S:8351 E:8366 ||| CD
p53  ||| S:8366 E:8370 ||| NN
is  ||| S:8370 E:8373 ||| VBZ
phosphorylated  ||| S:8373 E:8388 ||| VBN
by  ||| S:8388 E:8391 ||| IN
DNA-PK  ||| S:8391 E:8398 ||| JJ
at  ||| S:8398 E:8401 ||| IN
serines  ||| S:8401 E:8409 ||| CD
15  ||| S:8409 E:8412 ||| CD
and  ||| S:8412 E:8416 ||| CC
37  ||| S:8416 E:8419 ||| CD
[  ||| S:8419 E:8421 ||| -LRB-
32 ||| S:8421 E:8423 ||| CD
] ||| S:8423 E:8424 ||| -RRB-
.  ||| S:8424 E:8434 ||| .
Of  ||| S:8434 E:8437 ||| IN
these  ||| S:8437 E:8443 ||| DT
2  ||| S:8443 E:8445 ||| CD
sites ||| S:8445 E:8450 ||| NNS
,  ||| S:8450 E:8452 ||| ,
the  ||| S:8452 E:8456 ||| DT
sequence  ||| S:8456 E:8465 ||| NN
around  ||| S:8465 E:8472 ||| IN
serine  ||| S:8472 E:8479 ||| CD
37  ||| S:8479 E:8482 ||| CD
contains  ||| S:8482 E:8491 ||| VBZ
a  ||| S:8491 E:8501 ||| DT
predicted  ||| S:8501 E:8511 ||| VBD
GSK3  ||| S:8511 E:8516 ||| CD
phosphorylation  ||| S:8516 E:8532 ||| JJ
site  ||| S:8532 E:8537 ||| NN
at  ||| S:8537 E:8540 ||| IN
serine  ||| S:8540 E:8547 ||| CD
33  ||| S:8547 E:8550 ||| CD
( ||| S:8550 E:8551 ||| -LRB-
figure  ||| S:8551 E:8558 ||| NN
2 ||| S:8558 E:8559 ||| CD
,  ||| S:8559 E:8569 ||| ,
underlined ||| S:8569 E:8579 ||| CD
) ||| S:8579 E:8580 ||| -RRB-
.  ||| S:8580 E:8582 ||| .
Serine  ||| S:8582 E:8589 ||| NNP
33  ||| S:8589 E:8592 ||| CD
and  ||| S:8592 E:8596 ||| CC
37  ||| S:8596 E:8599 ||| CD
of  ||| S:8599 E:8602 ||| IN
p53  ||| S:8602 E:8606 ||| NN
were  ||| S:8606 E:8611 ||| VBD
individually  ||| S:8611 E:8632 ||| RB
mutated  ||| S:8632 E:8640 ||| VBN
to  ||| S:8640 E:8643 ||| TO
alanine ||| S:8643 E:8650 ||| VB
,  ||| S:8650 E:8652 ||| ,
and  ||| S:8652 E:8656 ||| CC
p53-GST  ||| S:8656 E:8664 ||| CD
fusion  ||| S:8664 E:8671 ||| NN
proteins  ||| S:8671 E:8680 ||| NNS
containing  ||| S:8680 E:8699 ||| VBG
these  ||| S:8699 E:8705 ||| DT
mutations  ||| S:8705 E:8715 ||| NN
prepared ||| S:8715 E:8723 ||| VBN
.  ||| S:8723 E:8725 ||| .
The  ||| S:8725 E:8729 ||| DT
ability  ||| S:8729 E:8737 ||| NN
of  ||| S:8737 E:8740 ||| IN
DNA-PK  ||| S:8740 E:8747 ||| JJ
to  ||| S:8747 E:8750 ||| TO
create  ||| S:8750 E:8757 ||| VB
a  ||| S:8757 E:8767 ||| DT
GSK3β  ||| S:8767 E:8773 ||| JJ
phosphorylation  ||| S:8773 E:8789 ||| JJ
site  ||| S:8789 E:8794 ||| NN
on  ||| S:8794 E:8797 ||| IN
these  ||| S:8797 E:8803 ||| DT
p53  ||| S:8803 E:8807 ||| NN
proteins  ||| S:8807 E:8816 ||| NNS
was  ||| S:8816 E:8820 ||| VBD
then  ||| S:8820 E:8833 ||| RB
examined ||| S:8833 E:8841 ||| VBN
.  ||| S:8841 E:8851 ||| .
In  ||| S:8851 E:8854 ||| IN
the  ||| S:8854 E:8858 ||| DT
absence  ||| S:8858 E:8866 ||| NN
of  ||| S:8866 E:8869 ||| IN
p53 ||| S:8869 E:8872 ||| NN
,  ||| S:8872 E:8874 ||| ,
no  ||| S:8874 E:8877 ||| DT
phosphorylation  ||| S:8877 E:8893 ||| NN
by  ||| S:8893 E:8896 ||| IN
GSK3β  ||| S:8896 E:8902 ||| NNP
was  ||| S:8902 E:8914 ||| VBD
detected  ||| S:8914 E:8923 ||| VBN
( ||| S:8923 E:8924 ||| -LRB-
fig  ||| S:8924 E:8928 ||| CD
2 ||| S:8928 E:8929 ||| CD
) ||| S:8929 E:8930 ||| -RRB-
.  ||| S:8930 E:8932 ||| .
Unphosphorylated  ||| S:8932 E:8949 ||| NNP
p53-GST  ||| S:8949 E:8957 ||| NNP
was  ||| S:8957 E:8961 ||| VBD
not  ||| S:8961 E:8965 ||| RB
a  ||| S:8965 E:8975 ||| DT
substrate  ||| S:8975 E:8985 ||| NN
for  ||| S:8985 E:8989 ||| IN
GSK3β ||| S:8989 E:8994 ||| NNP
,  ||| S:8994 E:8996 ||| ,
whereas  ||| S:8996 E:9004 ||| IN
p53-GST  ||| S:9004 E:9012 ||| CD
prephosphorylated  ||| S:9012 E:9030 ||| NN
by  ||| S:9030 E:9041 ||| IN
DNA-PK  ||| S:9041 E:9048 ||| NNP
was  ||| S:9048 E:9052 ||| VBD
( ||| S:9052 E:9053 ||| -LRB-
fig  ||| S:9053 E:9057 ||| CD
2 ||| S:9057 E:9058 ||| CD
) ||| S:9058 E:9059 ||| -RRB-
.  ||| S:9059 E:9061 ||| .
Mutation  ||| S:9061 E:9070 ||| NN
of  ||| S:9070 E:9073 ||| IN
serine  ||| S:9073 E:9080 ||| CD
33  ||| S:9080 E:9083 ||| CD
of  ||| S:9083 E:9086 ||| IN
p53  ||| S:9086 E:9090 ||| NN
to  ||| S:9090 E:9093 ||| TO
alanine  ||| S:9093 E:9109 ||| VB
( ||| S:9109 E:9110 ||| -LRB-
S33A ||| S:9110 E:9114 ||| NNP
)  ||| S:9114 E:9116 ||| -RRB-
blocked  ||| S:9116 E:9124 ||| VBD
the  ||| S:9124 E:9128 ||| DT
ability  ||| S:9128 E:9136 ||| NN
of  ||| S:9136 E:9139 ||| IN
GSK3β  ||| S:9139 E:9145 ||| CD
to  ||| S:9145 E:9148 ||| TO
phosphorylate  ||| S:9148 E:9162 ||| VB
p53 ||| S:9162 E:9165 ||| NN
,  ||| S:9165 E:9175 ||| ,
indicating  ||| S:9175 E:9186 ||| VBG
that  ||| S:9186 E:9191 ||| IN
serine  ||| S:9191 E:9198 ||| CD
33  ||| S:9198 E:9201 ||| CD
is  ||| S:9201 E:9204 ||| VBZ
the  ||| S:9204 E:9208 ||| DT
likely  ||| S:9208 E:9215 ||| JJ
target  ||| S:9215 E:9222 ||| NN
for  ||| S:9222 E:9226 ||| IN
GSK3β  ||| S:9226 E:9240 ||| NNP
( ||| S:9240 E:9241 ||| -LRB-
fig  ||| S:9241 E:9245 ||| CD
2 ||| S:9245 E:9246 ||| CD
,  ||| S:9246 E:9248 ||| ,
33 ||| S:9248 E:9250 ||| CD
) ||| S:9250 E:9251 ||| -RRB-
.  ||| S:9251 E:9253 ||| .
Similarly ||| S:9253 E:9262 ||| RB
,  ||| S:9262 E:9264 ||| ,
mutation  ||| S:9264 E:9273 ||| NN
of  ||| S:9273 E:9276 ||| IN
serine  ||| S:9276 E:9283 ||| CD
37 ||| S:9283 E:9285 ||| CD
,  ||| S:9285 E:9287 ||| ,
which  ||| S:9287 E:9301 ||| WDT
abolishes  ||| S:9301 E:9311 ||| VBZ
the  ||| S:9311 E:9315 ||| DT
DNA-PK  ||| S:9315 E:9322 ||| JJ
phosphorylation  ||| S:9322 E:9338 ||| JJ
site ||| S:9338 E:9342 ||| NN
,  ||| S:9342 E:9344 ||| ,
blocks  ||| S:9344 E:9359 ||| VBZ
phosphorylation  ||| S:9359 E:9375 ||| VBN
of  ||| S:9375 E:9378 ||| IN
p53  ||| S:9378 E:9382 ||| NN
by  ||| S:9382 E:9385 ||| IN
GSK3β ||| S:9385 E:9390 ||| CD
.  ||| S:9390 E:9392 ||| .
This  ||| S:9392 E:9397 ||| DT
indicates  ||| S:9397 E:9407 ||| VBZ
that  ||| S:9407 E:9412 ||| DT
p53  ||| S:9412 E:9424 ||| NN
must  ||| S:9424 E:9429 ||| MD
be  ||| S:9429 E:9432 ||| VB
phosphorylated  ||| S:9432 E:9447 ||| VBN
on  ||| S:9447 E:9450 ||| IN
serine  ||| S:9450 E:9457 ||| CD
37  ||| S:9457 E:9460 ||| CD
by  ||| S:9460 E:9463 ||| IN
DNA-PK  ||| S:9463 E:9470 ||| JJ
before  ||| S:9470 E:9477 ||| IN
it  ||| S:9477 E:9480 ||| PRP
can  ||| S:9480 E:9492 ||| MD
be  ||| S:9492 E:9495 ||| VB
phosphorylated  ||| S:9495 E:9510 ||| VBN
at  ||| S:9510 E:9513 ||| IN
serine  ||| S:9513 E:9520 ||| CD
33  ||| S:9520 E:9523 ||| CD
by  ||| S:9523 E:9526 ||| IN
GSK3β ||| S:9526 E:9531 ||| CD
.  ||| S:9531 E:9541 ||| .
To  ||| S:9541 E:9544 ||| TO
examine  ||| S:9544 E:9552 ||| VB
the  ||| S:9552 E:9565 ||| DT
in  ||| S:9565 E:9568 ||| IN
vivo  ||| S:9568 E:9573 ||| JJ
function  ||| S:9573 E:9582 ||| NN
of  ||| S:9582 E:9585 ||| IN
these  ||| S:9585 E:9600 ||| DT
in  ||| S:9600 E:9603 ||| IN
vitro  ||| S:9603 E:9609 ||| JJ
phosphorylations ||| S:9609 E:9625 ||| NN
,  ||| S:9625 E:9627 ||| ,
wtp53  ||| S:9627 E:9633 ||| NNP
and  ||| S:9633 E:9645 ||| CC
p53  ||| S:9645 E:9649 ||| NN
with  ||| S:9649 E:9654 ||| IN
the  ||| S:9654 E:9658 ||| DT
S33A  ||| S:9658 E:9663 ||| NNP
and  ||| S:9663 E:9667 ||| CC
S37A  ||| S:9667 E:9672 ||| CD
mutations  ||| S:9672 E:9682 ||| NNS
were  ||| S:9682 E:9687 ||| VBD
sub-cloned  ||| S:9687 E:9698 ||| JJ
into  ||| S:9698 E:9711 ||| IN
the  ||| S:9711 E:9715 ||| DT
expression  ||| S:9715 E:9726 ||| NN
vector  ||| S:9726 E:9733 ||| NN
pcDNA3.1 ||| S:9733 E:9741 ||| NN
.  ||| S:9741 E:9743 ||| .
These  ||| S:9743 E:9749 ||| DT
were  ||| S:9749 E:9754 ||| VBD
then  ||| S:9754 E:9759 ||| RB
expressed  ||| S:9759 E:9777 ||| VBN
in  ||| S:9777 E:9780 ||| IN
the  ||| S:9780 E:9784 ||| DT
human  ||| S:9784 E:9790 ||| JJ
osteosarcoma  ||| S:9790 E:9803 ||| JJ
cell  ||| S:9803 E:9808 ||| NN
line  ||| S:9808 E:9813 ||| NN
SAOS-2 ||| S:9813 E:9819 ||| NN
,  ||| S:9819 E:9821 ||| ,
which  ||| S:9821 E:9827 ||| WDT
does  ||| S:9827 E:9832 ||| VBZ
not  ||| S:9832 E:9844 ||| RB
express  ||| S:9844 E:9852 ||| VB
endogenous  ||| S:9852 E:9863 ||| JJ
p53  ||| S:9863 E:9867 ||| NN
protein  ||| S:9867 E:9875 ||| NN
[  ||| S:9875 E:9877 ||| -LRB-
33 ||| S:9877 E:9879 ||| CD
] ||| S:9879 E:9880 ||| -RRB-
.  ||| S:9880 E:9882 ||| .
First ||| S:9882 E:9887 ||| NNP
,  ||| S:9887 E:9889 ||| ,
we  ||| S:9889 E:9892 ||| PRP
analyzed  ||| S:9892 E:9909 ||| VBD
the  ||| S:9909 E:9913 ||| DT
level  ||| S:9913 E:9919 ||| NN
of  ||| S:9919 E:9922 ||| IN
expression  ||| S:9922 E:9933 ||| NN
of  ||| S:9933 E:9936 ||| IN
each  ||| S:9936 E:9941 ||| DT
of  ||| S:9941 E:9944 ||| IN
the  ||| S:9944 E:9948 ||| DT
p53  ||| S:9948 E:9952 ||| NN
proteins  ||| S:9952 E:9969 ||| NNS
following  ||| S:9969 E:9979 ||| VBG
transient  ||| S:9979 E:9989 ||| JJ
expression  ||| S:9989 E:10000 ||| NN
in  ||| S:10000 E:10003 ||| IN
SAOS-2  ||| S:10003 E:10010 ||| CD
cells ||| S:10010 E:10015 ||| NNS
.  ||| S:10015 E:10017 ||| .
In  ||| S:10017 E:10020 ||| IN
fig  ||| S:10020 E:10024 ||| CD
3A ||| S:10024 E:10026 ||| CD
,  ||| S:10026 E:10036 ||| ,
approx  ||| S:10036 E:10043 ||| JJ
equal  ||| S:10043 E:10049 ||| JJ
amounts  ||| S:10049 E:10057 ||| NNS
of  ||| S:10057 E:10060 ||| IN
wtp53 ||| S:10060 E:10065 ||| NNP
,  ||| S:10065 E:10067 ||| ,
p53S33A  ||| S:10067 E:10075 ||| NNP
and  ||| S:10075 E:10079 ||| CC
p53S37A  ||| S:10079 E:10087 ||| NNP
were  ||| S:10087 E:10100 ||| VBD
detected  ||| S:10100 E:10109 ||| VBN
by  ||| S:10109 E:10112 ||| IN
western  ||| S:10112 E:10120 ||| JJ
blot ||| S:10120 E:10124 ||| NN
,  ||| S:10124 E:10126 ||| ,
indicating  ||| S:10126 E:10137 ||| VBG
that  ||| S:10137 E:10142 ||| IN
they  ||| S:10142 E:10147 ||| PRP
were  ||| S:10147 E:10160 ||| VBD
expressed  ||| S:10160 E:10170 ||| VBN
at  ||| S:10170 E:10173 ||| IN
similar  ||| S:10173 E:10181 ||| JJ
levels ||| S:10181 E:10187 ||| NNS
.  ||| S:10187 E:10189 ||| .
In  ||| S:10189 E:10192 ||| IN
fig  ||| S:10192 E:10196 ||| CD
3B ||| S:10196 E:10198 ||| CD
,  ||| S:10198 E:10200 ||| ,
we  ||| S:10200 E:10203 ||| PRP
examined  ||| S:10203 E:10212 ||| VBD
the  ||| S:10212 E:10224 ||| DT
transcriptional  ||| S:10224 E:10240 ||| JJ
activity  ||| S:10240 E:10249 ||| NN
of  ||| S:10249 E:10252 ||| IN
these  ||| S:10252 E:10258 ||| DT
p53  ||| S:10258 E:10262 ||| NN
constructs ||| S:10262 E:10272 ||| NN
.  ||| S:10272 E:10274 ||| .
A  ||| S:10274 E:10284 ||| DT
p53-reporter  ||| S:10284 E:10297 ||| JJ
construct ||| S:10297 E:10306 ||| NN
,  ||| S:10306 E:10308 ||| ,
p50-2 ||| S:10308 E:10313 ||| NNP
,  ||| S:10313 E:10315 ||| ,
which  ||| S:10315 E:10321 ||| WDT
specifically  ||| S:10321 E:10334 ||| RB
responds  ||| S:10334 E:10351 ||| VBZ
to  ||| S:10351 E:10354 ||| TO
wtp53  ||| S:10354 E:10360 ||| CD
by  ||| S:10360 E:10363 ||| IN
increasing  ||| S:10363 E:10374 ||| VBG
transcription  ||| S:10374 E:10388 ||| NN
of  ||| S:10388 E:10391 ||| IN
the  ||| S:10391 E:10395 ||| DT
luciferase  ||| S:10395 E:10414 ||| JJ
gene ||| S:10414 E:10418 ||| NN
,  ||| S:10418 E:10420 ||| ,
was  ||| S:10420 E:10424 ||| VBD
used  ||| S:10424 E:10429 ||| VBN
[ ||| S:10429 E:10430 ||| -LRB-
described  ||| S:10430 E:10440 ||| VBN
in  ||| S:10440 E:10443 ||| IN
33 ||| S:10443 E:10445 ||| CD
] ||| S:10445 E:10446 ||| -RRB-
.  ||| S:10446 E:10448 ||| .
In  ||| S:10448 E:10451 ||| IN
fig  ||| S:10451 E:10455 ||| CD
3B ||| S:10455 E:10457 ||| CD
,  ||| S:10457 E:10459 ||| ,
SAOS-2  ||| S:10459 E:10466 ||| FW
cells  ||| S:10466 E:10480 ||| FW
transiently  ||| S:10480 E:10492 ||| FW
expressing  ||| S:10492 E:10503 ||| FW
vector  ||| S:10503 E:10510 ||| FW
( ||| S:10510 E:10511 ||| -LRB-
Con ||| S:10511 E:10514 ||| NNP
) ||| S:10514 E:10515 ||| -RRB-
,  ||| S:10515 E:10517 ||| ,
showed  ||| S:10517 E:10524 ||| VBD
minimal  ||| S:10524 E:10540 ||| JJ
activation  ||| S:10540 E:10551 ||| NN
of  ||| S:10551 E:10554 ||| IN
the  ||| S:10554 E:10558 ||| DT
p53-reporter  ||| S:10558 E:10571 ||| JJ
construct ||| S:10571 E:10580 ||| NN
.  ||| S:10580 E:10582 ||| .
Cells  ||| S:10582 E:10588 ||| NNS
expressing  ||| S:10588 E:10607 ||| VBG
wtp53  ||| S:10607 E:10613 ||| NNP
showed  ||| S:10613 E:10620 ||| VBD
significant  ||| S:10620 E:10632 ||| JJ
activation ||| S:10632 E:10642 ||| NN
,  ||| S:10642 E:10644 ||| ,
as  ||| S:10644 E:10647 ||| RB
did  ||| S:10647 E:10651 ||| VBD
cells  ||| S:10651 E:10665 ||| NNS
expressing  ||| S:10665 E:10676 ||| VBG
both  ||| S:10676 E:10681 ||| PDT
the  ||| S:10681 E:10685 ||| DT
S33A  ||| S:10685 E:10690 ||| NNP
and  ||| S:10690 E:10694 ||| CC
S37A  ||| S:10694 E:10699 ||| CD
mutations ||| S:10699 E:10708 ||| NNS
.  ||| S:10708 E:10710 ||| .
Both  ||| S:10710 E:10715 ||| PDT
the  ||| S:10715 E:10719 ||| DT
S33A  ||| S:10719 E:10732 ||| NNP
and  ||| S:10732 E:10736 ||| CC
S37A  ||| S:10736 E:10741 ||| CD
mutations  ||| S:10741 E:10751 ||| NNS
displayed  ||| S:10751 E:10761 ||| VBD
slightly  ||| S:10761 E:10770 ||| RB
higher  ||| S:10770 E:10777 ||| RBR
basal  ||| S:10777 E:10783 ||| JJ
levels  ||| S:10783 E:10798 ||| NNS
of  ||| S:10798 E:10801 ||| IN
transcriptional  ||| S:10801 E:10817 ||| JJ
activity  ||| S:10817 E:10826 ||| NN
than  ||| S:10826 E:10831 ||| IN
the  ||| S:10831 E:10835 ||| DT
wtp53  ||| S:10835 E:10841 ||| JJ
protein ||| S:10841 E:10848 ||| NN
.  ||| S:10848 E:10858 ||| .
Serines  ||| S:10858 E:10866 ||| NNP
33  ||| S:10866 E:10869 ||| CD
and  ||| S:10869 E:10873 ||| CC
37  ||| S:10873 E:10876 ||| CD
are  ||| S:10876 E:10880 ||| VBP
located  ||| S:10880 E:10888 ||| VBN
within  ||| S:10888 E:10895 ||| IN
the  ||| S:10895 E:10899 ||| DT
N-terminal  ||| S:10899 E:10918 ||| JJ
transcriptional  ||| S:10918 E:10934 ||| JJ
activation  ||| S:10934 E:10945 ||| JJ
domain  ||| S:10945 E:10952 ||| NN
of  ||| S:10952 E:10955 ||| IN
the  ||| S:10955 E:10959 ||| DT
p53  ||| S:10959 E:10963 ||| NN
protein ||| S:10963 E:10970 ||| NN
.  ||| S:10970 E:10972 ||| .
To  ||| S:10972 E:10983 ||| TO
determine  ||| S:10983 E:10993 ||| VB
if  ||| S:10993 E:10996 ||| IN
GSK3β  ||| S:10996 E:11002 ||| NNP
regulates  ||| S:11002 E:11012 ||| VBZ
p53 ||| S:11012 E:11015 ||| NN
's  ||| S:11015 E:11018 ||| POS
transcriptional  ||| S:11018 E:11034 ||| JJ
activity  ||| S:11034 E:11060 ||| NN
in  ||| S:11060 E:11063 ||| IN
vivo ||| S:11063 E:11067 ||| NN
,  ||| S:11067 E:11069 ||| ,
a  ||| S:11069 E:11071 ||| DT
wild  ||| S:11071 E:11076 ||| JJ
type  ||| S:11076 E:11081 ||| NN
GSK3β  ||| S:11081 E:11087 ||| CD
expression  ||| S:11087 E:11106 ||| NN
vector  ||| S:11106 E:11113 ||| NN
was  ||| S:11113 E:11117 ||| VBD
cotransfected  ||| S:11117 E:11131 ||| VBN
with  ||| S:11131 E:11136 ||| IN
either  ||| S:11136 E:11143 ||| DT
wtp53  ||| S:11143 E:11149 ||| NNP
or  ||| S:11149 E:11152 ||| CC
p53  ||| S:11152 E:11156 ||| NN
with  ||| S:11156 E:11169 ||| IN
mutations  ||| S:11169 E:11179 ||| NNS
in  ||| S:11179 E:11182 ||| IN
serines  ||| S:11182 E:11190 ||| CD
33  ||| S:11190 E:11193 ||| CD
or  ||| S:11193 E:11196 ||| CC
37 ||| S:11196 E:11198 ||| CD
.  ||| S:11198 E:11200 ||| .
The  ||| S:11200 E:11204 ||| DT
ability  ||| S:11204 E:11212 ||| NN
of  ||| S:11212 E:11215 ||| IN
GSK3β  ||| S:11215 E:11221 ||| CD
to  ||| S:11221 E:11232 ||| TO
activate  ||| S:11232 E:11241 ||| VB
each  ||| S:11241 E:11246 ||| DT
construct  ||| S:11246 E:11256 ||| NN
was  ||| S:11256 E:11260 ||| VBD
calculated  ||| S:11260 E:11271 ||| VBN
by  ||| S:11271 E:11274 ||| IN
expressing  ||| S:11274 E:11285 ||| VBG
the  ||| S:11285 E:11297 ||| DT
p53  ||| S:11297 E:11301 ||| NN
transcriptional  ||| S:11301 E:11317 ||| NN
activity  ||| S:11317 E:11326 ||| NN
in  ||| S:11326 E:11329 ||| IN
the  ||| S:11329 E:11333 ||| DT
presence  ||| S:11333 E:11342 ||| NN
of  ||| S:11342 E:11345 ||| IN
GSK3β  ||| S:11345 E:11351 ||| CD
as  ||| S:11351 E:11354 ||| IN
a  ||| S:11354 E:11364 ||| DT
percentage  ||| S:11364 E:11375 ||| NN
of  ||| S:11375 E:11378 ||| IN
that  ||| S:11378 E:11383 ||| WDT
observed  ||| S:11383 E:11392 ||| VBD
in  ||| S:11392 E:11395 ||| IN
the  ||| S:11395 E:11399 ||| DT
absence  ||| S:11399 E:11407 ||| NN
of  ||| S:11407 E:11410 ||| IN
GSK3β ||| S:11410 E:11415 ||| CD
.  ||| S:11415 E:11417 ||| .
On  ||| S:11417 E:11428 ||| IN
this  ||| S:11428 E:11433 ||| DT
scale ||| S:11433 E:11438 ||| NN
,  ||| S:11438 E:11440 ||| ,
no  ||| S:11440 E:11443 ||| DT
activation  ||| S:11443 E:11454 ||| NN
by  ||| S:11454 E:11457 ||| IN
GSK3β  ||| S:11457 E:11463 ||| CD
yields  ||| S:11463 E:11470 ||| NNS
a  ||| S:11470 E:11472 ||| DT
zero  ||| S:11472 E:11477 ||| CD
percent  ||| S:11477 E:11493 ||| NN
increase  ||| S:11493 E:11502 ||| NN
in  ||| S:11502 E:11505 ||| IN
p53  ||| S:11505 E:11509 ||| NN
transcriptional  ||| S:11509 E:11525 ||| VBZ
relative  ||| S:11525 E:11534 ||| JJ
to  ||| S:11534 E:11537 ||| TO
p53  ||| S:11537 E:11541 ||| NN
alone ||| S:11541 E:11546 ||| RB
.  ||| S:11546 E:11556 ||| .
GSK3β  ||| S:11556 E:11562 ||| NNP
alone  ||| S:11562 E:11568 ||| RB
( ||| S:11568 E:11569 ||| -LRB-
fig  ||| S:11569 E:11573 ||| FW
3C ||| S:11573 E:11575 ||| FW
,  ||| S:11575 E:11577 ||| ,
Con ||| S:11577 E:11580 ||| NNP
)  ||| S:11580 E:11582 ||| -RRB-
did  ||| S:11582 E:11586 ||| VBD
not  ||| S:11586 E:11590 ||| RB
significantly  ||| S:11590 E:11604 ||| RB
increase  ||| S:11604 E:11621 ||| VB
the  ||| S:11621 E:11625 ||| DT
activity  ||| S:11625 E:11634 ||| NN
of  ||| S:11634 E:11637 ||| IN
the  ||| S:11637 E:11641 ||| DT
luciferase  ||| S:11641 E:11652 ||| JJ
reporter  ||| S:11652 E:11661 ||| NN
construct ||| S:11661 E:11670 ||| NN
.  ||| S:11670 E:11672 ||| .
When  ||| S:11672 E:11685 ||| WRB
GSK3β  ||| S:11685 E:11691 ||| NNP
was  ||| S:11691 E:11695 ||| VBD
cotransfected  ||| S:11695 E:11709 ||| VBN
with  ||| S:11709 E:11714 ||| IN
wtp53 ||| S:11714 E:11719 ||| NNP
,  ||| S:11719 E:11721 ||| ,
p53-dependent  ||| S:11721 E:11735 ||| CD
activity  ||| S:11735 E:11752 ||| NN
from  ||| S:11752 E:11757 ||| IN
the  ||| S:11757 E:11761 ||| DT
luciferase  ||| S:11761 E:11772 ||| JJ
reporter  ||| S:11772 E:11781 ||| NN
construct  ||| S:11781 E:11791 ||| NNS
was  ||| S:11791 E:11795 ||| VBD
increased  ||| S:11795 E:11805 ||| VBN
by  ||| S:11805 E:11816 ||| IN
160 ||| S:11816 E:11819 ||| CD
%  ||| S:11819 E:11821 ||| NN
compared  ||| S:11821 E:11830 ||| VBN
to  ||| S:11830 E:11833 ||| TO
wtp53  ||| S:11833 E:11839 ||| CD
alone ||| S:11839 E:11844 ||| RB
.  ||| S:11844 E:11846 ||| .
To  ||| S:11846 E:11849 ||| TO
determine  ||| S:11849 E:11859 ||| VB
if  ||| S:11859 E:11862 ||| IN
this  ||| S:11862 E:11875 ||| DT
activation  ||| S:11875 E:11886 ||| NN
of  ||| S:11886 E:11889 ||| IN
p53  ||| S:11889 E:11893 ||| NN
transcriptional  ||| S:11893 E:11909 ||| NN
activity  ||| S:11909 E:11918 ||| NN
required  ||| S:11918 E:11927 ||| VBD
the  ||| S:11927 E:11939 ||| DT
GSK3β  ||| S:11939 E:11945 ||| JJ
phosphorylation  ||| S:11945 E:11961 ||| JJ
site  ||| S:11961 E:11966 ||| NN
at  ||| S:11966 E:11969 ||| IN
serine  ||| S:11969 E:11976 ||| CD
33 ||| S:11976 E:11978 ||| CD
,  ||| S:11978 E:11980 ||| ,
wtp53  ||| S:11980 E:11986 ||| NNP
with  ||| S:11986 E:11991 ||| IN
serine  ||| S:11991 E:12006 ||| VBG
to  ||| S:12006 E:12009 ||| TO
alanine  ||| S:12009 E:12017 ||| VB
mutations  ||| S:12017 E:12027 ||| VBN
at  ||| S:12027 E:12030 ||| IN
either  ||| S:12030 E:12037 ||| DT
positions  ||| S:12037 E:12047 ||| NNS
33  ||| S:12047 E:12050 ||| CD
or  ||| S:12050 E:12053 ||| CC
37  ||| S:12053 E:12056 ||| CD
were  ||| S:12056 E:12069 ||| VBD
cotransfected  ||| S:12069 E:12083 ||| VBN
with  ||| S:12083 E:12088 ||| IN
GSK3β ||| S:12088 E:12093 ||| CD
.  ||| S:12093 E:12095 ||| .
Mutation  ||| S:12095 E:12104 ||| NN
of  ||| S:12104 E:12107 ||| IN
either  ||| S:12107 E:12114 ||| DT
serine  ||| S:12114 E:12121 ||| JJ
33  ||| S:12121 E:12124 ||| CD
or  ||| S:12124 E:12135 ||| CC
37  ||| S:12135 E:12138 ||| CD
significantly  ||| S:12138 E:12152 ||| RB
reduced  ||| S:12152 E:12160 ||| VBN
the  ||| S:12160 E:12164 ||| DT
ability  ||| S:12164 E:12172 ||| NN
of  ||| S:12172 E:12175 ||| IN
GSK3β  ||| S:12175 E:12181 ||| CD
to  ||| S:12181 E:12184 ||| TO
upregulate  ||| S:12184 E:12203 ||| VB
p53  ||| S:12203 E:12207 ||| NN
transcriptional  ||| S:12207 E:12223 ||| NN
activity ||| S:12223 E:12231 ||| NN
.  ||| S:12231 E:12233 ||| .
This  ||| S:12233 E:12238 ||| DT
is  ||| S:12238 E:12241 ||| VBZ
consistent  ||| S:12241 E:12252 ||| JJ
with  ||| S:12252 E:12257 ||| IN
the  ||| S:12257 E:12269 ||| DT
phosphorylation  ||| S:12269 E:12285 ||| JJ
data  ||| S:12285 E:12290 ||| NNS
in  ||| S:12290 E:12293 ||| IN
fig  ||| S:12293 E:12297 ||| CD
1and  ||| S:12297 E:12302 ||| CD
2 ||| S:12302 E:12303 ||| CD
,  ||| S:12303 E:12305 ||| ,
which  ||| S:12305 E:12311 ||| WDT
indicated  ||| S:12311 E:12321 ||| VBD
that  ||| S:12321 E:12334 ||| IN
serine  ||| S:12334 E:12341 ||| CD
37  ||| S:12341 E:12344 ||| CD
phosphorylation  ||| S:12344 E:12360 ||| NN
is  ||| S:12360 E:12363 ||| VBZ
required  ||| S:12363 E:12372 ||| VBN
for  ||| S:12372 E:12376 ||| IN
the  ||| S:12376 E:12380 ||| DT
subsequent  ||| S:12380 E:12399 ||| JJ
phosphorylation  ||| S:12399 E:12415 ||| NN
of  ||| S:12415 E:12418 ||| IN
serine  ||| S:12418 E:12425 ||| CD
33  ||| S:12425 E:12428 ||| CD
by  ||| S:12428 E:12431 ||| IN
GSK3β ||| S:12431 E:12436 ||| CD
.  ||| S:12436 E:12438 ||| .
These  ||| S:12438 E:12444 ||| DT
results  ||| S:12444 E:12460 ||| NNS
suggests  ||| S:12460 E:12469 ||| VBZ
that  ||| S:12469 E:12474 ||| IN
GSK3β  ||| S:12474 E:12480 ||| NNP
may  ||| S:12480 E:12484 ||| MD
be  ||| S:12484 E:12487 ||| VB
a  ||| S:12487 E:12489 ||| DT
physiological  ||| S:12489 E:12503 ||| JJ
regulator  ||| S:12503 E:12513 ||| NN
of  ||| S:12513 E:12516 ||| IN
the  ||| S:12516 E:12528 ||| DT
p53  ||| S:12528 E:12532 ||| NN
protein ||| S:12532 E:12539 ||| NN
.  ||| S:12539 E:12541 ||| .
GSK3β  ||| S:12541 E:12547 ||| NNP
is  ||| S:12547 E:12550 ||| VBZ
constitutively  ||| S:12550 E:12565 ||| JJ
active  ||| S:12565 E:12572 ||| JJ
in  ||| S:12572 E:12575 ||| IN
resting  ||| S:12575 E:12591 ||| JJ
cells ||| S:12591 E:12596 ||| NNS
,  ||| S:12596 E:12598 ||| ,
and  ||| S:12598 E:12602 ||| CC
is  ||| S:12602 E:12605 ||| VBZ
inactivated  ||| S:12605 E:12617 ||| VBN
by  ||| S:12617 E:12620 ||| IN
PKB  ||| S:12620 E:12624 ||| NNP
through  ||| S:12624 E:12632 ||| IN
the  ||| S:12632 E:12636 ||| DT
growth  ||| S:12636 E:12643 ||| NN
factor  ||| S:12643 E:12658 ||| NN
dependent  ||| S:12658 E:12668 ||| FW
p110-PI  ||| S:12668 E:12676 ||| FW
3-kinase  ||| S:12676 E:12685 ||| FW
pathway  ||| S:12685 E:12693 ||| FW
[  ||| S:12693 E:12695 ||| -LRB-
25 ||| S:12695 E:12697 ||| CD
,  ||| S:12697 E:12699 ||| ,
28 ||| S:12699 E:12701 ||| CD
,  ||| S:12701 E:12703 ||| ,
29 ||| S:12703 E:12705 ||| CD
] ||| S:12705 E:12706 ||| -RRB-
.  ||| S:12706 E:12708 ||| .
Thus  ||| S:12708 E:12713 ||| RB
the  ||| S:12713 E:12725 ||| DT
activity  ||| S:12725 E:12734 ||| NN
of  ||| S:12734 E:12737 ||| IN
GSK3β  ||| S:12737 E:12743 ||| CD
in  ||| S:12743 E:12746 ||| IN
growing  ||| S:12746 E:12754 ||| VBG
cells  ||| S:12754 E:12760 ||| NNS
is  ||| S:12760 E:12763 ||| VBZ
less  ||| S:12763 E:12768 ||| JJR
than  ||| S:12768 E:12773 ||| IN
that  ||| S:12773 E:12778 ||| DT
in  ||| S:12778 E:12789 ||| IN
cells  ||| S:12789 E:12795 ||| NNS
arrested  ||| S:12795 E:12804 ||| VBN
in  ||| S:12804 E:12807 ||| IN
Go.  ||| S:12807 E:12811 ||| CD
p53  ||| S:12811 E:12815 ||| NN
can  ||| S:12815 E:12819 ||| MD
be  ||| S:12819 E:12822 ||| VB
activated  ||| S:12822 E:12832 ||| VBN
by  ||| S:12832 E:12835 ||| IN
several  ||| S:12835 E:12851 ||| JJ
distinct  ||| S:12851 E:12860 ||| JJ
pathways ||| S:12860 E:12868 ||| NN
,  ||| S:12868 E:12870 ||| ,
including  ||| S:12870 E:12880 ||| VBG
DNA  ||| S:12880 E:12884 ||| NN
damage ||| S:12884 E:12890 ||| NN
.  ||| S:12890 E:12892 ||| .
If  ||| S:12892 E:12895 ||| IN
GSK3β  ||| S:12895 E:12901 ||| NNP
is  ||| S:12901 E:12912 ||| VBZ
involved  ||| S:12912 E:12921 ||| VBN
in  ||| S:12921 E:12924 ||| IN
the  ||| S:12924 E:12928 ||| DT
activation  ||| S:12928 E:12939 ||| NN
of  ||| S:12939 E:12942 ||| IN
p53  ||| S:12942 E:12946 ||| NN
by  ||| S:12946 E:12949 ||| IN
DNA  ||| S:12949 E:12953 ||| NNP
damage ||| S:12953 E:12959 ||| NN
,  ||| S:12959 E:12961 ||| ,
then  ||| S:12961 E:12966 ||| RB
GSK3β  ||| S:12966 E:12980 ||| RB
is  ||| S:12980 E:12983 ||| VBZ
predicted  ||| S:12983 E:12993 ||| VBN
to  ||| S:12993 E:12996 ||| TO
be  ||| S:12996 E:12999 ||| VB
upregulated  ||| S:12999 E:13011 ||| VBN
in  ||| S:13011 E:13014 ||| IN
response  ||| S:13014 E:13023 ||| NN
to  ||| S:13023 E:13026 ||| TO
DNA  ||| S:13026 E:13030 ||| NNP
damage ||| S:13030 E:13036 ||| NN
.  ||| S:13036 E:13046 ||| .
In  ||| S:13046 E:13049 ||| IN
fig  ||| S:13049 E:13053 ||| CD
4 ||| S:13053 E:13054 ||| CD
,  ||| S:13054 E:13056 ||| ,
GSK3β  ||| S:13056 E:13062 ||| CD
kinase  ||| S:13062 E:13069 ||| JJ
activity  ||| S:13069 E:13078 ||| NN
was  ||| S:13078 E:13082 ||| VBD
monitored  ||| S:13082 E:13092 ||| VBN
by  ||| S:13092 E:13103 ||| IN
immunoprecipitating  ||| S:13103 E:13123 ||| JJ
GSK3β  ||| S:13123 E:13129 ||| NN
and  ||| S:13129 E:13133 ||| CC
then  ||| S:13133 E:13138 ||| RB
measuring  ||| S:13138 E:13148 ||| VBG
the  ||| S:13148 E:13152 ||| DT
ability  ||| S:13152 E:13160 ||| NN
of  ||| S:13160 E:13171 ||| IN
the  ||| S:13171 E:13175 ||| DT
immunoprecipitated  ||| S:13175 E:13194 ||| JJ
protein  ||| S:13194 E:13202 ||| NN
to  ||| S:13202 E:13205 ||| TO
phosphorylate  ||| S:13205 E:13219 ||| VB
a  ||| S:13219 E:13221 ||| DT
specific  ||| S:13221 E:13238 ||| JJ
GSK3β  ||| S:13238 E:13244 ||| FW
peptide  ||| S:13244 E:13252 ||| FW
substrate ||| S:13252 E:13261 ||| FW
.  ||| S:13261 E:13263 ||| .
In  ||| S:13263 E:13266 ||| IN
fig  ||| S:13266 E:13270 ||| CD
4 ||| S:13270 E:13271 ||| CD
,  ||| S:13271 E:13273 ||| ,
the  ||| S:13273 E:13277 ||| DT
omission  ||| S:13277 E:13286 ||| NN
of  ||| S:13286 E:13289 ||| IN
either  ||| S:13289 E:13304 ||| RB
the  ||| S:13304 E:13308 ||| DT
peptide  ||| S:13308 E:13316 ||| NN
or  ||| S:13316 E:13319 ||| CC
the  ||| S:13319 E:13323 ||| DT
GSK3β  ||| S:13323 E:13329 ||| JJ
antibody  ||| S:13329 E:13338 ||| NN
from  ||| S:13338 E:13343 ||| IN
the  ||| S:13343 E:13347 ||| DT
assay  ||| S:13347 E:13353 ||| NN
resulted  ||| S:13353 E:13370 ||| VBD
in  ||| S:13370 E:13373 ||| IN
minimal  ||| S:13373 E:13381 ||| JJ
phosphorylation  ||| S:13381 E:13397 ||| NN
of  ||| S:13397 E:13400 ||| IN
the  ||| S:13400 E:13404 ||| DT
substrate  ||| S:13404 E:13414 ||| JJ
peptide  ||| S:13414 E:13422 ||| NNS
( ||| S:13422 E:13423 ||| -LRB-
fig  ||| S:13423 E:13435 ||| CD
4 ||| S:13435 E:13436 ||| CD
) ||| S:13436 E:13437 ||| -RRB-
.  ||| S:13437 E:13439 ||| .
When  ||| S:13439 E:13444 ||| WRB
both  ||| S:13444 E:13449 ||| DT
GSK3β  ||| S:13449 E:13455 ||| JJ
antibody  ||| S:13455 E:13464 ||| NN
and  ||| S:13464 E:13468 ||| CC
substrate  ||| S:13468 E:13478 ||| JJ
peptide  ||| S:13478 E:13486 ||| NN
were  ||| S:13486 E:13499 ||| VBD
employed ||| S:13499 E:13507 ||| VBN
,  ||| S:13507 E:13509 ||| ,
high  ||| S:13509 E:13514 ||| JJ
levels  ||| S:13514 E:13521 ||| NNS
of  ||| S:13521 E:13524 ||| IN
GSK3β-dependent  ||| S:13524 E:13540 ||| CD
kinase  ||| S:13540 E:13547 ||| JJ
activity  ||| S:13547 E:13564 ||| NN
were  ||| S:13564 E:13569 ||| VBD
detected ||| S:13569 E:13577 ||| VBN
.  ||| S:13577 E:13579 ||| .
When  ||| S:13579 E:13584 ||| WRB
cells  ||| S:13584 E:13590 ||| NNS
were  ||| S:13590 E:13595 ||| VBD
incubated  ||| S:13595 E:13605 ||| VBN
for  ||| S:13605 E:13609 ||| IN
24  ||| S:13609 E:13612 ||| CD
h  ||| S:13612 E:13614 ||| NN
in  ||| S:13614 E:13617 ||| IN
low  ||| S:13617 E:13629 ||| JJ
serum  ||| S:13629 E:13635 ||| NNS
( ||| S:13635 E:13636 ||| -LRB-
0.5 ||| S:13636 E:13639 ||| CD
% ||| S:13639 E:13640 ||| NN
)  ||| S:13640 E:13642 ||| -RRB-
to  ||| S:13642 E:13645 ||| TO
induce  ||| S:13645 E:13652 ||| VB
growth  ||| S:13652 E:13659 ||| NN
arrest  ||| S:13659 E:13666 ||| NN
in  ||| S:13666 E:13669 ||| IN
Go ||| S:13669 E:13671 ||| NNP
,  ||| S:13671 E:13673 ||| ,
the  ||| S:13673 E:13677 ||| DT
levels  ||| S:13677 E:13684 ||| NNS
of  ||| S:13684 E:13695 ||| IN
GSK3β  ||| S:13695 E:13701 ||| CD
activity  ||| S:13701 E:13710 ||| NN
were  ||| S:13710 E:13715 ||| VBD
increased  ||| S:13715 E:13725 ||| VBN
compared  ||| S:13725 E:13734 ||| VBN
to  ||| S:13734 E:13737 ||| TO
asynchronously  ||| S:13737 E:13760 ||| VB
growing  ||| S:13760 E:13768 ||| VBG
cells  ||| S:13768 E:13774 ||| NNS
( ||| S:13774 E:13775 ||| -LRB-
fig  ||| S:13775 E:13779 ||| CD
4 ||| S:13779 E:13780 ||| CD
,  ||| S:13780 E:13782 ||| ,
Go ||| S:13782 E:13784 ||| NNP
) ||| S:13784 E:13785 ||| -RRB-
.  ||| S:13785 E:13787 ||| .
When  ||| S:13787 E:13792 ||| WRB
asynchronously  ||| S:13792 E:13807 ||| NNS
growing  ||| S:13807 E:13823 ||| VBG
cells  ||| S:13823 E:13829 ||| NNS
were  ||| S:13829 E:13834 ||| VBD
exposed  ||| S:13834 E:13842 ||| VBN
to  ||| S:13842 E:13845 ||| TO
5Gy  ||| S:13845 E:13849 ||| CD
or  ||| S:13849 E:13852 ||| CC
10Gy  ||| S:13852 E:13857 ||| CD
of  ||| S:13857 E:13860 ||| IN
Ionizing  ||| S:13860 E:13869 ||| NNP
Radiation  ||| S:13869 E:13879 ||| NNP
to  ||| S:13879 E:13890 ||| TO
cause  ||| S:13890 E:13896 ||| VB
DNA  ||| S:13896 E:13900 ||| NN
damage ||| S:13900 E:13906 ||| NN
,  ||| S:13906 E:13908 ||| ,
the  ||| S:13908 E:13912 ||| DT
levels  ||| S:13912 E:13919 ||| NNS
of  ||| S:13919 E:13922 ||| IN
GSK3β  ||| S:13922 E:13928 ||| CD
activity  ||| S:13928 E:13937 ||| NN
were  ||| S:13937 E:13950 ||| VBD
reduced ||| S:13950 E:13957 ||| VBN
.  ||| S:13957 E:13959 ||| .
Similar  ||| S:13959 E:13967 ||| JJ
results  ||| S:13967 E:13975 ||| NNS
were  ||| S:13975 E:13980 ||| VBD
seen  ||| S:13980 E:13985 ||| VBN
using  ||| S:13985 E:13991 ||| VBG
p53-GST  ||| S:13991 E:13999 ||| NN
as  ||| S:13999 E:14002 ||| IN
the  ||| S:14002 E:14014 ||| DT
substrate  ||| S:14014 E:14024 ||| NN
for  ||| S:14024 E:14028 ||| IN
GSK3β  ||| S:14028 E:14034 ||| CD
phosphorylation  ||| S:14034 E:14050 ||| NN
in  ||| S:14050 E:14053 ||| IN
the  ||| S:14053 E:14057 ||| DT
kinase  ||| S:14057 E:14064 ||| JJ
assay  ||| S:14064 E:14078 ||| NNS
( ||| S:14078 E:14079 ||| -LRB-
data  ||| S:14079 E:14084 ||| NNS
not  ||| S:14084 E:14088 ||| RB
shown ||| S:14088 E:14093 ||| VBN
) ||| S:14093 E:14094 ||| -RRB-
.  ||| S:14094 E:14096 ||| .
This  ||| S:14096 E:14101 ||| DT
implies  ||| S:14101 E:14109 ||| NN
that  ||| S:14109 E:14114 ||| IN
the  ||| S:14114 E:14118 ||| DT
phosphorylation  ||| S:14118 E:14134 ||| NN
of  ||| S:14134 E:14145 ||| IN
serine  ||| S:14145 E:14152 ||| CD
33  ||| S:14152 E:14155 ||| CD
of  ||| S:14155 E:14158 ||| IN
p53  ||| S:14158 E:14162 ||| NN
by  ||| S:14162 E:14165 ||| IN
GSK3β  ||| S:14165 E:14171 ||| NNP
would  ||| S:14171 E:14177 ||| MD
be  ||| S:14177 E:14180 ||| VB
decreased  ||| S:14180 E:14190 ||| VBN
in  ||| S:14190 E:14193 ||| IN
cells  ||| S:14193 E:14207 ||| NNS
exposed  ||| S:14207 E:14215 ||| VBN
to  ||| S:14215 E:14218 ||| TO
DNA  ||| S:14218 E:14222 ||| NNP
damage ||| S:14222 E:14228 ||| NN
,  ||| S:14228 E:14230 ||| ,
but  ||| S:14230 E:14234 ||| CC
elevated  ||| S:14234 E:14243 ||| VBD
in  ||| S:14243 E:14246 ||| IN
cells  ||| S:14246 E:14252 ||| NNS
growth  ||| S:14252 E:14267 ||| NN
arrested  ||| S:14267 E:14276 ||| VBN
in  ||| S:14276 E:14279 ||| IN
Go ||| S:14279 E:14281 ||| NNP
.  ||| S:14281 E:14305 ||| .
Discussion  ||| S:14305 E:14324 ||| NN
Several  ||| S:14324 E:14332 ||| JJ
p53  ||| S:14332 E:14336 ||| NN
kinases  ||| S:14336 E:14344 ||| NNS
were  ||| S:14344 E:14349 ||| VBD
examined  ||| S:14349 E:14358 ||| VBN
for  ||| S:14358 E:14362 ||| IN
their  ||| S:14362 E:14368 ||| PRP$
ability  ||| S:14368 E:14376 ||| NN
to  ||| S:14376 E:14387 ||| TO
create  ||| S:14387 E:14403 ||| VB
in  ||| S:14403 E:14406 ||| IN
vitro  ||| S:14406 E:14412 ||| CD
GSK3  ||| S:14412 E:14417 ||| CD
phosphorylation  ||| S:14417 E:14433 ||| CD
sites  ||| S:14433 E:14447 ||| NNS
on  ||| S:14447 E:14450 ||| IN
p53 ||| S:14450 E:14453 ||| NN
.  ||| S:14453 E:14455 ||| .
Phosphorylation  ||| S:14455 E:14471 ||| NNP
of  ||| S:14471 E:14474 ||| IN
p53  ||| S:14474 E:14478 ||| NN
by  ||| S:14478 E:14481 ||| IN
DNA-PK  ||| S:14481 E:14488 ||| NNP
created  ||| S:14488 E:14496 ||| VBD
a  ||| S:14496 E:14506 ||| DT
phosphorylation  ||| S:14506 E:14522 ||| JJ
site  ||| S:14522 E:14527 ||| NN
for  ||| S:14527 E:14531 ||| IN
GSK3β ||| S:14531 E:14536 ||| NNP
,  ||| S:14536 E:14538 ||| ,
but  ||| S:14538 E:14542 ||| CC
not  ||| S:14542 E:14546 ||| RB
for  ||| S:14546 E:14550 ||| IN
GSK3α ||| S:14550 E:14555 ||| CD
.  ||| S:14555 E:14557 ||| .
GSK3α  ||| S:14557 E:14571 ||| NNP
and  ||| S:14571 E:14575 ||| CC
GSK3β  ||| S:14575 E:14581 ||| RB
have  ||| S:14581 E:14586 ||| VB
98 ||| S:14586 E:14588 ||| CD
%  ||| S:14588 E:14590 ||| NN
homology  ||| S:14590 E:14599 ||| NN
within  ||| S:14599 E:14606 ||| IN
the  ||| S:14606 E:14610 ||| DT
kinase  ||| S:14610 E:14617 ||| JJ
domain ||| S:14617 E:14623 ||| NN
,  ||| S:14623 E:14633 ||| ,
although  ||| S:14633 E:14642 ||| IN
regions  ||| S:14642 E:14650 ||| NNS
N-  ||| S:14650 E:14653 ||| JJ
and  ||| S:14653 E:14657 ||| CC
C-terminal  ||| S:14657 E:14668 ||| JJ
to  ||| S:14668 E:14671 ||| TO
this  ||| S:14671 E:14676 ||| DT
are  ||| S:14676 E:14680 ||| VBP
less  ||| S:14680 E:14685 ||| RBR
well  ||| S:14685 E:14698 ||| RB
conserved  ||| S:14698 E:14708 ||| JJ
[  ||| S:14708 E:14710 ||| -LRB-
36 ||| S:14710 E:14712 ||| CD
] ||| S:14712 E:14713 ||| -RRB-
.  ||| S:14713 E:14715 ||| .
GSK3α  ||| S:14715 E:14721 ||| NNP
and  ||| S:14721 E:14725 ||| CC
GSK3β  ||| S:14725 E:14731 ||| NNP
have  ||| S:14731 E:14736 ||| VBP
similar  ||| S:14736 E:14744 ||| JJ
substrate  ||| S:14744 E:14762 ||| JJ
specificity  ||| S:14762 E:14783 ||| NN
in  ||| S:14783 E:14786 ||| IN
vivo ||| S:14786 E:14790 ||| NN
,  ||| S:14790 E:14792 ||| ,
and  ||| S:14792 E:14796 ||| CC
are  ||| S:14796 E:14800 ||| VBP
regulated  ||| S:14800 E:14810 ||| VBN
in  ||| S:14810 E:14821 ||| IN
parallel  ||| S:14821 E:14830 ||| NN
in  ||| S:14830 E:14833 ||| IN
response  ||| S:14833 E:14842 ||| NN
to  ||| S:14842 E:14845 ||| TO
growth  ||| S:14845 E:14852 ||| NN
factors  ||| S:14852 E:14860 ||| NNS
[  ||| S:14860 E:14862 ||| -LRB-
24 ||| S:14862 E:14864 ||| CD
,  ||| S:14864 E:14866 ||| ,
27 ||| S:14866 E:14868 ||| CD
,  ||| S:14868 E:14870 ||| ,
28 ||| S:14870 E:14872 ||| CD
,  ||| S:14872 E:14874 ||| ,
29 ||| S:14874 E:14876 ||| CD
] ||| S:14876 E:14877 ||| -RRB-
.  ||| S:14877 E:14887 ||| .
However ||| S:14887 E:14894 ||| RB
,  ||| S:14894 E:14896 ||| ,
disruption  ||| S:14896 E:14907 ||| NN
of  ||| S:14907 E:14910 ||| IN
GSK3β  ||| S:14910 E:14916 ||| CD
in  ||| S:14916 E:14919 ||| IN
mice  ||| S:14919 E:14924 ||| JJ
results  ||| S:14924 E:14932 ||| NNS
in  ||| S:14932 E:14935 ||| IN
embryonic  ||| S:14935 E:14953 ||| JJ
lethality  ||| S:14953 E:14963 ||| NN
and  ||| S:14963 E:14967 ||| CC
impaired  ||| S:14967 E:14976 ||| JJ
NFκ  ||| S:14976 E:14980 ||| JJ
B  ||| S:14980 E:14982 ||| NN
function  ||| S:14982 E:14991 ||| NN
[  ||| S:14991 E:14993 ||| -LRB-
37 ||| S:14993 E:14995 ||| CD
] ||| S:14995 E:14996 ||| -RRB-
,  ||| S:14996 E:14998 ||| ,
indicating  ||| S:14998 E:15017 ||| VBG
that  ||| S:15017 E:15022 ||| IN
GSK3α  ||| S:15022 E:15028 ||| CD
cannot  ||| S:15028 E:15035 ||| JJ
substitute  ||| S:15035 E:15046 ||| NN
for  ||| S:15046 E:15050 ||| IN
GSK3β  ||| S:15050 E:15056 ||| CD
in  ||| S:15056 E:15059 ||| IN
this  ||| S:15059 E:15064 ||| DT
model  ||| S:15064 E:15078 ||| NN
system ||| S:15078 E:15084 ||| NN
.  ||| S:15084 E:15086 ||| .
GSK3α  ||| S:15086 E:15092 ||| NNP
and  ||| S:15092 E:15096 ||| CC
GSK3β  ||| S:15096 E:15102 ||| NNP
therefore  ||| S:15102 E:15112 ||| RB
have  ||| S:15112 E:15117 ||| VBP
overlapping  ||| S:15117 E:15129 ||| VBG
cellular  ||| S:15129 E:15146 ||| JJ
functions ||| S:15146 E:15155 ||| NNS
,  ||| S:15155 E:15157 ||| ,
but  ||| S:15157 E:15161 ||| CC
each  ||| S:15161 E:15166 ||| DT
isoform  ||| S:15166 E:15174 ||| NN
also  ||| S:15174 E:15179 ||| RB
regulates  ||| S:15179 E:15189 ||| VBZ
distinct  ||| S:15189 E:15206 ||| JJ
signaling  ||| S:15206 E:15216 ||| JJ
pathways ||| S:15216 E:15224 ||| NN
.  ||| S:15224 E:15226 ||| .
Our  ||| S:15226 E:15230 ||| PRP$
results  ||| S:15230 E:15238 ||| NNS
clearly  ||| S:15238 E:15246 ||| RB
show  ||| S:15246 E:15251 ||| VB
that  ||| S:15251 E:15256 ||| DT
p53  ||| S:15256 E:15268 ||| NN
phsophorylation  ||| S:15268 E:15284 ||| NN
is  ||| S:15284 E:15287 ||| VBZ
specific  ||| S:15287 E:15296 ||| JJ
for  ||| S:15296 E:15300 ||| IN
GSK3β ||| S:15300 E:15305 ||| CD
.  ||| S:15305 E:15315 ||| .
The  ||| S:15315 E:15319 ||| DT
GSK3β  ||| S:15319 E:15325 ||| JJ
phosphorylation  ||| S:15325 E:15341 ||| JJ
site  ||| S:15341 E:15346 ||| NN
was  ||| S:15346 E:15350 ||| VBD
identified  ||| S:15350 E:15361 ||| VBN
by  ||| S:15361 E:15372 ||| IN
mutagenesis  ||| S:15372 E:15384 ||| NN
as  ||| S:15384 E:15387 ||| IN
serine  ||| S:15387 E:15394 ||| CD
33  ||| S:15394 E:15397 ||| CD
of  ||| S:15397 E:15400 ||| IN
p53 ||| S:15400 E:15403 ||| NN
,  ||| S:15403 E:15405 ||| ,
and  ||| S:15405 E:15409 ||| CC
we  ||| S:15409 E:15412 ||| PRP
were  ||| S:15412 E:15417 ||| VBD
able  ||| S:15417 E:15422 ||| JJ
to  ||| S:15422 E:15425 ||| TO
show  ||| S:15425 E:15438 ||| VB
that  ||| S:15438 E:15443 ||| IN
this  ||| S:15443 E:15448 ||| DT
was  ||| S:15448 E:15452 ||| VBD
dependent  ||| S:15452 E:15462 ||| JJ
on  ||| S:15462 E:15465 ||| IN
prior  ||| S:15465 E:15471 ||| JJ
phosphorylation  ||| S:15471 E:15487 ||| NN
of  ||| S:15487 E:15490 ||| IN
serine  ||| S:15490 E:15505 ||| CD
37  ||| S:15505 E:15508 ||| CD
by  ||| S:15508 E:15511 ||| IN
DNA-PK ||| S:15511 E:15517 ||| JJ
.  ||| S:15517 E:15519 ||| .
We  ||| S:15519 E:15522 ||| PRP
also  ||| S:15522 E:15527 ||| RB
examined  ||| S:15527 E:15536 ||| VBN
if  ||| S:15536 E:15539 ||| IN
GSK3β  ||| S:15539 E:15545 ||| NNP
regulates  ||| S:15545 E:15564 ||| VBZ
in  ||| S:15564 E:15567 ||| IN
vivo  ||| S:15567 E:15572 ||| JJ
p53  ||| S:15572 E:15576 ||| NN
function  ||| S:15576 E:15585 ||| NN
through  ||| S:15585 E:15593 ||| IN
a  ||| S:15593 E:15603 ||| DT
mechanism  ||| S:15603 E:15613 ||| NN
involving  ||| S:15613 E:15623 ||| VBG
serines  ||| S:15623 E:15631 ||| CD
33  ||| S:15631 E:15634 ||| CD
and  ||| S:15634 E:15638 ||| CC
37  ||| S:15638 E:15641 ||| CD
of  ||| S:15641 E:15644 ||| IN
p53 ||| S:15644 E:15647 ||| NN
.  ||| S:15647 E:15649 ||| .
Previous  ||| S:15649 E:15666 ||| JJ
studies  ||| S:15666 E:15674 ||| NNS
have  ||| S:15674 E:15679 ||| VBP
shown  ||| S:15679 E:15685 ||| VBN
that  ||| S:15685 E:15690 ||| IN
phosphorylation  ||| S:15690 E:15706 ||| NN
of  ||| S:15706 E:15709 ||| IN
serines  ||| S:15709 E:15717 ||| CD
15 ||| S:15717 E:15719 ||| CD
,  ||| S:15719 E:15721 ||| ,
20 ||| S:15721 E:15723 ||| CD
,  ||| S:15723 E:15733 ||| ,
33  ||| S:15733 E:15736 ||| CD
and  ||| S:15736 E:15740 ||| CC
37  ||| S:15740 E:15743 ||| CD
of  ||| S:15743 E:15746 ||| IN
p53  ||| S:15746 E:15750 ||| NN
block  ||| S:15750 E:15756 ||| VB
the  ||| S:15756 E:15760 ||| DT
interaction  ||| S:15760 E:15772 ||| NN
of  ||| S:15772 E:15775 ||| IN
p53  ||| S:15775 E:15779 ||| NN
with  ||| S:15779 E:15784 ||| IN
mdm2 ||| S:15784 E:15788 ||| NNP
,  ||| S:15788 E:15798 ||| ,
leading  ||| S:15798 E:15806 ||| VBG
to  ||| S:15806 E:15809 ||| TO
stabilization  ||| S:15809 E:15823 ||| VB
and  ||| S:15823 E:15827 ||| CC
accumulation  ||| S:15827 E:15840 ||| NN
of  ||| S:15840 E:15843 ||| IN
p53  ||| S:15843 E:15847 ||| NN
protein  ||| S:15847 E:15855 ||| NN
in  ||| S:15855 E:15866 ||| IN
the  ||| S:15866 E:15870 ||| DT
cell  ||| S:15870 E:15875 ||| NN
[  ||| S:15875 E:15877 ||| -LRB-
10 ||| S:15877 E:15879 ||| CD
,  ||| S:15879 E:15881 ||| ,
11 ||| S:15881 E:15883 ||| CD
,  ||| S:15883 E:15885 ||| ,
13 ||| S:15885 E:15887 ||| CD
,  ||| S:15887 E:15889 ||| ,
14 ||| S:15889 E:15891 ||| CD
,  ||| S:15891 E:15893 ||| ,
15 ||| S:15893 E:15895 ||| CD
,  ||| S:15895 E:15897 ||| ,
18 ||| S:15897 E:15899 ||| CD
] ||| S:15899 E:15900 ||| -RRB-
.  ||| S:15900 E:15902 ||| .
mdm2  ||| S:15902 E:15907 ||| FW
binding  ||| S:15907 E:15915 ||| FW
is  ||| S:15915 E:15926 ||| VBZ
dependent  ||| S:15926 E:15936 ||| JJ
on  ||| S:15936 E:15939 ||| IN
the  ||| S:15939 E:15943 ||| DT
phosphorylation  ||| S:15943 E:15959 ||| JJ
status  ||| S:15959 E:15966 ||| NN
of  ||| S:15966 E:15969 ||| IN
serine  ||| S:15969 E:15976 ||| CD
20  ||| S:15976 E:15979 ||| CD
of  ||| S:15979 E:15982 ||| IN
p53  ||| S:15982 E:15994 ||| NN
[  ||| S:15994 E:15996 ||| -LRB-
15 ||| S:15996 E:15998 ||| CD
] ||| S:15998 E:15999 ||| -RRB-
,  ||| S:15999 E:16001 ||| ,
although  ||| S:16001 E:16010 ||| IN
phosphorylation  ||| S:16010 E:16026 ||| NN
of  ||| S:16026 E:16029 ||| IN
serines  ||| S:16029 E:16037 ||| CD
15 ||| S:16037 E:16039 ||| CD
,  ||| S:16039 E:16041 ||| ,
33  ||| S:16041 E:16044 ||| CD
and  ||| S:16044 E:16048 ||| CC
37  ||| S:16048 E:16059 ||| CD
also  ||| S:16059 E:16064 ||| RB
play  ||| S:16064 E:16069 ||| VB
a  ||| S:16069 E:16071 ||| DT
role ||| S:16071 E:16075 ||| NN
.  ||| S:16075 E:16077 ||| .
We  ||| S:16077 E:16080 ||| PRP
did  ||| S:16080 E:16084 ||| VBD
not  ||| S:16084 E:16088 ||| RB
detect  ||| S:16088 E:16095 ||| VB
any  ||| S:16095 E:16099 ||| DT
significant  ||| S:16099 E:16119 ||| JJ
difference  ||| S:16119 E:16130 ||| NN
in  ||| S:16130 E:16133 ||| IN
the  ||| S:16133 E:16137 ||| DT
level  ||| S:16137 E:16143 ||| NN
of  ||| S:16143 E:16146 ||| IN
expression  ||| S:16146 E:16157 ||| NN
of  ||| S:16157 E:16160 ||| IN
p53  ||| S:16160 E:16164 ||| NN
with  ||| S:16164 E:16169 ||| IN
single  ||| S:16169 E:16184 ||| JJ
mutations  ||| S:16184 E:16194 ||| NNS
in  ||| S:16194 E:16197 ||| IN
either  ||| S:16197 E:16204 ||| DT
serines  ||| S:16204 E:16212 ||| JJ
33  ||| S:16212 E:16215 ||| CD
or  ||| S:16215 E:16218 ||| CC
37  ||| S:16218 E:16221 ||| CD
when  ||| S:16221 E:16226 ||| WRB
compared  ||| S:16226 E:16235 ||| VBN
to  ||| S:16235 E:16246 ||| TO
wtp53 ||| S:16246 E:16251 ||| CD
,  ||| S:16251 E:16253 ||| ,
indicating  ||| S:16253 E:16264 ||| VBG
that  ||| S:16264 E:16269 ||| IN
single  ||| S:16269 E:16276 ||| JJ
point  ||| S:16276 E:16282 ||| NN
mutations  ||| S:16282 E:16292 ||| NNS
in  ||| S:16292 E:16295 ||| IN
serines  ||| S:16295 E:16303 ||| CD
33  ||| S:16303 E:16314 ||| CD
or  ||| S:16314 E:16317 ||| CC
37  ||| S:16317 E:16320 ||| CD
do  ||| S:16320 E:16323 ||| VBP
not  ||| S:16323 E:16327 ||| RB
greatly  ||| S:16327 E:16335 ||| RB
alter  ||| S:16335 E:16341 ||| VB
p53  ||| S:16341 E:16345 ||| NN
stability ||| S:16345 E:16354 ||| NN
.  ||| S:16354 E:16364 ||| .
A  ||| S:16364 E:16366 ||| DT
key  ||| S:16366 E:16370 ||| JJ
function  ||| S:16370 E:16379 ||| NN
of  ||| S:16379 E:16382 ||| IN
p53  ||| S:16382 E:16386 ||| NN
is  ||| S:16386 E:16389 ||| VBZ
the  ||| S:16389 E:16393 ||| DT
transcriptional  ||| S:16393 E:16409 ||| JJ
activation  ||| S:16409 E:16428 ||| NN
of  ||| S:16428 E:16431 ||| IN
genes  ||| S:16431 E:16437 ||| NNS
which  ||| S:16437 E:16443 ||| WDT
regulate  ||| S:16443 E:16452 ||| JJ
growth  ||| S:16452 E:16459 ||| NN
arrest  ||| S:16459 E:16466 ||| NN
and  ||| S:16466 E:16470 ||| CC
apoptosis  ||| S:16470 E:16480 ||| NNS
[  ||| S:16480 E:16482 ||| -LRB-
1 ||| S:16482 E:16483 ||| CD
,  ||| S:16483 E:16485 ||| ,
2 ||| S:16485 E:16486 ||| CD
,  ||| S:16486 E:16496 ||| ,
3 ||| S:16496 E:16497 ||| CD
,  ||| S:16497 E:16499 ||| ,
4 ||| S:16499 E:16500 ||| LS
] ||| S:16500 E:16501 ||| -RRB-
.  ||| S:16501 E:16503 ||| .
Individual  ||| S:16503 E:16514 ||| JJ
mutation  ||| S:16514 E:16523 ||| NN
of  ||| S:16523 E:16526 ||| IN
either  ||| S:16526 E:16533 ||| DT
serine  ||| S:16533 E:16540 ||| JJ
33  ||| S:16540 E:16543 ||| CD
or  ||| S:16543 E:16546 ||| CC
37  ||| S:16546 E:16557 ||| CD
slightly  ||| S:16557 E:16566 ||| RB
increased  ||| S:16566 E:16576 ||| VBD
the  ||| S:16576 E:16580 ||| DT
basal  ||| S:16580 E:16586 ||| JJ
transcriptional  ||| S:16586 E:16602 ||| JJ
activity  ||| S:16602 E:16611 ||| NN
of  ||| S:16611 E:16622 ||| IN
the  ||| S:16622 E:16626 ||| DT
p53  ||| S:16626 E:16630 ||| NN
protein ||| S:16630 E:16637 ||| NN
.  ||| S:16637 E:16639 ||| .
This  ||| S:16639 E:16644 ||| DT
is  ||| S:16644 E:16647 ||| VBZ
in  ||| S:16647 E:16650 ||| IN
keeping  ||| S:16650 E:16658 ||| VBG
with  ||| S:16658 E:16663 ||| IN
observations  ||| S:16663 E:16676 ||| NNS
made  ||| S:16676 E:16689 ||| VBN
by  ||| S:16689 E:16692 ||| IN
other  ||| S:16692 E:16698 ||| JJ
groups ||| S:16698 E:16704 ||| NNS
,  ||| S:16704 E:16706 ||| ,
who  ||| S:16706 E:16710 ||| WP
demonstrated  ||| S:16710 E:16723 ||| VBD
that  ||| S:16723 E:16728 ||| DT
single  ||| S:16728 E:16735 ||| JJ
or  ||| S:16735 E:16738 ||| CC
multiple  ||| S:16738 E:16755 ||| JJ
mutations  ||| S:16755 E:16765 ||| NNS
in  ||| S:16765 E:16768 ||| IN
p53  ||| S:16768 E:16772 ||| NN
phosphorylation  ||| S:16772 E:16788 ||| NN
sites  ||| S:16788 E:16794 ||| NNS
has  ||| S:16794 E:16798 ||| VBZ
minimal  ||| S:16798 E:16806 ||| JJ
effect  ||| S:16806 E:16821 ||| NN
on  ||| S:16821 E:16824 ||| IN
the  ||| S:16824 E:16828 ||| DT
basal  ||| S:16828 E:16834 ||| JJ
transcriptional  ||| S:16834 E:16850 ||| JJ
activity  ||| S:16850 E:16859 ||| NN
of  ||| S:16859 E:16862 ||| IN
the  ||| S:16862 E:16866 ||| DT
p53  ||| S:16866 E:16870 ||| NN
protein  ||| S:16870 E:16878 ||| NN
[  ||| S:16878 E:16888 ||| -LRB-
38 ||| S:16888 E:16890 ||| CD
,  ||| S:16890 E:16892 ||| ,
39 ||| S:16892 E:16894 ||| CD
,  ||| S:16894 E:16896 ||| ,
40 ||| S:16896 E:16898 ||| CD
] ||| S:16898 E:16899 ||| -RRB-
.  ||| S:16899 E:16901 ||| .
We  ||| S:16901 E:16904 ||| PRP
also  ||| S:16904 E:16909 ||| RB
determined  ||| S:16909 E:16920 ||| VBN
if  ||| S:16920 E:16923 ||| IN
GSK3β  ||| S:16923 E:16929 ||| NNP
could  ||| S:16929 E:16935 ||| MD
regulate  ||| S:16935 E:16944 ||| VB
p53  ||| S:16944 E:16956 ||| NN
transcriptional  ||| S:16956 E:16972 ||| NN
activity  ||| S:16972 E:16990 ||| NN
in  ||| S:16990 E:16993 ||| IN
vivo ||| S:16993 E:16997 ||| NN
.  ||| S:16997 E:16999 ||| .
GSK3β  ||| S:16999 E:17005 ||| NNP
is  ||| S:17005 E:17008 ||| VBZ
constitutively  ||| S:17008 E:17031 ||| JJ
active  ||| S:17031 E:17038 ||| JJ
in  ||| S:17038 E:17041 ||| IN
resting  ||| S:17041 E:17049 ||| JJ
cells ||| S:17049 E:17054 ||| NNS
,  ||| S:17054 E:17056 ||| ,
but  ||| S:17056 E:17060 ||| CC
exhibits  ||| S:17060 E:17069 ||| VBZ
lower  ||| S:17069 E:17075 ||| JJR
activity  ||| S:17075 E:17084 ||| NN
in  ||| S:17084 E:17095 ||| IN
asynchronously  ||| S:17095 E:17110 ||| NNS
growing  ||| S:17110 E:17118 ||| VBG
cells  ||| S:17118 E:17124 ||| NNS
[  ||| S:17124 E:17126 ||| -LRB-
24 ||| S:17126 E:17128 ||| CD
] ||| S:17128 E:17129 ||| -RRB-
.  ||| S:17129 E:17131 ||| .
To  ||| S:17131 E:17134 ||| TO
increase  ||| S:17134 E:17143 ||| VB
the  ||| S:17143 E:17155 ||| DT
activity  ||| S:17155 E:17164 ||| NN
of  ||| S:17164 E:17167 ||| IN
GSK3β ||| S:17167 E:17172 ||| NNP
,  ||| S:17172 E:17174 ||| ,
we  ||| S:17174 E:17177 ||| PRP
co-transfected  ||| S:17177 E:17192 ||| JJ
GSK3β  ||| S:17192 E:17198 ||| NN
with  ||| S:17198 E:17203 ||| IN
either  ||| S:17203 E:17218 ||| DT
wtp53  ||| S:17218 E:17224 ||| NNP
or  ||| S:17224 E:17227 ||| CC
p53  ||| S:17227 E:17231 ||| NN
bearing  ||| S:17231 E:17239 ||| NN
serine  ||| S:17239 E:17246 ||| NN
to  ||| S:17246 E:17249 ||| TO
alanine  ||| S:17249 E:17257 ||| VB
mutations  ||| S:17257 E:17267 ||| VBN
at  ||| S:17267 E:17278 ||| IN
positions  ||| S:17278 E:17288 ||| NNS
33  ||| S:17288 E:17291 ||| CD
or  ||| S:17291 E:17294 ||| CC
37 ||| S:17294 E:17296 ||| CD
.  ||| S:17296 E:17298 ||| .
GSK3β  ||| S:17298 E:17304 ||| NNP
increased  ||| S:17304 E:17314 ||| VBD
the  ||| S:17314 E:17318 ||| DT
transcriptional  ||| S:17318 E:17342 ||| JJ
activity  ||| S:17342 E:17351 ||| NN
of  ||| S:17351 E:17354 ||| IN
wtp53 ||| S:17354 E:17359 ||| NNP
,  ||| S:17359 E:17361 ||| ,
but  ||| S:17361 E:17365 ||| CC
not  ||| S:17365 E:17369 ||| RB
of  ||| S:17369 E:17372 ||| IN
p53  ||| S:17372 E:17376 ||| NN
with  ||| S:17376 E:17381 ||| IN
mutations  ||| S:17381 E:17391 ||| NNS
in  ||| S:17391 E:17394 ||| IN
either  ||| S:17394 E:17409 ||| DT
serine  ||| S:17409 E:17416 ||| JJ
33  ||| S:17416 E:17419 ||| CD
or  ||| S:17419 E:17422 ||| CC
37 ||| S:17422 E:17424 ||| CD
.  ||| S:17424 E:17426 ||| .
Therefore  ||| S:17426 E:17436 ||| RB
both  ||| S:17436 E:17441 ||| DT
serine  ||| S:17441 E:17448 ||| JJ
33  ||| S:17448 E:17451 ||| CD
and  ||| S:17451 E:17455 ||| CC
serine  ||| S:17455 E:17462 ||| CD
37  ||| S:17462 E:17465 ||| CD
are  ||| S:17465 E:17477 ||| VBP
required  ||| S:17477 E:17486 ||| VBN
for  ||| S:17486 E:17490 ||| IN
GSK3β  ||| S:17490 E:17496 ||| CD
to  ||| S:17496 E:17499 ||| TO
activate  ||| S:17499 E:17508 ||| VB
p53  ||| S:17508 E:17512 ||| NN
transcriptional  ||| S:17512 E:17528 ||| NN
activity  ||| S:17528 E:17554 ||| NN
in  ||| S:17554 E:17557 ||| IN
vivo ||| S:17557 E:17561 ||| NN
.  ||| S:17561 E:17563 ||| .
GSK3β  ||| S:17563 E:17569 ||| NNP
regulates  ||| S:17569 E:17579 ||| VBZ
many  ||| S:17579 E:17584 ||| JJ
stress  ||| S:17584 E:17599 ||| NN
activated  ||| S:17599 E:17609 ||| VBN
transcription  ||| S:17609 E:17623 ||| JJ
factors ||| S:17623 E:17630 ||| NNS
.  ||| S:17630 E:17632 ||| .
For  ||| S:17632 E:17636 ||| IN
example ||| S:17636 E:17643 ||| NN
,  ||| S:17643 E:17645 ||| ,
GSK3β  ||| S:17645 E:17651 ||| NNP
is  ||| S:17651 E:17662 ||| VBZ
required  ||| S:17662 E:17671 ||| VBN
for  ||| S:17671 E:17675 ||| IN
activation  ||| S:17675 E:17686 ||| NN
of  ||| S:17686 E:17689 ||| IN
NFκ  ||| S:17689 E:17693 ||| NNP
B  ||| S:17693 E:17695 ||| NNP
[  ||| S:17695 E:17697 ||| -LRB-
37 ||| S:17697 E:17699 ||| CD
] ||| S:17699 E:17700 ||| -RRB-
,  ||| S:17700 E:17702 ||| ,
but  ||| S:17702 E:17706 ||| CC
inhibits  ||| S:17706 E:17723 ||| JJ
activation  ||| S:17723 E:17734 ||| NN
of  ||| S:17734 E:17737 ||| IN
Heat  ||| S:17737 E:17742 ||| NNP
Shock  ||| S:17742 E:17748 ||| NNP
Factor-1  ||| S:17748 E:17757 ||| NNP
[  ||| S:17757 E:17759 ||| -LRB-
27 ||| S:17759 E:17761 ||| CD
] ||| S:17761 E:17762 ||| -RRB-
.  ||| S:17762 E:17764 ||| .
Our  ||| S:17764 E:17768 ||| PRP$
results  ||| S:17768 E:17784 ||| NNS
indicate  ||| S:17784 E:17793 ||| VBP
that  ||| S:17793 E:17798 ||| IN
GSK3β  ||| S:17798 E:17804 ||| NNP
may  ||| S:17804 E:17808 ||| MD
also  ||| S:17808 E:17813 ||| RB
be  ||| S:17813 E:17816 ||| VB
involved  ||| S:17816 E:17825 ||| VBN
in  ||| S:17825 E:17828 ||| IN
the  ||| S:17828 E:17832 ||| DT
activation  ||| S:17832 E:17851 ||| NN
of  ||| S:17851 E:17854 ||| IN
the  ||| S:17854 E:17858 ||| DT
p53  ||| S:17858 E:17862 ||| NN
protein  ||| S:17862 E:17870 ||| NN
as  ||| S:17870 E:17873 ||| IN
well ||| S:17873 E:17877 ||| RB
.  ||| S:17877 E:17887 ||| .
A  ||| S:17887 E:17889 ||| DT
key  ||| S:17889 E:17893 ||| JJ
question  ||| S:17893 E:17902 ||| NN
is  ||| S:17902 E:17905 ||| VBZ
whether  ||| S:17905 E:17913 ||| IN
DNA-PK  ||| S:17913 E:17920 ||| JJ
or  ||| S:17920 E:17923 ||| CC
some  ||| S:17923 E:17928 ||| DT
other  ||| S:17928 E:17934 ||| JJ
kinase  ||| S:17934 E:17949 ||| NN
phosphorylates  ||| S:17949 E:17964 ||| VBD
serine  ||| S:17964 E:17971 ||| CD
37  ||| S:17971 E:17974 ||| CD
of  ||| S:17974 E:17977 ||| IN
p53  ||| S:17977 E:17990 ||| NN
in  ||| S:17990 E:17993 ||| IN
vivo ||| S:17993 E:17997 ||| NN
.  ||| S:17997 E:17999 ||| .
DNA-PK  ||| S:17999 E:18006 ||| NNP
is  ||| S:18006 E:18009 ||| VBZ
460  ||| S:18009 E:18013 ||| CD
kd  ||| S:18013 E:18024 ||| CD
DNA-activated  ||| S:18024 E:18038 ||| JJ
protein  ||| S:18038 E:18046 ||| NN
kinase  ||| S:18046 E:18053 ||| NNS
which  ||| S:18053 E:18059 ||| WDT
participates  ||| S:18059 E:18072 ||| VBZ
in  ||| S:18072 E:18075 ||| IN
the  ||| S:18075 E:18087 ||| DT
cellular  ||| S:18087 E:18096 ||| JJ
response  ||| S:18096 E:18105 ||| NN
to  ||| S:18105 E:18108 ||| TO
DNA  ||| S:18108 E:18112 ||| NNP
damage  ||| S:18112 E:18119 ||| NN
[  ||| S:18119 E:18121 ||| -LRB-
41 ||| S:18121 E:18123 ||| CD
] ||| S:18123 E:18124 ||| -RRB-
.  ||| S:18124 E:18126 ||| .
DNA-PK  ||| S:18126 E:18133 ||| NNP
is  ||| S:18133 E:18136 ||| VBZ
involved  ||| S:18136 E:18153 ||| VBN
in  ||| S:18153 E:18156 ||| IN
DNA  ||| S:18156 E:18160 ||| NNP
strand-break  ||| S:18160 E:18173 ||| JJ
repair ||| S:18173 E:18179 ||| NN
,  ||| S:18179 E:18181 ||| ,
and  ||| S:18181 E:18185 ||| CC
can  ||| S:18185 E:18189 ||| MD
phosphorylate  ||| S:18189 E:18203 ||| VB
serines  ||| S:18203 E:18219 ||| CD
15  ||| S:18219 E:18222 ||| CD
and  ||| S:18222 E:18226 ||| CC
serine  ||| S:18226 E:18233 ||| CD
37  ||| S:18233 E:18236 ||| CD
of  ||| S:18236 E:18239 ||| IN
p53  ||| S:18239 E:18252 ||| NN
in  ||| S:18252 E:18255 ||| IN
vitro  ||| S:18255 E:18261 ||| NNS
[  ||| S:18261 E:18263 ||| -LRB-
32 ||| S:18263 E:18265 ||| CD
] ||| S:18265 E:18266 ||| -RRB-
.  ||| S:18266 E:18268 ||| .
Some  ||| S:18268 E:18273 ||| DT
reports  ||| S:18273 E:18281 ||| NNS
indicate  ||| S:18281 E:18298 ||| VBP
that  ||| S:18298 E:18303 ||| IN
DNA-PK  ||| S:18303 E:18310 ||| NNP
is  ||| S:18310 E:18313 ||| VBZ
required  ||| S:18313 E:18322 ||| VBN
for  ||| S:18322 E:18326 ||| IN
the  ||| S:18326 E:18330 ||| DT
activation  ||| S:18330 E:18341 ||| NN
of  ||| S:18341 E:18344 ||| IN
p53  ||| S:18344 E:18348 ||| NN
[  ||| S:18348 E:18350 ||| -LRB-
42 ||| S:18350 E:18352 ||| CD
] ||| S:18352 E:18353 ||| -RRB-
,  ||| S:18353 E:18363 ||| ,
but  ||| S:18363 E:18367 ||| CC
recent  ||| S:18367 E:18374 ||| JJ
genetic  ||| S:18374 E:18382 ||| JJ
studies  ||| S:18382 E:18390 ||| NNS
have  ||| S:18390 E:18395 ||| VBP
shown  ||| S:18395 E:18401 ||| VBN
clearly  ||| S:18401 E:18409 ||| RB
that  ||| S:18409 E:18414 ||| IN
DNA-PK  ||| S:18414 E:18429 ||| NNP
is  ||| S:18429 E:18432 ||| VBZ
not  ||| S:18432 E:18436 ||| RB
required  ||| S:18436 E:18445 ||| VBN
for  ||| S:18445 E:18449 ||| IN
p53  ||| S:18449 E:18453 ||| NN
activation  ||| S:18453 E:18464 ||| NN
by  ||| S:18464 E:18467 ||| IN
Ionizing  ||| S:18467 E:18476 ||| NNP
Radiation  ||| S:18476 E:18486 ||| NNP
[  ||| S:18486 E:18496 ||| -LRB-
43 ||| S:18496 E:18498 ||| CD
] ||| S:18498 E:18499 ||| -RRB-
.  ||| S:18499 E:18501 ||| .
Whether  ||| S:18501 E:18509 ||| IN
DNA-PK  ||| S:18509 E:18516 ||| NNP
is  ||| S:18516 E:18519 ||| VBZ
required  ||| S:18519 E:18528 ||| VBN
for  ||| S:18528 E:18532 ||| IN
p53  ||| S:18532 E:18536 ||| NN
activation  ||| S:18536 E:18547 ||| NN
in  ||| S:18547 E:18558 ||| IN
response  ||| S:18558 E:18567 ||| NN
to  ||| S:18567 E:18570 ||| TO
other  ||| S:18570 E:18576 ||| JJ
stimuli  ||| S:18576 E:18584 ||| NN
is  ||| S:18584 E:18587 ||| VBZ
not  ||| S:18587 E:18591 ||| RB
known ||| S:18591 E:18596 ||| VBN
.  ||| S:18596 E:18598 ||| .
A  ||| S:18598 E:18600 ||| DT
more  ||| S:18600 E:18605 ||| RBR
likely  ||| S:18605 E:18620 ||| JJ
candidate  ||| S:18620 E:18630 ||| NN
is  ||| S:18630 E:18633 ||| VBZ
the  ||| S:18633 E:18637 ||| DT
Atr  ||| S:18637 E:18641 ||| JJ
protein  ||| S:18641 E:18649 ||| NN
kinase ||| S:18649 E:18655 ||| NN
,  ||| S:18655 E:18657 ||| ,
a  ||| S:18657 E:18659 ||| DT
kinase  ||| S:18659 E:18666 ||| NN
related  ||| S:18666 E:18674 ||| VBN
to  ||| S:18674 E:18685 ||| TO
DNA-PK  ||| S:18685 E:18692 ||| NNP
[  ||| S:18692 E:18694 ||| -LRB-
44 ||| S:18694 E:18696 ||| CD
] ||| S:18696 E:18697 ||| -RRB-
,  ||| S:18697 E:18699 ||| ,
which  ||| S:18699 E:18705 ||| WDT
can  ||| S:18705 E:18709 ||| MD
regulate  ||| S:18709 E:18718 ||| VB
the  ||| S:18718 E:18722 ||| DT
phosphorylation  ||| S:18722 E:18738 ||| NN
of  ||| S:18738 E:18749 ||| IN
serine  ||| S:18749 E:18756 ||| CD
37  ||| S:18756 E:18759 ||| CD
of  ||| S:18759 E:18762 ||| IN
p53  ||| S:18762 E:18766 ||| NN
in  ||| S:18766 E:18769 ||| IN
response  ||| S:18769 E:18778 ||| NN
to  ||| S:18778 E:18781 ||| TO
DNA  ||| S:18781 E:18785 ||| NNP
damage ||| S:18785 E:18791 ||| NN
.  ||| S:18791 E:18793 ||| .
The  ||| S:18793 E:18797 ||| DT
present  ||| S:18797 E:18813 ||| JJ
data  ||| S:18813 E:18818 ||| NN
indicates  ||| S:18818 E:18828 ||| VBZ
that  ||| S:18828 E:18833 ||| DT
transcriptional  ||| S:18833 E:18849 ||| JJ
activation  ||| S:18849 E:18860 ||| NN
of  ||| S:18860 E:18863 ||| IN
p53  ||| S:18863 E:18867 ||| NN
by  ||| S:18867 E:18878 ||| IN
GSK3β  ||| S:18878 E:18884 ||| NNP
requires  ||| S:18884 E:18893 ||| VBZ
both  ||| S:18893 E:18898 ||| DT
serines  ||| S:18898 E:18906 ||| JJ
33  ||| S:18906 E:18909 ||| CD
and  ||| S:18909 E:18913 ||| CC
37 ||| S:18913 E:18915 ||| CD
,  ||| S:18915 E:18917 ||| ,
but  ||| S:18917 E:18921 ||| CC
it  ||| S:18921 E:18924 ||| PRP
does  ||| S:18924 E:18929 ||| VBZ
not  ||| S:18929 E:18941 ||| RB
allow  ||| S:18941 E:18947 ||| VB
us  ||| S:18947 E:18950 ||| PRP
to  ||| S:18950 E:18953 ||| TO
determine  ||| S:18953 E:18963 ||| VB
if  ||| S:18963 E:18966 ||| IN
phosphorylation  ||| S:18966 E:18982 ||| NN
of  ||| S:18982 E:18985 ||| IN
serine  ||| S:18985 E:18992 ||| CD
33  ||| S:18992 E:18995 ||| CD
is  ||| S:18995 E:19006 ||| VBZ
dependent  ||| S:19006 E:19016 ||| JJ
on  ||| S:19016 E:19019 ||| IN
phosphorylation  ||| S:19019 E:19035 ||| NN
of  ||| S:19035 E:19038 ||| IN
serine  ||| S:19038 E:19045 ||| CD
37  ||| S:19045 E:19057 ||| CD
in  ||| S:19057 E:19060 ||| IN
vivo ||| S:19060 E:19064 ||| NN
.  ||| S:19064 E:19066 ||| .
It  ||| S:19066 E:19069 ||| PRP
is  ||| S:19069 E:19072 ||| VBZ
possible  ||| S:19072 E:19081 ||| JJ
that ||| S:19081 E:19085 ||| IN
,  ||| S:19085 E:19096 ||| ,
in  ||| S:19096 E:19099 ||| IN
vivo ||| S:19099 E:19103 ||| NN
,  ||| S:19103 E:19105 ||| ,
GSK3β  ||| S:19105 E:19111 ||| NNP
directly  ||| S:19111 E:19128 ||| RB
phosphorylates  ||| S:19128 E:19143 ||| CD
serine  ||| S:19143 E:19150 ||| CD
33  ||| S:19150 E:19153 ||| CD
independently  ||| S:19153 E:19167 ||| NN
of  ||| S:19167 E:19170 ||| IN
serine  ||| S:19170 E:19177 ||| CD
37 ||| S:19177 E:19179 ||| CD
,  ||| S:19179 E:19181 ||| ,
but  ||| S:19181 E:19193 ||| CC
that  ||| S:19193 E:19198 ||| IN
both  ||| S:19198 E:19203 ||| DT
residues  ||| S:19203 E:19212 ||| NN
must  ||| S:19212 E:19217 ||| MD
be  ||| S:19217 E:19220 ||| VB
phosphorylated  ||| S:19220 E:19235 ||| VBN
for  ||| S:19235 E:19247 ||| IN
transcriptional  ||| S:19247 E:19263 ||| JJ
activation  ||| S:19263 E:19274 ||| NN
to  ||| S:19274 E:19277 ||| TO
occur  ||| S:19277 E:19292 ||| VB
in  ||| S:19292 E:19295 ||| IN
vivo ||| S:19295 E:19299 ||| NN
.  ||| S:19299 E:19301 ||| .
Future  ||| S:19301 E:19308 ||| JJ
studies  ||| S:19308 E:19316 ||| NNS
will  ||| S:19316 E:19321 ||| MD
address  ||| S:19321 E:19337 ||| VB
this  ||| S:19337 E:19342 ||| DT
issue.  ||| S:19342 E:19357 ||| JJ
p53  ||| S:19357 E:19361 ||| NN
is  ||| S:19361 E:19364 ||| VBZ
activated  ||| S:19364 E:19374 ||| VBN
by  ||| S:19374 E:19377 ||| IN
multiple  ||| S:19377 E:19386 ||| JJ
pathways ||| S:19386 E:19394 ||| NN
,  ||| S:19394 E:19396 ||| ,
including  ||| S:19396 E:19406 ||| VBG
DNA  ||| S:19406 E:19418 ||| NN
damage  ||| S:19418 E:19425 ||| NN
and  ||| S:19425 E:19429 ||| CC
oncogene  ||| S:19429 E:19438 ||| JJ
activation  ||| S:19438 E:19449 ||| NNS
[  ||| S:19449 E:19451 ||| -LRB-
1 ||| S:19451 E:19452 ||| CD
,  ||| S:19452 E:19454 ||| ,
2 ||| S:19454 E:19455 ||| CD
,  ||| S:19455 E:19457 ||| ,
3 ||| S:19457 E:19458 ||| LS
] ||| S:19458 E:19459 ||| -RRB-
.  ||| S:19459 E:19461 ||| .
If  ||| S:19461 E:19464 ||| IN
GSK3β  ||| S:19464 E:19470 ||| NNP
is  ||| S:19470 E:19481 ||| VBZ
required  ||| S:19481 E:19490 ||| VBN
for  ||| S:19490 E:19494 ||| IN
the  ||| S:19494 E:19498 ||| DT
activation  ||| S:19498 E:19509 ||| NN
of  ||| S:19509 E:19512 ||| IN
p53  ||| S:19512 E:19516 ||| NN
by  ||| S:19516 E:19519 ||| IN
DNA  ||| S:19519 E:19523 ||| NNP
damage ||| S:19523 E:19529 ||| NN
,  ||| S:19529 E:19531 ||| ,
GSK3β  ||| S:19531 E:19545 ||| CD
activity  ||| S:19545 E:19554 ||| NN
should  ||| S:19554 E:19561 ||| MD
be  ||| S:19561 E:19564 ||| VB
regulated  ||| S:19564 E:19574 ||| VBN
by  ||| S:19574 E:19577 ||| IN
DNA  ||| S:19577 E:19581 ||| NNP
damage ||| S:19581 E:19587 ||| NN
.  ||| S:19587 E:19589 ||| .
However ||| S:19589 E:19596 ||| RB
,  ||| S:19596 E:19598 ||| ,
when  ||| S:19598 E:19611 ||| WRB
cells  ||| S:19611 E:19617 ||| NNS
were  ||| S:19617 E:19622 ||| VBD
exposed  ||| S:19622 E:19630 ||| VBN
to  ||| S:19630 E:19633 ||| TO
Ionizing  ||| S:19633 E:19642 ||| NNP
Radiation ||| S:19642 E:19651 ||| NNP
,  ||| S:19651 E:19653 ||| ,
GSK3β  ||| S:19653 E:19659 ||| CD
kinase  ||| S:19659 E:19674 ||| JJ
activity  ||| S:19674 E:19683 ||| NN
was  ||| S:19683 E:19687 ||| VBD
inhibited  ||| S:19687 E:19697 ||| VBN
rather  ||| S:19697 E:19704 ||| RB
than  ||| S:19704 E:19709 ||| IN
enhanced ||| S:19709 E:19717 ||| JJ
,  ||| S:19717 E:19719 ||| ,
implying  ||| S:19719 E:19736 ||| VBG
decreased  ||| S:19736 E:19746 ||| VBN
GSK3β-dependent  ||| S:19746 E:19762 ||| CD
phosphorylation  ||| S:19762 E:19778 ||| NN
of  ||| S:19778 E:19781 ||| IN
p53  ||| S:19781 E:19785 ||| NN
after  ||| S:19785 E:19791 ||| IN
DNA  ||| S:19791 E:19803 ||| NNP
damage ||| S:19803 E:19809 ||| NN
.  ||| S:19809 E:19811 ||| .
Serine  ||| S:19811 E:19818 ||| NNP
33  ||| S:19818 E:19821 ||| CD
of  ||| S:19821 E:19824 ||| IN
p53  ||| S:19824 E:19828 ||| NN
is  ||| S:19828 E:19831 ||| VBZ
also  ||| S:19831 E:19836 ||| RB
phosphorylated  ||| S:19836 E:19851 ||| VBN
by  ||| S:19851 E:19854 ||| IN
other  ||| S:19854 E:19868 ||| JJ
kinases ||| S:19868 E:19875 ||| NN
,  ||| S:19875 E:19877 ||| ,
including  ||| S:19877 E:19887 ||| VBG
the  ||| S:19887 E:19891 ||| DT
CDK7-cyclin  ||| S:19891 E:19903 ||| NNP
H  ||| S:19903 E:19905 ||| NNP
complex  ||| S:19905 E:19913 ||| NN
[  ||| S:19913 E:19915 ||| -LRB-
45 ||| S:19915 E:19917 ||| CD
]  ||| S:19917 E:19919 ||| -RRB-
and  ||| S:19919 E:19923 ||| CC
p38  ||| S:19923 E:19935 ||| NNP
MAPK  ||| S:19935 E:19940 ||| NNP
[  ||| S:19940 E:19942 ||| -LRB-
46 ||| S:19942 E:19944 ||| CD
] ||| S:19944 E:19945 ||| -RRB-
.  ||| S:19945 E:19947 ||| .
p38  ||| S:19947 E:19951 ||| FW
MAPK  ||| S:19951 E:19956 ||| FW
is  ||| S:19956 E:19959 ||| VBZ
involved  ||| S:19959 E:19968 ||| VBN
in  ||| S:19968 E:19971 ||| IN
p53  ||| S:19971 E:19975 ||| NN
activation  ||| S:19975 E:19986 ||| NN
by  ||| S:19986 E:19997 ||| IN
genotoxic  ||| S:19997 E:20007 ||| JJ
stress  ||| S:20007 E:20014 ||| NN
[  ||| S:20014 E:20016 ||| -LRB-
46 ||| S:20016 E:20018 ||| CD
] ||| S:20018 E:20019 ||| -RRB-
,  ||| S:20019 E:20021 ||| ,
and  ||| S:20021 E:20025 ||| CC
may  ||| S:20025 E:20029 ||| MD
be  ||| S:20029 E:20032 ||| VB
responsible  ||| S:20032 E:20044 ||| JJ
for  ||| S:20044 E:20048 ||| IN
p53  ||| S:20048 E:20060 ||| NN
phosphorylation  ||| S:20060 E:20076 ||| NN
at  ||| S:20076 E:20079 ||| IN
serine  ||| S:20079 E:20086 ||| CD
33  ||| S:20086 E:20089 ||| CD
in  ||| S:20089 E:20092 ||| IN
response  ||| S:20092 E:20101 ||| NN
to  ||| S:20101 E:20104 ||| TO
DNA  ||| S:20104 E:20108 ||| NNP
damage ||| S:20108 E:20114 ||| NN
.  ||| S:20114 E:20124 ||| .
GSK3β-dependent  ||| S:20124 E:20140 ||| NNP
phosphorylation  ||| S:20140 E:20156 ||| NN
of  ||| S:20156 E:20159 ||| IN
p53  ||| S:20159 E:20163 ||| NN
at  ||| S:20163 E:20166 ||| IN
serine  ||| S:20166 E:20173 ||| CD
33  ||| S:20173 E:20176 ||| CD
may  ||| S:20176 E:20180 ||| MD
be  ||| S:20180 E:20191 ||| VB
part  ||| S:20191 E:20196 ||| NN
of  ||| S:20196 E:20199 ||| IN
other  ||| S:20199 E:20205 ||| JJ
p53-regulatory  ||| S:20205 E:20220 ||| CD
pathways ||| S:20220 E:20228 ||| NN
,  ||| S:20228 E:20230 ||| ,
such  ||| S:20230 E:20235 ||| JJ
as  ||| S:20235 E:20238 ||| IN
oncogene  ||| S:20238 E:20255 ||| JJ
activation  ||| S:20255 E:20266 ||| NN
or  ||| S:20266 E:20269 ||| CC
apoptosis ||| S:20269 E:20278 ||| NN
,  ||| S:20278 E:20280 ||| ,
which  ||| S:20280 E:20286 ||| WDT
are  ||| S:20286 E:20290 ||| VBP
not  ||| S:20290 E:20294 ||| RB
directly  ||| S:20294 E:20303 ||| RB
activated  ||| S:20303 E:20321 ||| VBN
by  ||| S:20321 E:20324 ||| IN
DNA-damage ||| S:20324 E:20334 ||| JJ
.  ||| S:20334 E:20336 ||| .
For  ||| S:20336 E:20340 ||| IN
example ||| S:20340 E:20347 ||| NN
,  ||| S:20347 E:20349 ||| ,
activation  ||| S:20349 E:20360 ||| VBG
of  ||| S:20360 E:20363 ||| IN
the  ||| S:20363 E:20367 ||| DT
p110-PI  ||| S:20367 E:20383 ||| NNP
3-kinase ||| S:20383 E:20391 ||| NNP
/ ||| S:20391 E:20392 ||| NNP
PKB  ||| S:20392 E:20396 ||| NNP
pathway  ||| S:20396 E:20404 ||| NN
delivers  ||| S:20404 E:20413 ||| VBZ
an  ||| S:20413 E:20416 ||| DT
anti-apoptotic  ||| S:20416 E:20431 ||| JJ
signal  ||| S:20431 E:20438 ||| NN
to  ||| S:20438 E:20449 ||| TO
the  ||| S:20449 E:20453 ||| DT
cell  ||| S:20453 E:20458 ||| NN
[  ||| S:20458 E:20460 ||| -LRB-
23 ||| S:20460 E:20462 ||| CD
,  ||| S:20462 E:20464 ||| ,
25 ||| S:20464 E:20466 ||| CD
,  ||| S:20466 E:20468 ||| ,
47 ||| S:20468 E:20470 ||| CD
] ||| S:20470 E:20471 ||| -RRB-
.  ||| S:20471 E:20473 ||| .
Further ||| S:20473 E:20480 ||| RB
,  ||| S:20480 E:20482 ||| ,
activation  ||| S:20482 E:20493 ||| VBG
of  ||| S:20493 E:20496 ||| IN
the  ||| S:20496 E:20500 ||| DT
p110-PI  ||| S:20500 E:20516 ||| NNP
3-kinase ||| S:20516 E:20524 ||| NNP
/ ||| S:20524 E:20525 ||| NNP
PKB  ||| S:20525 E:20529 ||| NNP
is  ||| S:20529 E:20532 ||| VBZ
associated  ||| S:20532 E:20543 ||| VBN
with  ||| S:20543 E:20548 ||| IN
inhibition  ||| S:20548 E:20559 ||| NN
of  ||| S:20559 E:20562 ||| IN
both  ||| S:20562 E:20567 ||| DT
p53  ||| S:20567 E:20579 ||| NN
dependent  ||| S:20579 E:20589 ||| JJ
apoptosis  ||| S:20589 E:20599 ||| NNS
[  ||| S:20599 E:20601 ||| -LRB-
48 ||| S:20601 E:20603 ||| CD
]  ||| S:20603 E:20605 ||| -RRB-
and  ||| S:20605 E:20609 ||| CC
p53  ||| S:20609 E:20613 ||| NN
transcriptional  ||| S:20613 E:20629 ||| NN
activity  ||| S:20629 E:20646 ||| NN
[  ||| S:20646 E:20648 ||| -LRB-
49 ||| S:20648 E:20650 ||| CD
,  ||| S:20650 E:20652 ||| ,
50 ||| S:20652 E:20654 ||| CD
] ||| S:20654 E:20655 ||| -RRB-
.  ||| S:20655 E:20657 ||| .
Although  ||| S:20657 E:20666 ||| IN
PKB  ||| S:20666 E:20670 ||| NNP
has  ||| S:20670 E:20674 ||| VBZ
many  ||| S:20674 E:20679 ||| JJ
down  ||| S:20679 E:20684 ||| IN
stream  ||| S:20684 E:20691 ||| NN
targets  ||| S:20691 E:20699 ||| NNS
which  ||| S:20699 E:20713 ||| WDT
may  ||| S:20713 E:20717 ||| MD
regulate  ||| S:20717 E:20726 ||| VB
these  ||| S:20726 E:20732 ||| DT
effects  ||| S:20732 E:20740 ||| NNS
[  ||| S:20740 E:20742 ||| -LRB-
47 ||| S:20742 E:20744 ||| CD
]  ||| S:20744 E:20746 ||| -RRB-
a  ||| S:20746 E:20748 ||| DT
key  ||| S:20748 E:20752 ||| JJ
target  ||| S:20752 E:20759 ||| NN
of  ||| S:20759 E:20762 ||| IN
PKB  ||| S:20762 E:20766 ||| NNP
is  ||| S:20766 E:20777 ||| VBZ
GSK3β  ||| S:20777 E:20783 ||| NNP
[  ||| S:20783 E:20785 ||| -LRB-
29 ||| S:20785 E:20787 ||| CD
] ||| S:20787 E:20788 ||| -RRB-
.  ||| S:20788 E:20790 ||| .
Phosphorylation  ||| S:20790 E:20806 ||| NNP
of  ||| S:20806 E:20809 ||| IN
GSK3β  ||| S:20809 E:20815 ||| CD
by  ||| S:20815 E:20818 ||| IN
PKB  ||| S:20818 E:20822 ||| NNP
inhibits  ||| S:20822 E:20831 ||| FW
GSK3β  ||| S:20831 E:20845 ||| FW
kinase  ||| S:20845 E:20852 ||| FW
activity  ||| S:20852 E:20861 ||| FW
[  ||| S:20861 E:20863 ||| -LRB-
29 ||| S:20863 E:20865 ||| CD
] ||| S:20865 E:20866 ||| -RRB-
.  ||| S:20866 E:20868 ||| .
This  ||| S:20868 E:20873 ||| DT
would  ||| S:20873 E:20879 ||| MD
be  ||| S:20879 E:20882 ||| VB
predicted  ||| S:20882 E:20892 ||| VBN
to  ||| S:20892 E:20895 ||| TO
block  ||| S:20895 E:20909 ||| VB
phosphorylation  ||| S:20909 E:20925 ||| VBN
of  ||| S:20925 E:20928 ||| IN
serine  ||| S:20928 E:20935 ||| CD
33  ||| S:20935 E:20938 ||| CD
of  ||| S:20938 E:20941 ||| IN
p53  ||| S:20941 E:20945 ||| NN
by  ||| S:20945 E:20948 ||| IN
GSK3β ||| S:20948 E:20953 ||| NNP
,  ||| S:20953 E:20955 ||| ,
decreasing  ||| S:20955 E:20974 ||| VBG
p53  ||| S:20974 E:20978 ||| NN
transcriptional  ||| S:20978 E:20994 ||| NN
activity  ||| S:20994 E:21003 ||| NN
and  ||| S:21003 E:21007 ||| CC
therefore  ||| S:21007 E:21017 ||| RB
reducing  ||| S:21017 E:21026 ||| VBG
the  ||| S:21026 E:21038 ||| DT
transcription  ||| S:21038 E:21052 ||| NN
of  ||| S:21052 E:21055 ||| IN
p53-regulated  ||| S:21055 E:21069 ||| CD
growth  ||| S:21069 E:21076 ||| NN
and  ||| S:21076 E:21080 ||| CC
pro-apoptotic  ||| S:21080 E:21102 ||| JJ
proteins ||| S:21102 E:21110 ||| NNS
.  ||| S:21110 E:21112 ||| .
However ||| S:21112 E:21119 ||| RB
,  ||| S:21119 E:21121 ||| ,
clarification  ||| S:21121 E:21135 ||| NN
of  ||| S:21135 E:21138 ||| IN
the  ||| S:21138 E:21142 ||| DT
potential  ||| S:21142 E:21152 ||| JJ
role  ||| S:21152 E:21157 ||| NN
of  ||| S:21157 E:21168 ||| IN
GSK3β  ||| S:21168 E:21174 ||| CD
in  ||| S:21174 E:21177 ||| IN
regulating  ||| S:21177 E:21188 ||| VBG
p53  ||| S:21188 E:21192 ||| NN
activation  ||| S:21192 E:21203 ||| NN
by  ||| S:21203 E:21206 ||| IN
non-DNA  ||| S:21206 E:21214 ||| JJ
damage  ||| S:21214 E:21229 ||| NN
pathways  ||| S:21229 E:21238 ||| NNS
will  ||| S:21238 E:21243 ||| MD
require  ||| S:21243 E:21251 ||| VB
additional  ||| S:21251 E:21262 ||| JJ
study ||| S:21262 E:21267 ||| NN
.  ||| S:21267 E:21291 ||| .
Conclusions  ||| S:21291 E:21311 ||| NNS
This  ||| S:21311 E:21316 ||| DT
study  ||| S:21316 E:21322 ||| NN
demonstrates  ||| S:21322 E:21335 ||| VBZ
that  ||| S:21335 E:21340 ||| IN
GSK3β ||| S:21340 E:21345 ||| NNP
,  ||| S:21345 E:21347 ||| ,
but  ||| S:21347 E:21351 ||| CC
not  ||| S:21351 E:21355 ||| RB
GSK3α ||| S:21355 E:21360 ||| CD
,  ||| S:21360 E:21362 ||| ,
can  ||| S:21362 E:21374 ||| MD
directly  ||| S:21374 E:21383 ||| RB
phosphorylate  ||| S:21383 E:21397 ||| CD
serine  ||| S:21397 E:21404 ||| CD
33  ||| S:21404 E:21407 ||| CD
of  ||| S:21407 E:21410 ||| IN
p53  ||| S:21410 E:21414 ||| NN
when  ||| S:21414 E:21419 ||| WRB
serine  ||| S:21419 E:21426 ||| JJ
37  ||| S:21426 E:21429 ||| CD
of  ||| S:21429 E:21440 ||| IN
p53  ||| S:21440 E:21444 ||| NN
is  ||| S:21444 E:21447 ||| VBZ
already  ||| S:21447 E:21455 ||| RB
phosphorylated ||| S:21455 E:21469 ||| VBN
.  ||| S:21469 E:21471 ||| .
GSK3β  ||| S:21471 E:21477 ||| NNP
can  ||| S:21477 E:21481 ||| MD
increase  ||| S:21481 E:21490 ||| VB
p53 ||| S:21490 E:21493 ||| NN
's  ||| S:21493 E:21504 ||| POS
transcriptional  ||| S:21504 E:21520 ||| JJ
activity  ||| S:21520 E:21538 ||| NN
in  ||| S:21538 E:21541 ||| IN
vivo ||| S:21541 E:21545 ||| NN
,  ||| S:21545 E:21547 ||| ,
and  ||| S:21547 E:21551 ||| CC
this  ||| S:21551 E:21556 ||| DT
activation  ||| S:21556 E:21567 ||| NN
requires  ||| S:21567 E:21584 ||| VBZ
serines  ||| S:21584 E:21592 ||| CD
33  ||| S:21592 E:21595 ||| CD
and  ||| S:21595 E:21599 ||| CC
37  ||| S:21599 E:21602 ||| CD
of  ||| S:21602 E:21605 ||| IN
the  ||| S:21605 E:21609 ||| DT
p53  ||| S:21609 E:21613 ||| NN
protein ||| S:21613 E:21620 ||| NN
.  ||| S:21620 E:21622 ||| .
Thus  ||| S:21622 E:21627 ||| RB
GSK3β  ||| S:21627 E:21633 ||| CD
may  ||| S:21633 E:21645 ||| MD
phosphorylate  ||| S:21645 E:21659 ||| VB
and  ||| S:21659 E:21663 ||| CC
activate  ||| S:21663 E:21672 ||| JJ
p53  ||| S:21672 E:21685 ||| NN
in  ||| S:21685 E:21688 ||| IN
vivo ||| S:21688 E:21692 ||| NN
.  ||| S:21692 E:21694 ||| .
However ||| S:21694 E:21701 ||| RB
,  ||| S:21701 E:21703 ||| ,
GSK3β  ||| S:21703 E:21709 ||| NNP
is  ||| S:21709 E:21712 ||| VBZ
not  ||| S:21712 E:21716 ||| RB
part  ||| S:21716 E:21729 ||| NN
of  ||| S:21729 E:21732 ||| IN
the  ||| S:21732 E:21736 ||| DT
p53-DNA  ||| S:21736 E:21744 ||| JJ
damage  ||| S:21744 E:21751 ||| NN
response  ||| S:21751 E:21760 ||| NN
pathway ||| S:21760 E:21767 ||| NN
.  ||| S:21767 E:21769 ||| .
Instead ||| S:21769 E:21776 ||| RB
,  ||| S:21776 E:21778 ||| ,
GSK3β  ||| S:21778 E:21784 ||| NNP
may  ||| S:21784 E:21796 ||| MD
provide  ||| S:21796 E:21804 ||| VB
the  ||| S:21804 E:21808 ||| DT
link  ||| S:21808 E:21813 ||| NN
between  ||| S:21813 E:21821 ||| IN
p53  ||| S:21821 E:21825 ||| NN
and  ||| S:21825 E:21829 ||| CC
non-DNA  ||| S:21829 E:21837 ||| JJ
damage  ||| S:21837 E:21844 ||| NN
mechanisms  ||| S:21844 E:21863 ||| NNS
for  ||| S:21863 E:21867 ||| IN
p53  ||| S:21867 E:21871 ||| NN
activation ||| S:21871 E:21881 ||| NN
,  ||| S:21881 E:21883 ||| ,
such  ||| S:21883 E:21888 ||| JJ
as  ||| S:21888 E:21891 ||| IN
oncogene  ||| S:21891 E:21900 ||| JJ
activation ||| S:21900 E:21910 ||| NN
.  ||| S:21910 E:21934 ||| .
Materials  ||| S:21934 E:21944 ||| NNS
and  ||| S:21944 E:21948 ||| CC
methods  ||| S:21948 E:21975 ||| NNS
Phosphorylation  ||| S:21975 E:21991 ||| NNP
Reactions  ||| S:21991 E:22011 ||| NNP
Wild  ||| S:22011 E:22016 ||| NNP
type  ||| S:22016 E:22021 ||| NN
p53  ||| S:22021 E:22025 ||| NN
or  ||| S:22025 E:22028 ||| CC
p53  ||| S:22028 E:22032 ||| NN
bearing  ||| S:22032 E:22040 ||| NN
mutations  ||| S:22040 E:22050 ||| NNS
in  ||| S:22050 E:22053 ||| IN
serines  ||| S:22053 E:22061 ||| CD
33  ||| S:22061 E:22074 ||| CD
or  ||| S:22074 E:22077 ||| CC
37  ||| S:22077 E:22080 ||| CD
were  ||| S:22080 E:22085 ||| VBD
subcloned  ||| S:22085 E:22095 ||| VBN
into  ||| S:22095 E:22100 ||| IN
pGEX-2T  ||| S:22100 E:22108 ||| NNP
GST  ||| S:22108 E:22112 ||| NNP
fusion  ||| S:22112 E:22119 ||| NN
vector  ||| S:22119 E:22136 ||| NN
( ||| S:22136 E:22137 ||| -LRB-
Pharmacia ||| S:22137 E:22146 ||| NNP
,  ||| S:22146 E:22148 ||| ,
NJ ||| S:22148 E:22150 ||| NNP
)  ||| S:22150 E:22152 ||| -RRB-
and  ||| S:22152 E:22156 ||| CC
p53-GST  ||| S:22156 E:22164 ||| CD
purified  ||| S:22164 E:22173 ||| NN
as  ||| S:22173 E:22176 ||| IN
previously  ||| S:22176 E:22197 ||| RB
described  ||| S:22197 E:22207 ||| VBN
[  ||| S:22207 E:22209 ||| -LRB-
33 ||| S:22209 E:22211 ||| CD
] ||| S:22211 E:22212 ||| -RRB-
.  ||| S:22212 E:22214 ||| .
p53-GST  ||| S:22214 E:22222 ||| FW
protein  ||| S:22222 E:22230 ||| FW
( ||| S:22230 E:22231 ||| -LRB-
2  ||| S:22231 E:22233 ||| CD
μg ||| S:22233 E:22235 ||| NNS
;  ||| S:22235 E:22237 ||| :
measured  ||| S:22237 E:22246 ||| VBN
using  ||| S:22246 E:22262 ||| VBG
Bio-Rad  ||| S:22262 E:22270 ||| JJ
Protein  ||| S:22270 E:22278 ||| NNP
assay  ||| S:22278 E:22284 ||| VBD
Kit ||| S:22284 E:22287 ||| NNP
,  ||| S:22287 E:22289 ||| ,
Biorad ||| S:22289 E:22295 ||| NNP
,  ||| S:22295 E:22297 ||| ,
CA ||| S:22297 E:22299 ||| NNP
)  ||| S:22299 E:22301 ||| -RRB-
was  ||| S:22301 E:22305 ||| VBD
incubated  ||| S:22305 E:22315 ||| VBN
with  ||| S:22315 E:22330 ||| IN
MAP  ||| S:22330 E:22334 ||| NNP
kinase  ||| S:22334 E:22341 ||| NNS
( ||| S:22341 E:22342 ||| -LRB-
Erk2 ||| S:22342 E:22346 ||| NNP
,  ||| S:22346 E:22348 ||| ,
10  ||| S:22348 E:22351 ||| CD
Units ||| S:22351 E:22356 ||| NNS
,  ||| S:22356 E:22358 ||| ,
New  ||| S:22358 E:22362 ||| NNP
England  ||| S:22362 E:22370 ||| NNP
Biolabs ||| S:22370 E:22377 ||| NNP
,  ||| S:22377 E:22379 ||| ,
MA ||| S:22379 E:22381 ||| NNP
) ||| S:22381 E:22382 ||| -RRB-
,  ||| S:22382 E:22394 ||| ,
Protein  ||| S:22394 E:22402 ||| NNP
Kinase  ||| S:22402 E:22409 ||| NNP
A  ||| S:22409 E:22411 ||| NNP
( ||| S:22411 E:22412 ||| -LRB-
Catalytic  ||| S:22412 E:22422 ||| NNP
sub-unit ||| S:22422 E:22430 ||| NNP
,  ||| S:22430 E:22432 ||| ,
5  ||| S:22432 E:22434 ||| CD
Units ||| S:22434 E:22439 ||| NNS
,  ||| S:22439 E:22451 ||| ,
Calbiochem ||| S:22451 E:22461 ||| NNP
,  ||| S:22461 E:22463 ||| ,
CA ||| S:22463 E:22465 ||| NNP
) ||| S:22465 E:22466 ||| -RRB-
,  ||| S:22466 E:22468 ||| ,
S6  ||| S:22468 E:22471 ||| CD
kinase  ||| S:22471 E:22478 ||| NNS
( ||| S:22478 E:22479 ||| -LRB-
0.2  ||| S:22479 E:22483 ||| CD
Units ||| S:22483 E:22488 ||| NNS
,  ||| S:22488 E:22490 ||| ,
Upstate  ||| S:22490 E:22508 ||| NNP
Biotechnology ||| S:22508 E:22521 ||| NNP
,  ||| S:22521 E:22523 ||| ,
NY ||| S:22523 E:22525 ||| NNP
) ||| S:22525 E:22526 ||| -RRB-
,  ||| S:22526 E:22528 ||| ,
Protein  ||| S:22528 E:22536 ||| NNP
Kinase  ||| S:22536 E:22543 ||| NNP
C  ||| S:22543 E:22545 ||| NNP
( ||| S:22545 E:22546 ||| -LRB-
O.1  ||| S:22546 E:22550 ||| NNP
mUnits ||| S:22550 E:22556 ||| NNP
,  ||| S:22556 E:22558 ||| ,
Roche  ||| S:22558 E:22574 ||| NNP
Molecular  ||| S:22574 E:22584 ||| NNP
Biochemicals ||| S:22584 E:22596 ||| NNP
,  ||| S:22596 E:22598 ||| ,
IN ||| S:22598 E:22600 ||| IN
)  ||| S:22600 E:22602 ||| -RRB-
or  ||| S:22602 E:22605 ||| CC
DNA-PK  ||| S:22605 E:22612 ||| NNP
( ||| S:22612 E:22613 ||| -LRB-
20  ||| S:22613 E:22616 ||| CD
Units ||| S:22616 E:22621 ||| NNS
,  ||| S:22621 E:22623 ||| ,
Promega  ||| S:22623 E:22641 ||| NNP
Corp ||| S:22641 E:22645 ||| NNP
,  ||| S:22645 E:22647 ||| ,
Wl ||| S:22647 E:22649 ||| NNP
)  ||| S:22649 E:22651 ||| -RRB-
for  ||| S:22651 E:22655 ||| IN
5  ||| S:22655 E:22657 ||| CD
h  ||| S:22657 E:22659 ||| NN
at  ||| S:22659 E:22662 ||| IN
30°C  ||| S:22662 E:22667 ||| CD
in  ||| S:22667 E:22670 ||| IN
the  ||| S:22670 E:22674 ||| DT
following  ||| S:22674 E:22684 ||| JJ
buffers  ||| S:22684 E:22692 ||| NNS
( ||| S:22692 E:22693 ||| -LRB-
40  ||| S:22693 E:22696 ||| CD
μl  ||| S:22696 E:22709 ||| CD
final  ||| S:22709 E:22715 ||| JJ
volume ||| S:22715 E:22721 ||| NN
) ||| S:22721 E:22722 ||| -RRB-
.  ||| S:22722 E:22724 ||| .
MAP  ||| S:22724 E:22728 ||| NN
kinase  ||| S:22728 E:22735 ||| NNS
and  ||| S:22735 E:22739 ||| CC
Protein  ||| S:22739 E:22747 ||| NNP
Kinase  ||| S:22747 E:22754 ||| NNP
A ||| S:22754 E:22755 ||| NNP
:  ||| S:22755 E:22757 ||| :
20  ||| S:22757 E:22760 ||| CD
mM  ||| S:22760 E:22773 ||| JJ
Hepes  ||| S:22773 E:22779 ||| NNP
pH  ||| S:22779 E:22782 ||| NNP
7.2 ||| S:22782 E:22785 ||| CD
/ ||| S:22785 E:22786 ||| CD
10  ||| S:22786 E:22789 ||| CD
mM  ||| S:22789 E:22792 ||| JJ
Na-Acetate ||| S:22792 E:22802 ||| JJ
/ ||| S:22802 E:22803 ||| CD
30  ||| S:22803 E:22806 ||| CD
mM  ||| S:22806 E:22809 ||| JJ
MgCl  ||| S:22809 E:22825 ||| JJ
2  ||| S:22825 E:22827 ||| CD
/ ||| S:22827 E:22828 ||| CD
0.2  ||| S:22828 E:22832 ||| CD
mM  ||| S:22832 E:22835 ||| JJ
EDTA ||| S:22835 E:22839 ||| NNP
/ ||| S:22839 E:22840 ||| CD
1  ||| S:22840 E:22842 ||| CD
mM  ||| S:22842 E:22845 ||| JJ
EDTA ||| S:22845 E:22849 ||| NNP
/ ||| S:22849 E:22850 ||| NNP
I0  ||| S:22850 E:22853 ||| NNP
μM  ||| S:22853 E:22856 ||| NNP
ATP ||| S:22856 E:22859 ||| NNP
.  ||| S:22859 E:22861 ||| .
S6  ||| S:22861 E:22874 ||| NNP
Kinase ||| S:22874 E:22880 ||| NNP
:  ||| S:22880 E:22882 ||| :
20  ||| S:22882 E:22885 ||| CD
mM  ||| S:22885 E:22888 ||| JJ
MOPS  ||| S:22888 E:22893 ||| NNP
pH  ||| S:22893 E:22896 ||| NNP
7.2 ||| S:22896 E:22899 ||| CD
/ ||| S:22899 E:22900 ||| CD
30  ||| S:22900 E:22903 ||| CD
mM  ||| S:22903 E:22906 ||| JJ
MgCl  ||| S:22906 E:22922 ||| JJ
2  ||| S:22922 E:22924 ||| CD
/ ||| S:22924 E:22925 ||| CD
5  ||| S:22925 E:22927 ||| CD
mM  ||| S:22927 E:22930 ||| JJ
EGTA ||| S:22930 E:22934 ||| NNP
/ ||| S:22934 E:22935 ||| CD
1  ||| S:22935 E:22937 ||| CD
mM  ||| S:22937 E:22940 ||| JJ
DTT ||| S:22940 E:22943 ||| NNP
/ ||| S:22943 E:22944 ||| NNP
I0  ||| S:22944 E:22947 ||| NNP
μM  ||| S:22947 E:22950 ||| NNP
ATP ||| S:22950 E:22953 ||| NNP
.  ||| S:22953 E:22965 ||| .
DNA-PK ||| S:22965 E:22971 ||| NNP
: ||| S:22971 E:22972 ||| :
25  ||| S:22972 E:22975 ||| CD
mM  ||| S:22975 E:22978 ||| JJ
Hepes  ||| S:22978 E:22984 ||| NNP
pH7.5 ||| S:22984 E:22989 ||| CD
/ ||| S:22989 E:22990 ||| CD
150  ||| S:22990 E:22994 ||| CD
mM  ||| S:22994 E:22997 ||| JJ
KCI ||| S:22997 E:23000 ||| NNP
/ ||| S:23000 E:23001 ||| CD
10  ||| S:23001 E:23004 ||| CD
mM  ||| S:23004 E:23007 ||| JJ
MgCl  ||| S:23007 E:23023 ||| JJ
2  ||| S:23023 E:23025 ||| CD
/ ||| S:23025 E:23026 ||| CD
20 ||| S:23026 E:23028 ||| CD
%  ||| S:23028 E:23030 ||| NN
Glycerol ||| S:23030 E:23038 ||| NNP
/ ||| S:23038 E:23039 ||| CD
0.1 ||| S:23039 E:23042 ||| CD
%  ||| S:23042 E:23044 ||| NN
NP40 ||| S:23044 E:23048 ||| CD
/ ||| S:23048 E:23049 ||| CD
20  ||| S:23049 E:23052 ||| CD
μM  ||| S:23052 E:23055 ||| JJ
ZnCl  ||| S:23055 E:23071 ||| JJ
2  ||| S:23071 E:23073 ||| CD
/ ||| S:23073 E:23074 ||| CD
1  ||| S:23074 E:23076 ||| CD
mM  ||| S:23076 E:23079 ||| JJ
DTT ||| S:23079 E:23082 ||| NNP
/ ||| S:23082 E:23083 ||| CD
250  ||| S:23083 E:23087 ||| CD
ng  ||| S:23087 E:23090 ||| JJ
DNA ||| S:23090 E:23093 ||| NN
/ ||| S:23093 E:23094 ||| CD
4.2  ||| S:23094 E:23098 ||| CD
mM  ||| S:23098 E:23111 ||| JJ
spermidine ||| S:23111 E:23121 ||| NN
/  ||| S:23121 E:23123 ||| CD
10  ||| S:23123 E:23126 ||| CD
μM  ||| S:23126 E:23129 ||| JJ
ATP ||| S:23129 E:23132 ||| NNP
.  ||| S:23132 E:23134 ||| .
PKC ||| S:23134 E:23137 ||| NNP
:  ||| S:23137 E:23139 ||| :
20  ||| S:23139 E:23142 ||| CD
mM  ||| S:23142 E:23145 ||| JJ
Hepes  ||| S:23145 E:23151 ||| NNP
pH  ||| S:23151 E:23154 ||| NNP
7.4 ||| S:23154 E:23157 ||| CD
/  ||| S:23157 E:23159 ||| CD
20  ||| S:23159 E:23162 ||| CD
mM  ||| S:23162 E:23175 ||| JJ
MgCl  ||| S:23175 E:23191 ||| JJ
2  ||| S:23191 E:23193 ||| CD
/  ||| S:23193 E:23195 ||| CD
0.2  ||| S:23195 E:23199 ||| CD
mM  ||| S:23199 E:23202 ||| JJ
EGTA ||| S:23202 E:23206 ||| NNP
/  ||| S:23206 E:23208 ||| CD
1  ||| S:23208 E:23210 ||| CD
mM  ||| S:23210 E:23213 ||| JJ
CaCl  ||| S:23213 E:23229 ||| JJ
2  ||| S:23229 E:23231 ||| CD
/ ||| S:23231 E:23232 ||| CD
1.5  ||| S:23232 E:23236 ||| CD
μg  ||| S:23236 E:23239 ||| CD
phosphatidylserine ||| S:23239 E:23257 ||| NNS
.  ||| S:23257 E:23259 ||| .
Samples  ||| S:23259 E:23277 ||| NNS
were  ||| S:23277 E:23282 ||| VBD
then  ||| S:23282 E:23287 ||| RB
incubated  ||| S:23287 E:23297 ||| VBN
at  ||| S:23297 E:23300 ||| IN
65°C  ||| S:23300 E:23305 ||| CD
for  ||| S:23305 E:23309 ||| IN
20  ||| S:23309 E:23312 ||| CD
min  ||| S:23312 E:23316 ||| NN
to  ||| S:23316 E:23319 ||| TO
inactivate  ||| S:23319 E:23340 ||| VB
kinases ||| S:23340 E:23347 ||| NNS
,  ||| S:23347 E:23349 ||| ,
and  ||| S:23349 E:23353 ||| CC
25 ||| S:23353 E:23355 ||| CD
%  ||| S:23355 E:23357 ||| NN
of  ||| S:23357 E:23360 ||| IN
the  ||| S:23360 E:23364 ||| DT
reaction  ||| S:23364 E:23373 ||| NN
incubated  ||| S:23373 E:23383 ||| NN
for  ||| S:23383 E:23387 ||| IN
30  ||| S:23387 E:23390 ||| CD
min  ||| S:23390 E:23404 ||| NN
with  ||| S:23404 E:23409 ||| IN
GSK3α  ||| S:23409 E:23415 ||| NNP
or  ||| S:23415 E:23418 ||| CC
GSK3β  ||| S:23418 E:23424 ||| CD
in  ||| S:23424 E:23427 ||| IN
GSK3  ||| S:23427 E:23432 ||| FW
kinase  ||| S:23432 E:23439 ||| FW
buffer  ||| S:23439 E:23446 ||| FW
( ||| S:23446 E:23447 ||| -LRB-
KGB  ||| S:23447 E:23451 ||| NNP
Buffer ||| S:23451 E:23457 ||| NNP
:  ||| S:23457 E:23459 ||| :
8  ||| S:23459 E:23471 ||| CD
mM  ||| S:23471 E:23474 ||| JJ
MOPS ||| S:23474 E:23478 ||| NNP
,  ||| S:23478 E:23480 ||| ,
pH7.2 ||| S:23480 E:23485 ||| CD
/  ||| S:23485 E:23487 ||| CD
10  ||| S:23487 E:23490 ||| CD
mM  ||| S:23490 E:23493 ||| JJ
MgCl  ||| S:23493 E:23509 ||| JJ
2  ||| S:23509 E:23511 ||| CD
/  ||| S:23511 E:23513 ||| CD
0.2  ||| S:23513 E:23517 ||| CD
mM  ||| S:23517 E:23520 ||| JJ
EDTA ||| S:23520 E:23524 ||| NNP
/  ||| S:23524 E:23526 ||| CD
5  ||| S:23526 E:23528 ||| CD
μM  ||| S:23528 E:23531 ||| JJ
ATP ||| S:23531 E:23534 ||| NNP
/ ||| S:23534 E:23535 ||| CD
10  ||| S:23535 E:23538 ||| CD
μCi  ||| S:23538 E:23552 ||| JJ
32P-ATP ||| S:23552 E:23559 ||| CD
)  ||| S:23559 E:23561 ||| -RRB-
in  ||| S:23561 E:23564 ||| IN
a  ||| S:23564 E:23566 ||| DT
final  ||| S:23566 E:23572 ||| JJ
volume  ||| S:23572 E:23579 ||| NN
of  ||| S:23579 E:23582 ||| IN
40  ||| S:23582 E:23585 ||| CD
μl ||| S:23585 E:23587 ||| NNS
.  ||| S:23587 E:23589 ||| .
Reactions  ||| S:23589 E:23599 ||| NNS
were  ||| S:23599 E:23614 ||| VBD
terminated  ||| S:23614 E:23625 ||| VBN
by  ||| S:23625 E:23628 ||| IN
the  ||| S:23628 E:23632 ||| DT
addition  ||| S:23632 E:23641 ||| NN
of  ||| S:23641 E:23644 ||| IN
SDS  ||| S:23644 E:23648 ||| NNP
sample  ||| S:23648 E:23655 ||| NN
buffer  ||| S:23655 E:23662 ||| NN
and  ||| S:23662 E:23676 ||| CC
p53-GST  ||| S:23676 E:23684 ||| NNP
phosphorylation  ||| S:23684 E:23700 ||| VBD
detected  ||| S:23700 E:23709 ||| VBN
by  ||| S:23709 E:23712 ||| IN
SDS-PAGE  ||| S:23712 E:23721 ||| JJ
and  ||| S:23721 E:23735 ||| CC
auotradiography ||| S:23735 E:23750 ||| NN
.  ||| S:23750 E:23752 ||| .
Equal  ||| S:23752 E:23758 ||| JJ
amounts  ||| S:23758 E:23766 ||| NNS
of  ||| S:23766 E:23769 ||| IN
p53-GST  ||| S:23769 E:23777 ||| NNP
( ||| S:23777 E:23778 ||| -LRB-
0.25  ||| S:23778 E:23783 ||| CD
μg ||| S:23783 E:23785 ||| CD
)  ||| S:23785 E:23787 ||| -RRB-
were  ||| S:23787 E:23802 ||| VBD
analyzed  ||| S:23802 E:23811 ||| VBN
by  ||| S:23811 E:23814 ||| IN
SDS-PAGE  ||| S:23814 E:23823 ||| JJ
and  ||| S:23823 E:23827 ||| CC
equal  ||| S:23827 E:23833 ||| JJ
loading  ||| S:23833 E:23841 ||| NN
confirmed  ||| S:23841 E:23851 ||| VBD
by  ||| S:23851 E:23864 ||| IN
coomassie  ||| S:23864 E:23874 ||| JJ
blue  ||| S:23874 E:23879 ||| JJ
staining  ||| S:23879 E:23888 ||| NN
of  ||| S:23888 E:23891 ||| IN
the  ||| S:23891 E:23895 ||| DT
SDS-PAG ||| S:23895 E:23902 ||| JJ
.  ||| S:23902 E:23932 ||| .
GSK3  ||| S:23932 E:23937 ||| FW
immunokinase  ||| S:23937 E:23950 ||| FW
assay  ||| S:23950 E:23966 ||| FW
SAOS-2  ||| S:23966 E:23973 ||| FW
cells  ||| S:23973 E:23979 ||| FW
( ||| S:23979 E:23980 ||| -LRB-
5  ||| S:23980 E:23982 ||| CD
×  ||| S:23982 E:23984 ||| CD
10  ||| S:23984 E:23987 ||| CD
6 ||| S:23987 E:23988 ||| CD
)  ||| S:23988 E:23990 ||| -RRB-
were  ||| S:23990 E:23995 ||| VBD
lyzed  ||| S:23995 E:24001 ||| VBN
in  ||| S:24001 E:24004 ||| IN
0.5  ||| S:24004 E:24008 ||| CD
ml  ||| S:24008 E:24011 ||| NN
of  ||| S:24011 E:24014 ||| IN
GLB  ||| S:24014 E:24028 ||| NNP
buffer  ||| S:24028 E:24035 ||| NN
( ||| S:24035 E:24036 ||| -LRB-
50  ||| S:24036 E:24039 ||| CD
mM  ||| S:24039 E:24042 ||| JJ
Tris  ||| S:24042 E:24047 ||| NNP
pH7.5 ||| S:24047 E:24052 ||| CD
/ ||| S:24052 E:24053 ||| CD
1  ||| S:24053 E:24055 ||| CD
mM  ||| S:24055 E:24058 ||| JJ
EDTA ||| S:24058 E:24062 ||| NNP
/ ||| S:24062 E:24063 ||| CD
1  ||| S:24063 E:24065 ||| CD
mM  ||| S:24065 E:24068 ||| JJ
EGTA ||| S:24068 E:24072 ||| NNP
/ ||| S:24072 E:24073 ||| CD
0.5 ||| S:24073 E:24076 ||| CD
%  ||| S:24076 E:24088 ||| NN
NP40 ||| S:24088 E:24092 ||| CD
/ ||| S:24092 E:24093 ||| CD
0.5  ||| S:24093 E:24097 ||| CD
M  ||| S:24097 E:24099 ||| NNP
NaCI ||| S:24099 E:24103 ||| NNP
/ ||| S:24103 E:24104 ||| CD
1  ||| S:24104 E:24106 ||| CD
mM  ||| S:24106 E:24109 ||| JJ
DTT ||| S:24109 E:24112 ||| NNP
/ ||| S:24112 E:24113 ||| CD
1  ||| S:24113 E:24115 ||| CD
mM  ||| S:24115 E:24128 ||| JJ
PMSF ||| S:24128 E:24132 ||| NNP
/ ||| S:24132 E:24133 ||| CD
leupeptin ||| S:24133 E:24142 ||| CD
/ ||| S:24142 E:24143 ||| CD
aprotinin ||| S:24143 E:24152 ||| CD
/ ||| S:24152 E:24153 ||| CD
600  ||| S:24153 E:24157 ||| CD
μM  ||| S:24157 E:24160 ||| JJ
Na  ||| S:24160 E:24174 ||| NNP
3  ||| S:24174 E:24176 ||| CD
VO  ||| S:24176 E:24190 ||| CD
4  ||| S:24190 E:24192 ||| CD
/ ||| S:24192 E:24193 ||| CD
50  ||| S:24193 E:24196 ||| CD
mM  ||| S:24196 E:24199 ||| JJ
NaF ||| S:24199 E:24202 ||| NN
) ||| S:24202 E:24203 ||| -RRB-
.  ||| S:24203 E:24205 ||| .
Extracts  ||| S:24205 E:24214 ||| NNP
were  ||| S:24214 E:24219 ||| VBD
cleared  ||| S:24219 E:24237 ||| VBN
by  ||| S:24237 E:24240 ||| IN
centrifugation  ||| S:24240 E:24255 ||| NN
and  ||| S:24255 E:24259 ||| CC
incubated  ||| S:24259 E:24269 ||| NN
with  ||| S:24269 E:24274 ||| IN
GSK3  ||| S:24274 E:24279 ||| CD
antibody  ||| S:24279 E:24288 ||| NN
( ||| S:24288 E:24289 ||| -LRB-
1  ||| S:24289 E:24291 ||| CD
μg ||| S:24291 E:24293 ||| NNS
;  ||| S:24293 E:24305 ||| :
Upstate  ||| S:24305 E:24313 ||| NNP
Biotech ||| S:24313 E:24320 ||| NNP
,  ||| S:24320 E:24322 ||| ,
NY ||| S:24322 E:24324 ||| NNP
)  ||| S:24324 E:24326 ||| -RRB-
prebound  ||| S:24326 E:24335 ||| NN
to  ||| S:24335 E:24338 ||| TO
Sepharose  ||| S:24338 E:24348 ||| NNP
A ||| S:24348 E:24349 ||| NNP
/ ||| S:24349 E:24350 ||| NNP
G  ||| S:24350 E:24352 ||| NNP
agarose  ||| S:24352 E:24370 ||| VBD
beads  ||| S:24370 E:24376 ||| VBN
for  ||| S:24376 E:24380 ||| IN
2  ||| S:24380 E:24382 ||| CD
h ||| S:24382 E:24383 ||| NNS
.  ||| S:24383 E:24385 ||| .
The  ||| S:24385 E:24389 ||| DT
beads  ||| S:24389 E:24395 ||| NN
were  ||| S:24395 E:24400 ||| VBD
washed  ||| S:24400 E:24407 ||| VBN
in  ||| S:24407 E:24410 ||| IN
4  ||| S:24410 E:24412 ||| CD
×  ||| S:24412 E:24414 ||| CD
1  ||| S:24414 E:24416 ||| CD
ml  ||| S:24416 E:24419 ||| NN
of  ||| S:24419 E:24422 ||| IN
GLB  ||| S:24422 E:24436 ||| NNP
buffer  ||| S:24436 E:24443 ||| NN
and  ||| S:24443 E:24447 ||| CC
then  ||| S:24447 E:24452 ||| RB
in  ||| S:24452 E:24455 ||| IN
2  ||| S:24455 E:24457 ||| CD
×  ||| S:24457 E:24459 ||| CD
1  ||| S:24459 E:24461 ||| CD
ml  ||| S:24461 E:24464 ||| NN
of  ||| S:24464 E:24467 ||| IN
KGB  ||| S:24467 E:24471 ||| NNP
buffer ||| S:24471 E:24477 ||| NN
.  ||| S:24477 E:24479 ||| .
Kinase  ||| S:24479 E:24496 ||| JJ
reactions  ||| S:24496 E:24506 ||| NNS
contained  ||| S:24506 E:24516 ||| VBD
5  ||| S:24516 E:24518 ||| CD
μM  ||| S:24518 E:24521 ||| JJ
ATP ||| S:24521 E:24524 ||| NNP
/ ||| S:24524 E:24525 ||| CD
15  ||| S:24525 E:24528 ||| CD
μCi  ||| S:24528 E:24532 ||| JJ
32P-ATP ||| S:24532 E:24539 ||| CD
/ ||| S:24539 E:24540 ||| CD
0.5  ||| S:24540 E:24544 ||| CD
μg  ||| S:24544 E:24557 ||| CD
PhosphoCREB  ||| S:24557 E:24569 ||| JJ
peptide  ||| S:24569 E:24577 ||| NN
in  ||| S:24577 E:24580 ||| IN
30  ||| S:24580 E:24583 ||| CD
μl  ||| S:24583 E:24586 ||| NN
of  ||| S:24586 E:24589 ||| IN
KGB ||| S:24589 E:24592 ||| NNP
.  ||| S:24592 E:24594 ||| .
After  ||| S:24594 E:24600 ||| IN
incubate  ||| S:24600 E:24609 ||| NN
for  ||| S:24609 E:24623 ||| IN
10  ||| S:24623 E:24626 ||| CD
min  ||| S:24626 E:24630 ||| NN
at  ||| S:24630 E:24633 ||| IN
room  ||| S:24633 E:24638 ||| NN
temperature ||| S:24638 E:24649 ||| NN
,  ||| S:24649 E:24651 ||| ,
the  ||| S:24651 E:24655 ||| DT
beads  ||| S:24655 E:24661 ||| NN
were  ||| S:24661 E:24666 ||| VBD
collected  ||| S:24666 E:24676 ||| VBN
by  ||| S:24676 E:24689 ||| IN
centrifugation  ||| S:24689 E:24704 ||| NN
and  ||| S:24704 E:24708 ||| CC
20  ||| S:24708 E:24711 ||| CD
μl  ||| S:24711 E:24714 ||| NN
of  ||| S:24714 E:24717 ||| IN
the  ||| S:24717 E:24721 ||| DT
reaction  ||| S:24721 E:24730 ||| NN
mix  ||| S:24730 E:24734 ||| NN
spotted  ||| S:24734 E:24742 ||| VBD
onto  ||| S:24742 E:24757 ||| IN
circles  ||| S:24757 E:24765 ||| NNS
of  ||| S:24765 E:24768 ||| IN
P81  ||| S:24768 E:24772 ||| CD
paper  ||| S:24772 E:24778 ||| NN
( ||| S:24778 E:24779 ||| -LRB-
Whatman ||| S:24779 E:24786 ||| NNP
,  ||| S:24786 E:24788 ||| ,
USA ||| S:24788 E:24791 ||| NNP
) ||| S:24791 E:24792 ||| -RRB-
.  ||| S:24792 E:24794 ||| .
The  ||| S:24794 E:24798 ||| DT
P81  ||| S:24798 E:24802 ||| JJ
paper  ||| S:24802 E:24808 ||| NN
was  ||| S:24808 E:24822 ||| VBD
washed  ||| S:24822 E:24829 ||| VBN
in  ||| S:24829 E:24832 ||| IN
4  ||| S:24832 E:24834 ||| CD
×  ||| S:24834 E:24836 ||| CD
10  ||| S:24836 E:24839 ||| CD
ml  ||| S:24839 E:24842 ||| CD
changes  ||| S:24842 E:24850 ||| NNS
of  ||| S:24850 E:24853 ||| IN
100  ||| S:24853 E:24857 ||| CD
mM  ||| S:24857 E:24860 ||| JJ
phosphoric  ||| S:24860 E:24871 ||| JJ
acid ||| S:24871 E:24875 ||| NN
,  ||| S:24875 E:24887 ||| ,
dried  ||| S:24887 E:24893 ||| VBN
and  ||| S:24893 E:24897 ||| CC
counted ||| S:24897 E:24904 ||| VBN
.  ||| S:24904 E:24906 ||| .
PhosphoCREB  ||| S:24906 E:24918 ||| JJ
peptide  ||| S:24918 E:24926 ||| NNS
( ||| S:24926 E:24927 ||| -LRB-
sequence  ||| S:24927 E:24946 ||| FW
KRREILSRRPS ||| S:24946 E:24957 ||| FW
( ||| S:24957 E:24958 ||| -LRB-
P ||| S:24958 E:24959 ||| NN
) ||| S:24959 E:24960 ||| -RRB-
YR ||| S:24960 E:24962 ||| NNP
)  ||| S:24962 E:24964 ||| -RRB-
was  ||| S:24964 E:24968 ||| VBD
obtained  ||| S:24968 E:24977 ||| VBN
from  ||| S:24977 E:24982 ||| IN
New  ||| S:24982 E:24986 ||| NNP
England  ||| S:24986 E:24994 ||| NNP
Biolabs ||| S:24994 E:25001 ||| NNP
,  ||| S:25001 E:25013 ||| ,
MA ||| S:25013 E:25015 ||| NNP
.  ||| S:25015 E:25038 ||| .
Mutagenesis  ||| S:25038 E:25050 ||| NNP
was  ||| S:25050 E:25054 ||| VBD
carried  ||| S:25054 E:25062 ||| VBN
out  ||| S:25062 E:25066 ||| RP
using  ||| S:25066 E:25072 ||| VBG
the  ||| S:25072 E:25086 ||| DT
Altered  ||| S:25086 E:25094 ||| NNP
Sites  ||| S:25094 E:25100 ||| NNP
Mutagenesis  ||| S:25100 E:25112 ||| NNP
System  ||| S:25112 E:25119 ||| NNP
( ||| S:25119 E:25120 ||| -LRB-
Promega ||| S:25120 E:25127 ||| NNP
,  ||| S:25127 E:25129 ||| ,
Wl ||| S:25129 E:25131 ||| NNP
)  ||| S:25131 E:25133 ||| -RRB-
as  ||| S:25133 E:25146 ||| IN
previously  ||| S:25146 E:25157 ||| RB
described  ||| S:25157 E:25167 ||| VBN
by  ||| S:25167 E:25170 ||| IN
us  ||| S:25170 E:25173 ||| PRP
[  ||| S:25173 E:25175 ||| -LRB-
33 ||| S:25175 E:25177 ||| CD
] ||| S:25177 E:25178 ||| -RRB-
.  ||| S:25178 E:25180 ||| .
Human  ||| S:25180 E:25186 ||| JJ
wild  ||| S:25186 E:25191 ||| JJ
type  ||| S:25191 E:25196 ||| NN
p53  ||| S:25196 E:25200 ||| NN
or  ||| S:25200 E:25213 ||| CC
p53  ||| S:25213 E:25217 ||| NN
bearing  ||| S:25217 E:25225 ||| NN
mutations  ||| S:25225 E:25235 ||| NNS
in  ||| S:25235 E:25238 ||| IN
serines  ||| S:25238 E:25246 ||| CD
33  ||| S:25246 E:25249 ||| CD
or  ||| S:25249 E:25252 ||| CC
37  ||| S:25252 E:25255 ||| CD
were  ||| S:25255 E:25260 ||| VBD
inserted  ||| S:25260 E:25279 ||| VBN
into  ||| S:25279 E:25284 ||| IN
the  ||| S:25284 E:25288 ||| DT
BamH1  ||| S:25288 E:25294 ||| JJ
site  ||| S:25294 E:25299 ||| NN
of  ||| S:25299 E:25302 ||| IN
the  ||| S:25302 E:25306 ||| DT
pcDNA3.1  ||| S:25306 E:25315 ||| JJ
expression  ||| S:25315 E:25326 ||| NN
vector  ||| S:25326 E:25343 ||| NN
( ||| S:25343 E:25344 ||| -LRB-
Invitrogen ||| S:25344 E:25354 ||| NNP
,  ||| S:25354 E:25356 ||| ,
CA ||| S:25356 E:25358 ||| NNP
) ||| S:25358 E:25359 ||| -RRB-
.  ||| S:25359 E:25382 ||| .
Luciferase  ||| S:25382 E:25393 ||| JJ
reporter  ||| S:25393 E:25402 ||| NN
assays  ||| S:25402 E:25409 ||| NNS
were  ||| S:25409 E:25424 ||| VBD
carried  ||| S:25424 E:25432 ||| VBN
out  ||| S:25432 E:25436 ||| RP
in  ||| S:25436 E:25439 ||| IN
the  ||| S:25439 E:25443 ||| DT
p53  ||| S:25443 E:25447 ||| NN
null  ||| S:25447 E:25452 ||| NN
cell  ||| S:25452 E:25457 ||| NN
line  ||| S:25457 E:25462 ||| NN
SAOS-2  ||| S:25462 E:25469 ||| VBZ
using  ||| S:25469 E:25475 ||| VBG
the  ||| S:25475 E:25489 ||| DT
p53  ||| S:25489 E:25493 ||| NN
specific  ||| S:25493 E:25502 ||| JJ
luciferase  ||| S:25502 E:25513 ||| JJ
reporter  ||| S:25513 E:25522 ||| NN
construct  ||| S:25522 E:25532 ||| VBD
p50-Luc ||| S:25532 E:25539 ||| CD
,  ||| S:25539 E:25541 ||| ,
and  ||| S:25541 E:25555 ||| CC
pCMV-β-galatosidase  ||| S:25555 E:25575 ||| JJ
to  ||| S:25575 E:25578 ||| TO
control  ||| S:25578 E:25586 ||| VB
for  ||| S:25586 E:25590 ||| IN
transfection  ||| S:25590 E:25613 ||| JJ
efficiency ||| S:25613 E:25623 ||| NN
.  ||| S:25623 E:25625 ||| .
Cells  ||| S:25625 E:25631 ||| NNS
were  ||| S:25631 E:25636 ||| VBD
transfected  ||| S:25636 E:25648 ||| VBN
using  ||| S:25648 E:25654 ||| VBG
Lipofectin  ||| S:25654 E:25675 ||| NNP
( ||| S:25675 E:25676 ||| -LRB-
Gibco-BRL ||| S:25676 E:25685 ||| NNP
)  ||| S:25685 E:25687 ||| -RRB-
containing  ||| S:25687 E:25698 ||| VBG
p50-Luc  ||| S:25698 E:25706 ||| NNP
( ||| S:25706 E:25707 ||| -LRB-
1  ||| S:25707 E:25709 ||| CD
μg ||| S:25709 E:25711 ||| CD
) ||| S:25711 E:25712 ||| -RRB-
,  ||| S:25712 E:25714 ||| ,
pCMV-Gal  ||| S:25714 E:25723 ||| NNP
( ||| S:25723 E:25724 ||| -LRB-
1  ||| S:25724 E:25726 ||| CD
μg ||| S:25726 E:25728 ||| CD
)  ||| S:25728 E:25740 ||| -RRB-
and  ||| S:25740 E:25744 ||| CC
pcDNAp53  ||| S:25744 E:25753 ||| NNP
( ||| S:25753 E:25754 ||| -LRB-
50  ||| S:25754 E:25757 ||| CD
ng ||| S:25757 E:25759 ||| CD
)  ||| S:25759 E:25761 ||| -RRB-
in  ||| S:25761 E:25764 ||| IN
a  ||| S:25764 E:25766 ||| DT
final  ||| S:25766 E:25772 ||| JJ
volume  ||| S:25772 E:25779 ||| NN
of  ||| S:25779 E:25782 ||| IN
400  ||| S:25782 E:25786 ||| CD
μl  ||| S:25786 E:25789 ||| NNS
as  ||| S:25789 E:25802 ||| RB
described  ||| S:25802 E:25812 ||| VBN
in  ||| S:25812 E:25815 ||| IN
the  ||| S:25815 E:25819 ||| DT
manufacturers  ||| S:25819 E:25833 ||| NNS
protocol ||| S:25833 E:25841 ||| NN
.  ||| S:25841 E:25867 ||| .
